Upload
others
View
3
Download
0
Embed Size (px)
Citation preview
Prehypertension mdash a stage to think about
kliničnioddelek za
hipertenzijo
Greece 2017
Jana Brguljan MD PhD FESC
University Medical Centre LjubljanaHypertension DepartmentHospital drPDržaj
GBD 2013 Risk Factors Collaborators Lancet Published online September 11 2015
2000 2013
Global DALYs attributed to level 2 risk factors in 2000 and in 2013
When did story begin
bull Probably in 1939 Robinson and Brucer defined BPs in the range of 120-13980-89mmHg as prehypertensive (Robinson SC Brucer M Arch Inter Med 1939 64409-444)
bull 1999 Frolich reported that BP lt 14090mmHg is associated with increased risk for CV disease stroke nad premature death (Frolich ED J Am Coll Cardiol 1999)
When did story begin
Definition of prehypertension and high normal blood pressure
bull The USA Joint National Committee Guidelines (JNC 7) on hypertension published in 2003 unified the normal and high normal blood pressure categories into a single entity termed lsquolsquoprehypertensionrsquorsquo(120-13980-89mmHg)
bull The ESH ESC Committee 2013 has decided not to use this terminologydue to several resones and defined high normal blood pressure
Definitions and classification of blood pressure levels(mmHg)
Category Systolic DiastolicOptimal lt120 and lt80Normal 120ndash129 andor 80ndash84High normal 130ndash139 andor 85ndash89Hypertension gt140 andor gt90
Mortality from ischemic heart disease and stroke increases with increasing blood pressrue
Prospective Studies Collaboration Lancet 20023601903-13
stroke
Ishemic heart disease
Prospective Studies Collaboration Lancet 20023601903-13
Framingham Heart Study (n=6859)
Cumulative Incidence of Cardiovascular Events in Women (Panel A) and Men (Panel B) without
Hypertension According to Blood-Pressure Category at the Base-Line Examination
Vasan Larson et all IMPACT OF HIGH-NORMAL BLOOD PRESSURE ON THE RISK OF CARDIOVASCULAR DISEASE N Engl J Med 2001
Vertical bars indicate 95 percent confidence intervals Optimal blood pressure is a systolic pressure of less than 120 mm Hg and a diastolic pressure of less than 80 mm Hg Normal blood pressure is a systolic pressure of 120 to 129 mm Hg or a diastolic pressure of 80 to 84 mm Hg High-normal blood pressure is a systolic pressure of 130 to 139 mm Hg or a diastolic pressure of 85 to 89 mm Hg If the systolic and diastolic pressure readings for a subject were in different categories the higher of the two categories was used
Prevalence of prehypertension ( 40)bull De Marco M de Simone G Roman MJ Chinali M Lee ET Russell M Howard BV Devereux RBCardiovascular and metabolic
predictors of progression of prehypertension into hypertension the Strong Heart Study Hypertension 2009 Nov54(5)974-80 Epub 2009 Aug 31Strong Heart Study 625 American Indian 45-74y
22 of prevalence of pht 53 among diabetics 33 among non-diabeticHigher BMI SBP DBP pp HR diabetes TG fibrinogen CRP lower HDL higher LVM
bull Zhang Y Lee ET Devereux RB Yeh J Best LG Fabsitz RR Howard BV Prehypertension diabetes and cardiovascular disease risk in a population based sample the Strong Heart Study
Hypertension 2006 Mar47(3)410-4 Epub 2006 Jan 30 Strong Heart Study1532 no diabetic and 1097 diabetics American Indian 55 +-8y
Prevalence of prehypert 594 in diabetics and 482 in non diabeticsIn all age groups from 45-49 to 70-74 diabetics had higher prevalence than non-diabetic and
Kaplan Meier plots showed that prehyperte had higher CV disease incidence and when diabetes was added it was even higher
Only prehypertension was lower than diabetes itself
bull Mainous AG 3rd Everett CJ Liszka H King DE Egan BMPrehypertension and mortality in a nationally representative cohortAm J Cardiol 2004 Dec 1594(12)1496-500NHAES IIstart NH2MS followed 9087 USA 30-74y
31prevalence of pht 37hypertension
bull Liszka HA Mainous AG III King DEEverett CJ Egan BM Prehypertension and cardiovascular morbidity Ann Fam Med 20053294-9NHAES 8986Usa 86white
33prevalence of pht47hypertension
World Hypertension Day Slovenija 2016
(n=2651)
Huang et all Neurology 2014
Prevalenca of prehypertension
Prevalence of prehypertension and hypertension stratified by sex and age
Hu L Huang X You C Li J Hong K et al (2017) Prevalence and Risk Factors of Prehypertension and Hypertension in Southern China PLOS ONE 12(1) e0170238 doi101371journalpone0170238httpjournalsplosorgplosonearticleid=101371journalpone0170238
PLOS 2017
Why is it important
bull Stage by itself or progression to hypertension
SBP (mm Hg) of Total CHD Deaths Pop RR
gt180 72 09
170-179 68 12
160-169 101 27
150-159 195 62
140-149 234 128
130-139 207 228
120-129 99 284
110-119 13 190
lt110 00 61
MRFIT Systolic BP And CHD Mortality Risk Pyramid For Men
Stage 1 429 190 51
Adapted from Stamler et al Arch Intern Med 1993153596
Stage 2 245 46 107
Pre-HTN 306 532 11
Normal 13 251 1
prehypertension was a major unsolved--but soluble--mass public health problem
Prehypertension and stroke risk
Noumerous abnormalities in borderline hypertension according to ProfJulius
bull High cardiac output fast heart rate
bull Abnormal vascular resistance
bull Low plasma volume high hematocrit
bull Several metabolic abnormalities
Age distribution (Slovenia 2009)
0
5
10
15
20
25
30
35
20-29 30-39 40-49 50-59 60-69 70-79 80-89 90-99
Age
Age distribution
Normal BP
New diagnose
HNBP
Hypertension
Risk Factors - Tecumseh BP Study
Normotensive
(n=822) Borderline
(n=124)
p
Cholesterol (mgdL) 176 190 0001
HDL (mgdL) 43 40 001
Triglycerides
(mgdL) 95 135 0001
Insulin (UdL) 12 18 0001
Glucose (mgdL) 92 95 001
Insulin-glucose ratio 0155 0200 0001
Percent overweight 136 301 lt0001
Julius S et al JAMA 1990 264 354-358
Prevalence of prehypertension and hypertension stratified by Visceral Adipose Index and Body Fat Percentage
Hu L Huang X You C Li J Hong K et al (2017) Prevalence and Risk Factors of Prehypertension and Hypertension in Southern China PLOS ONE 12(1) e0170238 doi101371journalpone0170238httpjournalsplosorgplosonearticleid=101371journalpone0170238
PLOS 2017
Framingham Study incidence of hypertension
Vasan LarsonLevy Lancet 2001
Flemish Study Belgiumincidence of hypertension
(781 women 675 men)
Zhang H Fagard R Staessen J J Hypertension 2006
1 summary
bull Prehypertensives are more obese have higher cholesterol levels blood glucose insuline resistance heart rate
bull Stage by itself and progression to hypertension
Letrsquos go for a drink
Definition of prehypertension
stage Outpatient BP
(mmHg)
Home BP
(mmHg)
ABMP (mmHg)
24-h Day-time Night-time
Normotension lt12080
Prehypertension 120-13980-89
Hypertension ge14090 gt13585 gt13080 gt13585 gt12070
BP Thresholds for Definition of Hypertension
High office BP
Normal home BP
ldquoWhite-coatrdquo hypertension
Normal office BP
Normal home BP
ldquoNormotensionrdquo
High office BP
High home BP
Sustained hypertension
Normal office BP
High home BP
Masked hypertension
14090 mmHg
lt13585mmHgHome BP
Office BP
Masked hypertension
0
40
80
120
160
200
0
40
80
120
160
200
12 14 16 18 20 22 0 2 4 6 8 10 12 14
Blo
od
pre
ssure
(mm
Hg)
H
eart
rate
(min
-1)
Time (hour)
Blood pressureHeart rate
Man 20 yearsDaytime 152 87 mm Hg
Night-time 130 71 mm HgNight-time BP Drop -15 -18
Home blood pressure consistently hypertensiveClinic blood pressure 11070 mm Hg target organs damage
12 cohorts
Copenhagen (Denmark)
Dublin (Ireland)
Jingning (China)
Krakoacutew (Poland)
Maracaibo (Venezuela)
Montevideo (Uruguay)
Noorderkempen (Belgium)
Novosibirsk (Russia)
Ohasama (Japan)
Padova (Italy)
Pilsen (Czechia)
Uppsala (Sweden)
To study risk stratification by ABPM in people stratified by CBP
categories The International Database on Ambulatory blood
pressure in relation to Cardiovascular Outcomes (IDACO)
IDACO
Database
Standardised questionnaires
Anthropometric measurements
CBP and ABP
Blood sample (cholesterol glucose etc)
Outcome of participants
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
CV prediction
IDACOdatabase
Cardiovascualr risk based on BP measured in outpatient
8
7
6
5
4
3
2
1
0
0 3 6 9 12 15
20
15
10
05
0
0 3 6 9 12 15
Follow-up (years) Follow-up (years)
CV
eve
nts
(
)
Adjusted for cohort sex age BMI smoking and drinking serum cholesterol CV disease and DM
Cardiovascular events Stroke
Stro
ke(
)
HT
Pre-HT
NT
Plt00001
p=0012
HT
Pre-HT
NT
p=0015
Plt00001
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
05 1 2 4 8 05 1 2 4 8
NT 2441 63 2441 13
NT with masked HT 198 14 198 5
Pre-HT with masked HT 900 90 900 31
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
Daytime BP thresholds ge13585 mmHg
212 (p=00058)
222 (plt00001)
275 (p=0026)
301 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
NT 2527 67 2527 14
NT with masked HT 112 10 112 4
Pre-HT with masked HT 672 74 672 27
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
05 1 2 4 8 05 1 2 4 8
24h BP thresholds ge13080 mmHg
258 (p=00032)
213 (plt00001)
418 (p=00047)
317 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
Home blood pressure and ABPM in detecting masked hypertension (same sample N=128 )
CV riskUpgraded 117Downgraded 148No change 734
Masked hypertensionHome BPM748ABPM 131
MH = masked hypertensionNR = normotensionSH = sustained hypertension
RISHO2014
Baseline to follow-up reproducibility of home blood pressure measurements in tertiles of the follow up duration
RISHO2014
100 120 140 160
-40
-20
0
20
40
CR=176
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=161
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=198
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=218
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=212
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=242
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
a) 1tertile
b) 2tertile
c) 3tertile
Bland and Altman method CR=coefficient of reproducibility twice of SD of the difference between repeated measurement
Observation 24y
43y
59y
Home Blood Pressure as a Predictor of Future Blood Pressure Stability in Borderline HypertensionThe Tecumseh StudyS D Nesbitt J V Amerena EGrant K A Jamerson H Lu A Weder Stevo Julius
JAMA 2016315(23)2564-2575
Characteristics of Colorectal Cancer Screening Strategiesa
Screening for Colorectal Cancer vs ABPM in PrehypertensionUS Preventive Services Task Force Recommendation Statement
PrehypertensionOutpatient BP
Home BPEvery year
ABPMif expected risk MH or
large CV risk
Conformation of MH
Medical treatment on time
Confirmation with ABPM
Treat or not to treat prehypertension this is the question now
bull lifestyle modification for those with prehypertension-the good news is that it works
Ideal cardiovascular health behaviors and factors prevent the development of hypertension inprehypertensive subjects
Gao J Sun H Liang X Gao M Zhao H Qi Y Wang Y Liu Y Li J Zhu Y Zhao Y Wang W Ma L Wu SClinical amp Experimental Hypertension (New York) 37(8)650-5 2015
bull BACKGROUND Seven ideal health metrics were defined by AHA to monitor cardiovascular health This study aimed to investigate the impact of ideal cardiovascular health behaviors and factors on the development of hypertension in prehypertensive subjects
METHODS Thirty-two thousand eight-hundred and eighty-seven participants with prehypertension were included in the study after excluding for preexisting stroke myocardial infarction or malignancy Cox proportional hazards regression was used to calculate hazard ratios and 95 confidence intervals [CI] for the development of hypertension
RESULTS During a follow-up of 522 months 15500 prehypertensive participants developed hypertension The cumulative incidence of hypertension decreased with the number of ideal health metrics increased It was 7861 7108 6315 5607 and 6162 in prehypertensive individuals carrying lt 1 2 3 4 and gt 5 ideal health behaviors or factors respectively After adjustment for age gender family history of hypertension alcohol consumption resting heart rate plasma triglyceride high-density lipoprotein cholesterol low-density lipoprotein cholesterol and high-sensitivity C-reactive protein the risk ratios of incident hypertension in the subjects who carried 2 3 4 and gt 5 ideal health metrics were 0833 (95CI 0789-0880) 0710 (95CI 0672-0749) 0604 (95CI 0568-0642) and 0581 (95CI 0524-0643) respectively in comparison to those with lt 1 ideal health metric A similar trend was also observed in male and female populations Poor health metrics including body mass index diet (salt intake) physical activity total cholesterol and smoking were predictors for the development of hypertension in prehypertensive individuals
CONCLUSION Ideal cardiovascular health behaviors and factors are protective factors to prevent the progression from prehypertension to hypertension
Treat or not to treat prehypertension this is the question now
bull ProfBakris
bull The argument has always been to use lifestyle modification for those with prehypertension-the good news is that it works but the bad news is that nobody does it
How does story continue
bull TROPHY study (candesartan) Julius S Nesbitt SD Egan BM et al Feasibility of treating prehypertension with an angiotensin-receptor blocker N Engl J Med2006354(16)1685-1697
bull PHARAO study (Ramipril) Luumlders S Schrader J Berger J et al The PHARAO study prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure a prospective randomized controlled prevention trial of the German Hypertension League J Hypertens 200826(7)1487-1496
bull Small studies no effect
TROPHY studyKaplan-Meier Curves of New Onset of Clinical
Hypertension in the Two Groups
0 1 2 3 4
Years in study
0
01
02
03
04
05
06
07
08
09
10
C
um
ula
tive
inci
den
ce
Candesartan
Placebo
Candesartan 391 356 309 191 128
Placebo 381 269 184 118 85
Numbers under the graph refer to hypertension-free individuals
2 YearsRR darr66AR darr 26
4 YearsRR darr158AR darr 96
P lt 00001
Julius S NesbittSD N Engl J Med 20063541-13
No effect
bull Lowering the tresholds for the initiation of pharmacologic therapy would have a tremendous economic effect on public health care system (Grassi N Eng J Med 2006)
bull The high-risk strategy identifes and treats those at greatest risk (eg 10y coronary heart disease risk gt20) While there benefits individual the population attributale risk remains significant since most events occur among those at lower risk levels (Egan Nesbitt Julius Therapevtic Advances in CV Disease)
Conclusion for our practice
bull Prehypertension is not an innocent stage and could be dangerous condition
bull It needs to be monitorised excluded masked hypertension
bull Regular blood pressure measurements HBPM ABPM telemonitoring
bull Life style modification versus pharmacological treatment
bull Subclinical organ damage assessmentbull Medical treatment as soon as it is needed
according present ESH guidelines
GBD 2013 Risk Factors Collaborators Lancet Published online September 11 2015
2000 2013
Global DALYs attributed to level 2 risk factors in 2000 and in 2013
When did story begin
bull Probably in 1939 Robinson and Brucer defined BPs in the range of 120-13980-89mmHg as prehypertensive (Robinson SC Brucer M Arch Inter Med 1939 64409-444)
bull 1999 Frolich reported that BP lt 14090mmHg is associated with increased risk for CV disease stroke nad premature death (Frolich ED J Am Coll Cardiol 1999)
When did story begin
Definition of prehypertension and high normal blood pressure
bull The USA Joint National Committee Guidelines (JNC 7) on hypertension published in 2003 unified the normal and high normal blood pressure categories into a single entity termed lsquolsquoprehypertensionrsquorsquo(120-13980-89mmHg)
bull The ESH ESC Committee 2013 has decided not to use this terminologydue to several resones and defined high normal blood pressure
Definitions and classification of blood pressure levels(mmHg)
Category Systolic DiastolicOptimal lt120 and lt80Normal 120ndash129 andor 80ndash84High normal 130ndash139 andor 85ndash89Hypertension gt140 andor gt90
Mortality from ischemic heart disease and stroke increases with increasing blood pressrue
Prospective Studies Collaboration Lancet 20023601903-13
stroke
Ishemic heart disease
Prospective Studies Collaboration Lancet 20023601903-13
Framingham Heart Study (n=6859)
Cumulative Incidence of Cardiovascular Events in Women (Panel A) and Men (Panel B) without
Hypertension According to Blood-Pressure Category at the Base-Line Examination
Vasan Larson et all IMPACT OF HIGH-NORMAL BLOOD PRESSURE ON THE RISK OF CARDIOVASCULAR DISEASE N Engl J Med 2001
Vertical bars indicate 95 percent confidence intervals Optimal blood pressure is a systolic pressure of less than 120 mm Hg and a diastolic pressure of less than 80 mm Hg Normal blood pressure is a systolic pressure of 120 to 129 mm Hg or a diastolic pressure of 80 to 84 mm Hg High-normal blood pressure is a systolic pressure of 130 to 139 mm Hg or a diastolic pressure of 85 to 89 mm Hg If the systolic and diastolic pressure readings for a subject were in different categories the higher of the two categories was used
Prevalence of prehypertension ( 40)bull De Marco M de Simone G Roman MJ Chinali M Lee ET Russell M Howard BV Devereux RBCardiovascular and metabolic
predictors of progression of prehypertension into hypertension the Strong Heart Study Hypertension 2009 Nov54(5)974-80 Epub 2009 Aug 31Strong Heart Study 625 American Indian 45-74y
22 of prevalence of pht 53 among diabetics 33 among non-diabeticHigher BMI SBP DBP pp HR diabetes TG fibrinogen CRP lower HDL higher LVM
bull Zhang Y Lee ET Devereux RB Yeh J Best LG Fabsitz RR Howard BV Prehypertension diabetes and cardiovascular disease risk in a population based sample the Strong Heart Study
Hypertension 2006 Mar47(3)410-4 Epub 2006 Jan 30 Strong Heart Study1532 no diabetic and 1097 diabetics American Indian 55 +-8y
Prevalence of prehypert 594 in diabetics and 482 in non diabeticsIn all age groups from 45-49 to 70-74 diabetics had higher prevalence than non-diabetic and
Kaplan Meier plots showed that prehyperte had higher CV disease incidence and when diabetes was added it was even higher
Only prehypertension was lower than diabetes itself
bull Mainous AG 3rd Everett CJ Liszka H King DE Egan BMPrehypertension and mortality in a nationally representative cohortAm J Cardiol 2004 Dec 1594(12)1496-500NHAES IIstart NH2MS followed 9087 USA 30-74y
31prevalence of pht 37hypertension
bull Liszka HA Mainous AG III King DEEverett CJ Egan BM Prehypertension and cardiovascular morbidity Ann Fam Med 20053294-9NHAES 8986Usa 86white
33prevalence of pht47hypertension
World Hypertension Day Slovenija 2016
(n=2651)
Huang et all Neurology 2014
Prevalenca of prehypertension
Prevalence of prehypertension and hypertension stratified by sex and age
Hu L Huang X You C Li J Hong K et al (2017) Prevalence and Risk Factors of Prehypertension and Hypertension in Southern China PLOS ONE 12(1) e0170238 doi101371journalpone0170238httpjournalsplosorgplosonearticleid=101371journalpone0170238
PLOS 2017
Why is it important
bull Stage by itself or progression to hypertension
SBP (mm Hg) of Total CHD Deaths Pop RR
gt180 72 09
170-179 68 12
160-169 101 27
150-159 195 62
140-149 234 128
130-139 207 228
120-129 99 284
110-119 13 190
lt110 00 61
MRFIT Systolic BP And CHD Mortality Risk Pyramid For Men
Stage 1 429 190 51
Adapted from Stamler et al Arch Intern Med 1993153596
Stage 2 245 46 107
Pre-HTN 306 532 11
Normal 13 251 1
prehypertension was a major unsolved--but soluble--mass public health problem
Prehypertension and stroke risk
Noumerous abnormalities in borderline hypertension according to ProfJulius
bull High cardiac output fast heart rate
bull Abnormal vascular resistance
bull Low plasma volume high hematocrit
bull Several metabolic abnormalities
Age distribution (Slovenia 2009)
0
5
10
15
20
25
30
35
20-29 30-39 40-49 50-59 60-69 70-79 80-89 90-99
Age
Age distribution
Normal BP
New diagnose
HNBP
Hypertension
Risk Factors - Tecumseh BP Study
Normotensive
(n=822) Borderline
(n=124)
p
Cholesterol (mgdL) 176 190 0001
HDL (mgdL) 43 40 001
Triglycerides
(mgdL) 95 135 0001
Insulin (UdL) 12 18 0001
Glucose (mgdL) 92 95 001
Insulin-glucose ratio 0155 0200 0001
Percent overweight 136 301 lt0001
Julius S et al JAMA 1990 264 354-358
Prevalence of prehypertension and hypertension stratified by Visceral Adipose Index and Body Fat Percentage
Hu L Huang X You C Li J Hong K et al (2017) Prevalence and Risk Factors of Prehypertension and Hypertension in Southern China PLOS ONE 12(1) e0170238 doi101371journalpone0170238httpjournalsplosorgplosonearticleid=101371journalpone0170238
PLOS 2017
Framingham Study incidence of hypertension
Vasan LarsonLevy Lancet 2001
Flemish Study Belgiumincidence of hypertension
(781 women 675 men)
Zhang H Fagard R Staessen J J Hypertension 2006
1 summary
bull Prehypertensives are more obese have higher cholesterol levels blood glucose insuline resistance heart rate
bull Stage by itself and progression to hypertension
Letrsquos go for a drink
Definition of prehypertension
stage Outpatient BP
(mmHg)
Home BP
(mmHg)
ABMP (mmHg)
24-h Day-time Night-time
Normotension lt12080
Prehypertension 120-13980-89
Hypertension ge14090 gt13585 gt13080 gt13585 gt12070
BP Thresholds for Definition of Hypertension
High office BP
Normal home BP
ldquoWhite-coatrdquo hypertension
Normal office BP
Normal home BP
ldquoNormotensionrdquo
High office BP
High home BP
Sustained hypertension
Normal office BP
High home BP
Masked hypertension
14090 mmHg
lt13585mmHgHome BP
Office BP
Masked hypertension
0
40
80
120
160
200
0
40
80
120
160
200
12 14 16 18 20 22 0 2 4 6 8 10 12 14
Blo
od
pre
ssure
(mm
Hg)
H
eart
rate
(min
-1)
Time (hour)
Blood pressureHeart rate
Man 20 yearsDaytime 152 87 mm Hg
Night-time 130 71 mm HgNight-time BP Drop -15 -18
Home blood pressure consistently hypertensiveClinic blood pressure 11070 mm Hg target organs damage
12 cohorts
Copenhagen (Denmark)
Dublin (Ireland)
Jingning (China)
Krakoacutew (Poland)
Maracaibo (Venezuela)
Montevideo (Uruguay)
Noorderkempen (Belgium)
Novosibirsk (Russia)
Ohasama (Japan)
Padova (Italy)
Pilsen (Czechia)
Uppsala (Sweden)
To study risk stratification by ABPM in people stratified by CBP
categories The International Database on Ambulatory blood
pressure in relation to Cardiovascular Outcomes (IDACO)
IDACO
Database
Standardised questionnaires
Anthropometric measurements
CBP and ABP
Blood sample (cholesterol glucose etc)
Outcome of participants
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
CV prediction
IDACOdatabase
Cardiovascualr risk based on BP measured in outpatient
8
7
6
5
4
3
2
1
0
0 3 6 9 12 15
20
15
10
05
0
0 3 6 9 12 15
Follow-up (years) Follow-up (years)
CV
eve
nts
(
)
Adjusted for cohort sex age BMI smoking and drinking serum cholesterol CV disease and DM
Cardiovascular events Stroke
Stro
ke(
)
HT
Pre-HT
NT
Plt00001
p=0012
HT
Pre-HT
NT
p=0015
Plt00001
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
05 1 2 4 8 05 1 2 4 8
NT 2441 63 2441 13
NT with masked HT 198 14 198 5
Pre-HT with masked HT 900 90 900 31
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
Daytime BP thresholds ge13585 mmHg
212 (p=00058)
222 (plt00001)
275 (p=0026)
301 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
NT 2527 67 2527 14
NT with masked HT 112 10 112 4
Pre-HT with masked HT 672 74 672 27
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
05 1 2 4 8 05 1 2 4 8
24h BP thresholds ge13080 mmHg
258 (p=00032)
213 (plt00001)
418 (p=00047)
317 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
Home blood pressure and ABPM in detecting masked hypertension (same sample N=128 )
CV riskUpgraded 117Downgraded 148No change 734
Masked hypertensionHome BPM748ABPM 131
MH = masked hypertensionNR = normotensionSH = sustained hypertension
RISHO2014
Baseline to follow-up reproducibility of home blood pressure measurements in tertiles of the follow up duration
RISHO2014
100 120 140 160
-40
-20
0
20
40
CR=176
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=161
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=198
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=218
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=212
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=242
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
a) 1tertile
b) 2tertile
c) 3tertile
Bland and Altman method CR=coefficient of reproducibility twice of SD of the difference between repeated measurement
Observation 24y
43y
59y
Home Blood Pressure as a Predictor of Future Blood Pressure Stability in Borderline HypertensionThe Tecumseh StudyS D Nesbitt J V Amerena EGrant K A Jamerson H Lu A Weder Stevo Julius
JAMA 2016315(23)2564-2575
Characteristics of Colorectal Cancer Screening Strategiesa
Screening for Colorectal Cancer vs ABPM in PrehypertensionUS Preventive Services Task Force Recommendation Statement
PrehypertensionOutpatient BP
Home BPEvery year
ABPMif expected risk MH or
large CV risk
Conformation of MH
Medical treatment on time
Confirmation with ABPM
Treat or not to treat prehypertension this is the question now
bull lifestyle modification for those with prehypertension-the good news is that it works
Ideal cardiovascular health behaviors and factors prevent the development of hypertension inprehypertensive subjects
Gao J Sun H Liang X Gao M Zhao H Qi Y Wang Y Liu Y Li J Zhu Y Zhao Y Wang W Ma L Wu SClinical amp Experimental Hypertension (New York) 37(8)650-5 2015
bull BACKGROUND Seven ideal health metrics were defined by AHA to monitor cardiovascular health This study aimed to investigate the impact of ideal cardiovascular health behaviors and factors on the development of hypertension in prehypertensive subjects
METHODS Thirty-two thousand eight-hundred and eighty-seven participants with prehypertension were included in the study after excluding for preexisting stroke myocardial infarction or malignancy Cox proportional hazards regression was used to calculate hazard ratios and 95 confidence intervals [CI] for the development of hypertension
RESULTS During a follow-up of 522 months 15500 prehypertensive participants developed hypertension The cumulative incidence of hypertension decreased with the number of ideal health metrics increased It was 7861 7108 6315 5607 and 6162 in prehypertensive individuals carrying lt 1 2 3 4 and gt 5 ideal health behaviors or factors respectively After adjustment for age gender family history of hypertension alcohol consumption resting heart rate plasma triglyceride high-density lipoprotein cholesterol low-density lipoprotein cholesterol and high-sensitivity C-reactive protein the risk ratios of incident hypertension in the subjects who carried 2 3 4 and gt 5 ideal health metrics were 0833 (95CI 0789-0880) 0710 (95CI 0672-0749) 0604 (95CI 0568-0642) and 0581 (95CI 0524-0643) respectively in comparison to those with lt 1 ideal health metric A similar trend was also observed in male and female populations Poor health metrics including body mass index diet (salt intake) physical activity total cholesterol and smoking were predictors for the development of hypertension in prehypertensive individuals
CONCLUSION Ideal cardiovascular health behaviors and factors are protective factors to prevent the progression from prehypertension to hypertension
Treat or not to treat prehypertension this is the question now
bull ProfBakris
bull The argument has always been to use lifestyle modification for those with prehypertension-the good news is that it works but the bad news is that nobody does it
How does story continue
bull TROPHY study (candesartan) Julius S Nesbitt SD Egan BM et al Feasibility of treating prehypertension with an angiotensin-receptor blocker N Engl J Med2006354(16)1685-1697
bull PHARAO study (Ramipril) Luumlders S Schrader J Berger J et al The PHARAO study prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure a prospective randomized controlled prevention trial of the German Hypertension League J Hypertens 200826(7)1487-1496
bull Small studies no effect
TROPHY studyKaplan-Meier Curves of New Onset of Clinical
Hypertension in the Two Groups
0 1 2 3 4
Years in study
0
01
02
03
04
05
06
07
08
09
10
C
um
ula
tive
inci
den
ce
Candesartan
Placebo
Candesartan 391 356 309 191 128
Placebo 381 269 184 118 85
Numbers under the graph refer to hypertension-free individuals
2 YearsRR darr66AR darr 26
4 YearsRR darr158AR darr 96
P lt 00001
Julius S NesbittSD N Engl J Med 20063541-13
No effect
bull Lowering the tresholds for the initiation of pharmacologic therapy would have a tremendous economic effect on public health care system (Grassi N Eng J Med 2006)
bull The high-risk strategy identifes and treats those at greatest risk (eg 10y coronary heart disease risk gt20) While there benefits individual the population attributale risk remains significant since most events occur among those at lower risk levels (Egan Nesbitt Julius Therapevtic Advances in CV Disease)
Conclusion for our practice
bull Prehypertension is not an innocent stage and could be dangerous condition
bull It needs to be monitorised excluded masked hypertension
bull Regular blood pressure measurements HBPM ABPM telemonitoring
bull Life style modification versus pharmacological treatment
bull Subclinical organ damage assessmentbull Medical treatment as soon as it is needed
according present ESH guidelines
When did story begin
bull Probably in 1939 Robinson and Brucer defined BPs in the range of 120-13980-89mmHg as prehypertensive (Robinson SC Brucer M Arch Inter Med 1939 64409-444)
bull 1999 Frolich reported that BP lt 14090mmHg is associated with increased risk for CV disease stroke nad premature death (Frolich ED J Am Coll Cardiol 1999)
When did story begin
Definition of prehypertension and high normal blood pressure
bull The USA Joint National Committee Guidelines (JNC 7) on hypertension published in 2003 unified the normal and high normal blood pressure categories into a single entity termed lsquolsquoprehypertensionrsquorsquo(120-13980-89mmHg)
bull The ESH ESC Committee 2013 has decided not to use this terminologydue to several resones and defined high normal blood pressure
Definitions and classification of blood pressure levels(mmHg)
Category Systolic DiastolicOptimal lt120 and lt80Normal 120ndash129 andor 80ndash84High normal 130ndash139 andor 85ndash89Hypertension gt140 andor gt90
Mortality from ischemic heart disease and stroke increases with increasing blood pressrue
Prospective Studies Collaboration Lancet 20023601903-13
stroke
Ishemic heart disease
Prospective Studies Collaboration Lancet 20023601903-13
Framingham Heart Study (n=6859)
Cumulative Incidence of Cardiovascular Events in Women (Panel A) and Men (Panel B) without
Hypertension According to Blood-Pressure Category at the Base-Line Examination
Vasan Larson et all IMPACT OF HIGH-NORMAL BLOOD PRESSURE ON THE RISK OF CARDIOVASCULAR DISEASE N Engl J Med 2001
Vertical bars indicate 95 percent confidence intervals Optimal blood pressure is a systolic pressure of less than 120 mm Hg and a diastolic pressure of less than 80 mm Hg Normal blood pressure is a systolic pressure of 120 to 129 mm Hg or a diastolic pressure of 80 to 84 mm Hg High-normal blood pressure is a systolic pressure of 130 to 139 mm Hg or a diastolic pressure of 85 to 89 mm Hg If the systolic and diastolic pressure readings for a subject were in different categories the higher of the two categories was used
Prevalence of prehypertension ( 40)bull De Marco M de Simone G Roman MJ Chinali M Lee ET Russell M Howard BV Devereux RBCardiovascular and metabolic
predictors of progression of prehypertension into hypertension the Strong Heart Study Hypertension 2009 Nov54(5)974-80 Epub 2009 Aug 31Strong Heart Study 625 American Indian 45-74y
22 of prevalence of pht 53 among diabetics 33 among non-diabeticHigher BMI SBP DBP pp HR diabetes TG fibrinogen CRP lower HDL higher LVM
bull Zhang Y Lee ET Devereux RB Yeh J Best LG Fabsitz RR Howard BV Prehypertension diabetes and cardiovascular disease risk in a population based sample the Strong Heart Study
Hypertension 2006 Mar47(3)410-4 Epub 2006 Jan 30 Strong Heart Study1532 no diabetic and 1097 diabetics American Indian 55 +-8y
Prevalence of prehypert 594 in diabetics and 482 in non diabeticsIn all age groups from 45-49 to 70-74 diabetics had higher prevalence than non-diabetic and
Kaplan Meier plots showed that prehyperte had higher CV disease incidence and when diabetes was added it was even higher
Only prehypertension was lower than diabetes itself
bull Mainous AG 3rd Everett CJ Liszka H King DE Egan BMPrehypertension and mortality in a nationally representative cohortAm J Cardiol 2004 Dec 1594(12)1496-500NHAES IIstart NH2MS followed 9087 USA 30-74y
31prevalence of pht 37hypertension
bull Liszka HA Mainous AG III King DEEverett CJ Egan BM Prehypertension and cardiovascular morbidity Ann Fam Med 20053294-9NHAES 8986Usa 86white
33prevalence of pht47hypertension
World Hypertension Day Slovenija 2016
(n=2651)
Huang et all Neurology 2014
Prevalenca of prehypertension
Prevalence of prehypertension and hypertension stratified by sex and age
Hu L Huang X You C Li J Hong K et al (2017) Prevalence and Risk Factors of Prehypertension and Hypertension in Southern China PLOS ONE 12(1) e0170238 doi101371journalpone0170238httpjournalsplosorgplosonearticleid=101371journalpone0170238
PLOS 2017
Why is it important
bull Stage by itself or progression to hypertension
SBP (mm Hg) of Total CHD Deaths Pop RR
gt180 72 09
170-179 68 12
160-169 101 27
150-159 195 62
140-149 234 128
130-139 207 228
120-129 99 284
110-119 13 190
lt110 00 61
MRFIT Systolic BP And CHD Mortality Risk Pyramid For Men
Stage 1 429 190 51
Adapted from Stamler et al Arch Intern Med 1993153596
Stage 2 245 46 107
Pre-HTN 306 532 11
Normal 13 251 1
prehypertension was a major unsolved--but soluble--mass public health problem
Prehypertension and stroke risk
Noumerous abnormalities in borderline hypertension according to ProfJulius
bull High cardiac output fast heart rate
bull Abnormal vascular resistance
bull Low plasma volume high hematocrit
bull Several metabolic abnormalities
Age distribution (Slovenia 2009)
0
5
10
15
20
25
30
35
20-29 30-39 40-49 50-59 60-69 70-79 80-89 90-99
Age
Age distribution
Normal BP
New diagnose
HNBP
Hypertension
Risk Factors - Tecumseh BP Study
Normotensive
(n=822) Borderline
(n=124)
p
Cholesterol (mgdL) 176 190 0001
HDL (mgdL) 43 40 001
Triglycerides
(mgdL) 95 135 0001
Insulin (UdL) 12 18 0001
Glucose (mgdL) 92 95 001
Insulin-glucose ratio 0155 0200 0001
Percent overweight 136 301 lt0001
Julius S et al JAMA 1990 264 354-358
Prevalence of prehypertension and hypertension stratified by Visceral Adipose Index and Body Fat Percentage
Hu L Huang X You C Li J Hong K et al (2017) Prevalence and Risk Factors of Prehypertension and Hypertension in Southern China PLOS ONE 12(1) e0170238 doi101371journalpone0170238httpjournalsplosorgplosonearticleid=101371journalpone0170238
PLOS 2017
Framingham Study incidence of hypertension
Vasan LarsonLevy Lancet 2001
Flemish Study Belgiumincidence of hypertension
(781 women 675 men)
Zhang H Fagard R Staessen J J Hypertension 2006
1 summary
bull Prehypertensives are more obese have higher cholesterol levels blood glucose insuline resistance heart rate
bull Stage by itself and progression to hypertension
Letrsquos go for a drink
Definition of prehypertension
stage Outpatient BP
(mmHg)
Home BP
(mmHg)
ABMP (mmHg)
24-h Day-time Night-time
Normotension lt12080
Prehypertension 120-13980-89
Hypertension ge14090 gt13585 gt13080 gt13585 gt12070
BP Thresholds for Definition of Hypertension
High office BP
Normal home BP
ldquoWhite-coatrdquo hypertension
Normal office BP
Normal home BP
ldquoNormotensionrdquo
High office BP
High home BP
Sustained hypertension
Normal office BP
High home BP
Masked hypertension
14090 mmHg
lt13585mmHgHome BP
Office BP
Masked hypertension
0
40
80
120
160
200
0
40
80
120
160
200
12 14 16 18 20 22 0 2 4 6 8 10 12 14
Blo
od
pre
ssure
(mm
Hg)
H
eart
rate
(min
-1)
Time (hour)
Blood pressureHeart rate
Man 20 yearsDaytime 152 87 mm Hg
Night-time 130 71 mm HgNight-time BP Drop -15 -18
Home blood pressure consistently hypertensiveClinic blood pressure 11070 mm Hg target organs damage
12 cohorts
Copenhagen (Denmark)
Dublin (Ireland)
Jingning (China)
Krakoacutew (Poland)
Maracaibo (Venezuela)
Montevideo (Uruguay)
Noorderkempen (Belgium)
Novosibirsk (Russia)
Ohasama (Japan)
Padova (Italy)
Pilsen (Czechia)
Uppsala (Sweden)
To study risk stratification by ABPM in people stratified by CBP
categories The International Database on Ambulatory blood
pressure in relation to Cardiovascular Outcomes (IDACO)
IDACO
Database
Standardised questionnaires
Anthropometric measurements
CBP and ABP
Blood sample (cholesterol glucose etc)
Outcome of participants
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
CV prediction
IDACOdatabase
Cardiovascualr risk based on BP measured in outpatient
8
7
6
5
4
3
2
1
0
0 3 6 9 12 15
20
15
10
05
0
0 3 6 9 12 15
Follow-up (years) Follow-up (years)
CV
eve
nts
(
)
Adjusted for cohort sex age BMI smoking and drinking serum cholesterol CV disease and DM
Cardiovascular events Stroke
Stro
ke(
)
HT
Pre-HT
NT
Plt00001
p=0012
HT
Pre-HT
NT
p=0015
Plt00001
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
05 1 2 4 8 05 1 2 4 8
NT 2441 63 2441 13
NT with masked HT 198 14 198 5
Pre-HT with masked HT 900 90 900 31
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
Daytime BP thresholds ge13585 mmHg
212 (p=00058)
222 (plt00001)
275 (p=0026)
301 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
NT 2527 67 2527 14
NT with masked HT 112 10 112 4
Pre-HT with masked HT 672 74 672 27
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
05 1 2 4 8 05 1 2 4 8
24h BP thresholds ge13080 mmHg
258 (p=00032)
213 (plt00001)
418 (p=00047)
317 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
Home blood pressure and ABPM in detecting masked hypertension (same sample N=128 )
CV riskUpgraded 117Downgraded 148No change 734
Masked hypertensionHome BPM748ABPM 131
MH = masked hypertensionNR = normotensionSH = sustained hypertension
RISHO2014
Baseline to follow-up reproducibility of home blood pressure measurements in tertiles of the follow up duration
RISHO2014
100 120 140 160
-40
-20
0
20
40
CR=176
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=161
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=198
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=218
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=212
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=242
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
a) 1tertile
b) 2tertile
c) 3tertile
Bland and Altman method CR=coefficient of reproducibility twice of SD of the difference between repeated measurement
Observation 24y
43y
59y
Home Blood Pressure as a Predictor of Future Blood Pressure Stability in Borderline HypertensionThe Tecumseh StudyS D Nesbitt J V Amerena EGrant K A Jamerson H Lu A Weder Stevo Julius
JAMA 2016315(23)2564-2575
Characteristics of Colorectal Cancer Screening Strategiesa
Screening for Colorectal Cancer vs ABPM in PrehypertensionUS Preventive Services Task Force Recommendation Statement
PrehypertensionOutpatient BP
Home BPEvery year
ABPMif expected risk MH or
large CV risk
Conformation of MH
Medical treatment on time
Confirmation with ABPM
Treat or not to treat prehypertension this is the question now
bull lifestyle modification for those with prehypertension-the good news is that it works
Ideal cardiovascular health behaviors and factors prevent the development of hypertension inprehypertensive subjects
Gao J Sun H Liang X Gao M Zhao H Qi Y Wang Y Liu Y Li J Zhu Y Zhao Y Wang W Ma L Wu SClinical amp Experimental Hypertension (New York) 37(8)650-5 2015
bull BACKGROUND Seven ideal health metrics were defined by AHA to monitor cardiovascular health This study aimed to investigate the impact of ideal cardiovascular health behaviors and factors on the development of hypertension in prehypertensive subjects
METHODS Thirty-two thousand eight-hundred and eighty-seven participants with prehypertension were included in the study after excluding for preexisting stroke myocardial infarction or malignancy Cox proportional hazards regression was used to calculate hazard ratios and 95 confidence intervals [CI] for the development of hypertension
RESULTS During a follow-up of 522 months 15500 prehypertensive participants developed hypertension The cumulative incidence of hypertension decreased with the number of ideal health metrics increased It was 7861 7108 6315 5607 and 6162 in prehypertensive individuals carrying lt 1 2 3 4 and gt 5 ideal health behaviors or factors respectively After adjustment for age gender family history of hypertension alcohol consumption resting heart rate plasma triglyceride high-density lipoprotein cholesterol low-density lipoprotein cholesterol and high-sensitivity C-reactive protein the risk ratios of incident hypertension in the subjects who carried 2 3 4 and gt 5 ideal health metrics were 0833 (95CI 0789-0880) 0710 (95CI 0672-0749) 0604 (95CI 0568-0642) and 0581 (95CI 0524-0643) respectively in comparison to those with lt 1 ideal health metric A similar trend was also observed in male and female populations Poor health metrics including body mass index diet (salt intake) physical activity total cholesterol and smoking were predictors for the development of hypertension in prehypertensive individuals
CONCLUSION Ideal cardiovascular health behaviors and factors are protective factors to prevent the progression from prehypertension to hypertension
Treat or not to treat prehypertension this is the question now
bull ProfBakris
bull The argument has always been to use lifestyle modification for those with prehypertension-the good news is that it works but the bad news is that nobody does it
How does story continue
bull TROPHY study (candesartan) Julius S Nesbitt SD Egan BM et al Feasibility of treating prehypertension with an angiotensin-receptor blocker N Engl J Med2006354(16)1685-1697
bull PHARAO study (Ramipril) Luumlders S Schrader J Berger J et al The PHARAO study prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure a prospective randomized controlled prevention trial of the German Hypertension League J Hypertens 200826(7)1487-1496
bull Small studies no effect
TROPHY studyKaplan-Meier Curves of New Onset of Clinical
Hypertension in the Two Groups
0 1 2 3 4
Years in study
0
01
02
03
04
05
06
07
08
09
10
C
um
ula
tive
inci
den
ce
Candesartan
Placebo
Candesartan 391 356 309 191 128
Placebo 381 269 184 118 85
Numbers under the graph refer to hypertension-free individuals
2 YearsRR darr66AR darr 26
4 YearsRR darr158AR darr 96
P lt 00001
Julius S NesbittSD N Engl J Med 20063541-13
No effect
bull Lowering the tresholds for the initiation of pharmacologic therapy would have a tremendous economic effect on public health care system (Grassi N Eng J Med 2006)
bull The high-risk strategy identifes and treats those at greatest risk (eg 10y coronary heart disease risk gt20) While there benefits individual the population attributale risk remains significant since most events occur among those at lower risk levels (Egan Nesbitt Julius Therapevtic Advances in CV Disease)
Conclusion for our practice
bull Prehypertension is not an innocent stage and could be dangerous condition
bull It needs to be monitorised excluded masked hypertension
bull Regular blood pressure measurements HBPM ABPM telemonitoring
bull Life style modification versus pharmacological treatment
bull Subclinical organ damage assessmentbull Medical treatment as soon as it is needed
according present ESH guidelines
When did story begin
Definition of prehypertension and high normal blood pressure
bull The USA Joint National Committee Guidelines (JNC 7) on hypertension published in 2003 unified the normal and high normal blood pressure categories into a single entity termed lsquolsquoprehypertensionrsquorsquo(120-13980-89mmHg)
bull The ESH ESC Committee 2013 has decided not to use this terminologydue to several resones and defined high normal blood pressure
Definitions and classification of blood pressure levels(mmHg)
Category Systolic DiastolicOptimal lt120 and lt80Normal 120ndash129 andor 80ndash84High normal 130ndash139 andor 85ndash89Hypertension gt140 andor gt90
Mortality from ischemic heart disease and stroke increases with increasing blood pressrue
Prospective Studies Collaboration Lancet 20023601903-13
stroke
Ishemic heart disease
Prospective Studies Collaboration Lancet 20023601903-13
Framingham Heart Study (n=6859)
Cumulative Incidence of Cardiovascular Events in Women (Panel A) and Men (Panel B) without
Hypertension According to Blood-Pressure Category at the Base-Line Examination
Vasan Larson et all IMPACT OF HIGH-NORMAL BLOOD PRESSURE ON THE RISK OF CARDIOVASCULAR DISEASE N Engl J Med 2001
Vertical bars indicate 95 percent confidence intervals Optimal blood pressure is a systolic pressure of less than 120 mm Hg and a diastolic pressure of less than 80 mm Hg Normal blood pressure is a systolic pressure of 120 to 129 mm Hg or a diastolic pressure of 80 to 84 mm Hg High-normal blood pressure is a systolic pressure of 130 to 139 mm Hg or a diastolic pressure of 85 to 89 mm Hg If the systolic and diastolic pressure readings for a subject were in different categories the higher of the two categories was used
Prevalence of prehypertension ( 40)bull De Marco M de Simone G Roman MJ Chinali M Lee ET Russell M Howard BV Devereux RBCardiovascular and metabolic
predictors of progression of prehypertension into hypertension the Strong Heart Study Hypertension 2009 Nov54(5)974-80 Epub 2009 Aug 31Strong Heart Study 625 American Indian 45-74y
22 of prevalence of pht 53 among diabetics 33 among non-diabeticHigher BMI SBP DBP pp HR diabetes TG fibrinogen CRP lower HDL higher LVM
bull Zhang Y Lee ET Devereux RB Yeh J Best LG Fabsitz RR Howard BV Prehypertension diabetes and cardiovascular disease risk in a population based sample the Strong Heart Study
Hypertension 2006 Mar47(3)410-4 Epub 2006 Jan 30 Strong Heart Study1532 no diabetic and 1097 diabetics American Indian 55 +-8y
Prevalence of prehypert 594 in diabetics and 482 in non diabeticsIn all age groups from 45-49 to 70-74 diabetics had higher prevalence than non-diabetic and
Kaplan Meier plots showed that prehyperte had higher CV disease incidence and when diabetes was added it was even higher
Only prehypertension was lower than diabetes itself
bull Mainous AG 3rd Everett CJ Liszka H King DE Egan BMPrehypertension and mortality in a nationally representative cohortAm J Cardiol 2004 Dec 1594(12)1496-500NHAES IIstart NH2MS followed 9087 USA 30-74y
31prevalence of pht 37hypertension
bull Liszka HA Mainous AG III King DEEverett CJ Egan BM Prehypertension and cardiovascular morbidity Ann Fam Med 20053294-9NHAES 8986Usa 86white
33prevalence of pht47hypertension
World Hypertension Day Slovenija 2016
(n=2651)
Huang et all Neurology 2014
Prevalenca of prehypertension
Prevalence of prehypertension and hypertension stratified by sex and age
Hu L Huang X You C Li J Hong K et al (2017) Prevalence and Risk Factors of Prehypertension and Hypertension in Southern China PLOS ONE 12(1) e0170238 doi101371journalpone0170238httpjournalsplosorgplosonearticleid=101371journalpone0170238
PLOS 2017
Why is it important
bull Stage by itself or progression to hypertension
SBP (mm Hg) of Total CHD Deaths Pop RR
gt180 72 09
170-179 68 12
160-169 101 27
150-159 195 62
140-149 234 128
130-139 207 228
120-129 99 284
110-119 13 190
lt110 00 61
MRFIT Systolic BP And CHD Mortality Risk Pyramid For Men
Stage 1 429 190 51
Adapted from Stamler et al Arch Intern Med 1993153596
Stage 2 245 46 107
Pre-HTN 306 532 11
Normal 13 251 1
prehypertension was a major unsolved--but soluble--mass public health problem
Prehypertension and stroke risk
Noumerous abnormalities in borderline hypertension according to ProfJulius
bull High cardiac output fast heart rate
bull Abnormal vascular resistance
bull Low plasma volume high hematocrit
bull Several metabolic abnormalities
Age distribution (Slovenia 2009)
0
5
10
15
20
25
30
35
20-29 30-39 40-49 50-59 60-69 70-79 80-89 90-99
Age
Age distribution
Normal BP
New diagnose
HNBP
Hypertension
Risk Factors - Tecumseh BP Study
Normotensive
(n=822) Borderline
(n=124)
p
Cholesterol (mgdL) 176 190 0001
HDL (mgdL) 43 40 001
Triglycerides
(mgdL) 95 135 0001
Insulin (UdL) 12 18 0001
Glucose (mgdL) 92 95 001
Insulin-glucose ratio 0155 0200 0001
Percent overweight 136 301 lt0001
Julius S et al JAMA 1990 264 354-358
Prevalence of prehypertension and hypertension stratified by Visceral Adipose Index and Body Fat Percentage
Hu L Huang X You C Li J Hong K et al (2017) Prevalence and Risk Factors of Prehypertension and Hypertension in Southern China PLOS ONE 12(1) e0170238 doi101371journalpone0170238httpjournalsplosorgplosonearticleid=101371journalpone0170238
PLOS 2017
Framingham Study incidence of hypertension
Vasan LarsonLevy Lancet 2001
Flemish Study Belgiumincidence of hypertension
(781 women 675 men)
Zhang H Fagard R Staessen J J Hypertension 2006
1 summary
bull Prehypertensives are more obese have higher cholesterol levels blood glucose insuline resistance heart rate
bull Stage by itself and progression to hypertension
Letrsquos go for a drink
Definition of prehypertension
stage Outpatient BP
(mmHg)
Home BP
(mmHg)
ABMP (mmHg)
24-h Day-time Night-time
Normotension lt12080
Prehypertension 120-13980-89
Hypertension ge14090 gt13585 gt13080 gt13585 gt12070
BP Thresholds for Definition of Hypertension
High office BP
Normal home BP
ldquoWhite-coatrdquo hypertension
Normal office BP
Normal home BP
ldquoNormotensionrdquo
High office BP
High home BP
Sustained hypertension
Normal office BP
High home BP
Masked hypertension
14090 mmHg
lt13585mmHgHome BP
Office BP
Masked hypertension
0
40
80
120
160
200
0
40
80
120
160
200
12 14 16 18 20 22 0 2 4 6 8 10 12 14
Blo
od
pre
ssure
(mm
Hg)
H
eart
rate
(min
-1)
Time (hour)
Blood pressureHeart rate
Man 20 yearsDaytime 152 87 mm Hg
Night-time 130 71 mm HgNight-time BP Drop -15 -18
Home blood pressure consistently hypertensiveClinic blood pressure 11070 mm Hg target organs damage
12 cohorts
Copenhagen (Denmark)
Dublin (Ireland)
Jingning (China)
Krakoacutew (Poland)
Maracaibo (Venezuela)
Montevideo (Uruguay)
Noorderkempen (Belgium)
Novosibirsk (Russia)
Ohasama (Japan)
Padova (Italy)
Pilsen (Czechia)
Uppsala (Sweden)
To study risk stratification by ABPM in people stratified by CBP
categories The International Database on Ambulatory blood
pressure in relation to Cardiovascular Outcomes (IDACO)
IDACO
Database
Standardised questionnaires
Anthropometric measurements
CBP and ABP
Blood sample (cholesterol glucose etc)
Outcome of participants
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
CV prediction
IDACOdatabase
Cardiovascualr risk based on BP measured in outpatient
8
7
6
5
4
3
2
1
0
0 3 6 9 12 15
20
15
10
05
0
0 3 6 9 12 15
Follow-up (years) Follow-up (years)
CV
eve
nts
(
)
Adjusted for cohort sex age BMI smoking and drinking serum cholesterol CV disease and DM
Cardiovascular events Stroke
Stro
ke(
)
HT
Pre-HT
NT
Plt00001
p=0012
HT
Pre-HT
NT
p=0015
Plt00001
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
05 1 2 4 8 05 1 2 4 8
NT 2441 63 2441 13
NT with masked HT 198 14 198 5
Pre-HT with masked HT 900 90 900 31
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
Daytime BP thresholds ge13585 mmHg
212 (p=00058)
222 (plt00001)
275 (p=0026)
301 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
NT 2527 67 2527 14
NT with masked HT 112 10 112 4
Pre-HT with masked HT 672 74 672 27
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
05 1 2 4 8 05 1 2 4 8
24h BP thresholds ge13080 mmHg
258 (p=00032)
213 (plt00001)
418 (p=00047)
317 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
Home blood pressure and ABPM in detecting masked hypertension (same sample N=128 )
CV riskUpgraded 117Downgraded 148No change 734
Masked hypertensionHome BPM748ABPM 131
MH = masked hypertensionNR = normotensionSH = sustained hypertension
RISHO2014
Baseline to follow-up reproducibility of home blood pressure measurements in tertiles of the follow up duration
RISHO2014
100 120 140 160
-40
-20
0
20
40
CR=176
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=161
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=198
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=218
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=212
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=242
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
a) 1tertile
b) 2tertile
c) 3tertile
Bland and Altman method CR=coefficient of reproducibility twice of SD of the difference between repeated measurement
Observation 24y
43y
59y
Home Blood Pressure as a Predictor of Future Blood Pressure Stability in Borderline HypertensionThe Tecumseh StudyS D Nesbitt J V Amerena EGrant K A Jamerson H Lu A Weder Stevo Julius
JAMA 2016315(23)2564-2575
Characteristics of Colorectal Cancer Screening Strategiesa
Screening for Colorectal Cancer vs ABPM in PrehypertensionUS Preventive Services Task Force Recommendation Statement
PrehypertensionOutpatient BP
Home BPEvery year
ABPMif expected risk MH or
large CV risk
Conformation of MH
Medical treatment on time
Confirmation with ABPM
Treat or not to treat prehypertension this is the question now
bull lifestyle modification for those with prehypertension-the good news is that it works
Ideal cardiovascular health behaviors and factors prevent the development of hypertension inprehypertensive subjects
Gao J Sun H Liang X Gao M Zhao H Qi Y Wang Y Liu Y Li J Zhu Y Zhao Y Wang W Ma L Wu SClinical amp Experimental Hypertension (New York) 37(8)650-5 2015
bull BACKGROUND Seven ideal health metrics were defined by AHA to monitor cardiovascular health This study aimed to investigate the impact of ideal cardiovascular health behaviors and factors on the development of hypertension in prehypertensive subjects
METHODS Thirty-two thousand eight-hundred and eighty-seven participants with prehypertension were included in the study after excluding for preexisting stroke myocardial infarction or malignancy Cox proportional hazards regression was used to calculate hazard ratios and 95 confidence intervals [CI] for the development of hypertension
RESULTS During a follow-up of 522 months 15500 prehypertensive participants developed hypertension The cumulative incidence of hypertension decreased with the number of ideal health metrics increased It was 7861 7108 6315 5607 and 6162 in prehypertensive individuals carrying lt 1 2 3 4 and gt 5 ideal health behaviors or factors respectively After adjustment for age gender family history of hypertension alcohol consumption resting heart rate plasma triglyceride high-density lipoprotein cholesterol low-density lipoprotein cholesterol and high-sensitivity C-reactive protein the risk ratios of incident hypertension in the subjects who carried 2 3 4 and gt 5 ideal health metrics were 0833 (95CI 0789-0880) 0710 (95CI 0672-0749) 0604 (95CI 0568-0642) and 0581 (95CI 0524-0643) respectively in comparison to those with lt 1 ideal health metric A similar trend was also observed in male and female populations Poor health metrics including body mass index diet (salt intake) physical activity total cholesterol and smoking were predictors for the development of hypertension in prehypertensive individuals
CONCLUSION Ideal cardiovascular health behaviors and factors are protective factors to prevent the progression from prehypertension to hypertension
Treat or not to treat prehypertension this is the question now
bull ProfBakris
bull The argument has always been to use lifestyle modification for those with prehypertension-the good news is that it works but the bad news is that nobody does it
How does story continue
bull TROPHY study (candesartan) Julius S Nesbitt SD Egan BM et al Feasibility of treating prehypertension with an angiotensin-receptor blocker N Engl J Med2006354(16)1685-1697
bull PHARAO study (Ramipril) Luumlders S Schrader J Berger J et al The PHARAO study prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure a prospective randomized controlled prevention trial of the German Hypertension League J Hypertens 200826(7)1487-1496
bull Small studies no effect
TROPHY studyKaplan-Meier Curves of New Onset of Clinical
Hypertension in the Two Groups
0 1 2 3 4
Years in study
0
01
02
03
04
05
06
07
08
09
10
C
um
ula
tive
inci
den
ce
Candesartan
Placebo
Candesartan 391 356 309 191 128
Placebo 381 269 184 118 85
Numbers under the graph refer to hypertension-free individuals
2 YearsRR darr66AR darr 26
4 YearsRR darr158AR darr 96
P lt 00001
Julius S NesbittSD N Engl J Med 20063541-13
No effect
bull Lowering the tresholds for the initiation of pharmacologic therapy would have a tremendous economic effect on public health care system (Grassi N Eng J Med 2006)
bull The high-risk strategy identifes and treats those at greatest risk (eg 10y coronary heart disease risk gt20) While there benefits individual the population attributale risk remains significant since most events occur among those at lower risk levels (Egan Nesbitt Julius Therapevtic Advances in CV Disease)
Conclusion for our practice
bull Prehypertension is not an innocent stage and could be dangerous condition
bull It needs to be monitorised excluded masked hypertension
bull Regular blood pressure measurements HBPM ABPM telemonitoring
bull Life style modification versus pharmacological treatment
bull Subclinical organ damage assessmentbull Medical treatment as soon as it is needed
according present ESH guidelines
Definition of prehypertension and high normal blood pressure
bull The USA Joint National Committee Guidelines (JNC 7) on hypertension published in 2003 unified the normal and high normal blood pressure categories into a single entity termed lsquolsquoprehypertensionrsquorsquo(120-13980-89mmHg)
bull The ESH ESC Committee 2013 has decided not to use this terminologydue to several resones and defined high normal blood pressure
Definitions and classification of blood pressure levels(mmHg)
Category Systolic DiastolicOptimal lt120 and lt80Normal 120ndash129 andor 80ndash84High normal 130ndash139 andor 85ndash89Hypertension gt140 andor gt90
Mortality from ischemic heart disease and stroke increases with increasing blood pressrue
Prospective Studies Collaboration Lancet 20023601903-13
stroke
Ishemic heart disease
Prospective Studies Collaboration Lancet 20023601903-13
Framingham Heart Study (n=6859)
Cumulative Incidence of Cardiovascular Events in Women (Panel A) and Men (Panel B) without
Hypertension According to Blood-Pressure Category at the Base-Line Examination
Vasan Larson et all IMPACT OF HIGH-NORMAL BLOOD PRESSURE ON THE RISK OF CARDIOVASCULAR DISEASE N Engl J Med 2001
Vertical bars indicate 95 percent confidence intervals Optimal blood pressure is a systolic pressure of less than 120 mm Hg and a diastolic pressure of less than 80 mm Hg Normal blood pressure is a systolic pressure of 120 to 129 mm Hg or a diastolic pressure of 80 to 84 mm Hg High-normal blood pressure is a systolic pressure of 130 to 139 mm Hg or a diastolic pressure of 85 to 89 mm Hg If the systolic and diastolic pressure readings for a subject were in different categories the higher of the two categories was used
Prevalence of prehypertension ( 40)bull De Marco M de Simone G Roman MJ Chinali M Lee ET Russell M Howard BV Devereux RBCardiovascular and metabolic
predictors of progression of prehypertension into hypertension the Strong Heart Study Hypertension 2009 Nov54(5)974-80 Epub 2009 Aug 31Strong Heart Study 625 American Indian 45-74y
22 of prevalence of pht 53 among diabetics 33 among non-diabeticHigher BMI SBP DBP pp HR diabetes TG fibrinogen CRP lower HDL higher LVM
bull Zhang Y Lee ET Devereux RB Yeh J Best LG Fabsitz RR Howard BV Prehypertension diabetes and cardiovascular disease risk in a population based sample the Strong Heart Study
Hypertension 2006 Mar47(3)410-4 Epub 2006 Jan 30 Strong Heart Study1532 no diabetic and 1097 diabetics American Indian 55 +-8y
Prevalence of prehypert 594 in diabetics and 482 in non diabeticsIn all age groups from 45-49 to 70-74 diabetics had higher prevalence than non-diabetic and
Kaplan Meier plots showed that prehyperte had higher CV disease incidence and when diabetes was added it was even higher
Only prehypertension was lower than diabetes itself
bull Mainous AG 3rd Everett CJ Liszka H King DE Egan BMPrehypertension and mortality in a nationally representative cohortAm J Cardiol 2004 Dec 1594(12)1496-500NHAES IIstart NH2MS followed 9087 USA 30-74y
31prevalence of pht 37hypertension
bull Liszka HA Mainous AG III King DEEverett CJ Egan BM Prehypertension and cardiovascular morbidity Ann Fam Med 20053294-9NHAES 8986Usa 86white
33prevalence of pht47hypertension
World Hypertension Day Slovenija 2016
(n=2651)
Huang et all Neurology 2014
Prevalenca of prehypertension
Prevalence of prehypertension and hypertension stratified by sex and age
Hu L Huang X You C Li J Hong K et al (2017) Prevalence and Risk Factors of Prehypertension and Hypertension in Southern China PLOS ONE 12(1) e0170238 doi101371journalpone0170238httpjournalsplosorgplosonearticleid=101371journalpone0170238
PLOS 2017
Why is it important
bull Stage by itself or progression to hypertension
SBP (mm Hg) of Total CHD Deaths Pop RR
gt180 72 09
170-179 68 12
160-169 101 27
150-159 195 62
140-149 234 128
130-139 207 228
120-129 99 284
110-119 13 190
lt110 00 61
MRFIT Systolic BP And CHD Mortality Risk Pyramid For Men
Stage 1 429 190 51
Adapted from Stamler et al Arch Intern Med 1993153596
Stage 2 245 46 107
Pre-HTN 306 532 11
Normal 13 251 1
prehypertension was a major unsolved--but soluble--mass public health problem
Prehypertension and stroke risk
Noumerous abnormalities in borderline hypertension according to ProfJulius
bull High cardiac output fast heart rate
bull Abnormal vascular resistance
bull Low plasma volume high hematocrit
bull Several metabolic abnormalities
Age distribution (Slovenia 2009)
0
5
10
15
20
25
30
35
20-29 30-39 40-49 50-59 60-69 70-79 80-89 90-99
Age
Age distribution
Normal BP
New diagnose
HNBP
Hypertension
Risk Factors - Tecumseh BP Study
Normotensive
(n=822) Borderline
(n=124)
p
Cholesterol (mgdL) 176 190 0001
HDL (mgdL) 43 40 001
Triglycerides
(mgdL) 95 135 0001
Insulin (UdL) 12 18 0001
Glucose (mgdL) 92 95 001
Insulin-glucose ratio 0155 0200 0001
Percent overweight 136 301 lt0001
Julius S et al JAMA 1990 264 354-358
Prevalence of prehypertension and hypertension stratified by Visceral Adipose Index and Body Fat Percentage
Hu L Huang X You C Li J Hong K et al (2017) Prevalence and Risk Factors of Prehypertension and Hypertension in Southern China PLOS ONE 12(1) e0170238 doi101371journalpone0170238httpjournalsplosorgplosonearticleid=101371journalpone0170238
PLOS 2017
Framingham Study incidence of hypertension
Vasan LarsonLevy Lancet 2001
Flemish Study Belgiumincidence of hypertension
(781 women 675 men)
Zhang H Fagard R Staessen J J Hypertension 2006
1 summary
bull Prehypertensives are more obese have higher cholesterol levels blood glucose insuline resistance heart rate
bull Stage by itself and progression to hypertension
Letrsquos go for a drink
Definition of prehypertension
stage Outpatient BP
(mmHg)
Home BP
(mmHg)
ABMP (mmHg)
24-h Day-time Night-time
Normotension lt12080
Prehypertension 120-13980-89
Hypertension ge14090 gt13585 gt13080 gt13585 gt12070
BP Thresholds for Definition of Hypertension
High office BP
Normal home BP
ldquoWhite-coatrdquo hypertension
Normal office BP
Normal home BP
ldquoNormotensionrdquo
High office BP
High home BP
Sustained hypertension
Normal office BP
High home BP
Masked hypertension
14090 mmHg
lt13585mmHgHome BP
Office BP
Masked hypertension
0
40
80
120
160
200
0
40
80
120
160
200
12 14 16 18 20 22 0 2 4 6 8 10 12 14
Blo
od
pre
ssure
(mm
Hg)
H
eart
rate
(min
-1)
Time (hour)
Blood pressureHeart rate
Man 20 yearsDaytime 152 87 mm Hg
Night-time 130 71 mm HgNight-time BP Drop -15 -18
Home blood pressure consistently hypertensiveClinic blood pressure 11070 mm Hg target organs damage
12 cohorts
Copenhagen (Denmark)
Dublin (Ireland)
Jingning (China)
Krakoacutew (Poland)
Maracaibo (Venezuela)
Montevideo (Uruguay)
Noorderkempen (Belgium)
Novosibirsk (Russia)
Ohasama (Japan)
Padova (Italy)
Pilsen (Czechia)
Uppsala (Sweden)
To study risk stratification by ABPM in people stratified by CBP
categories The International Database on Ambulatory blood
pressure in relation to Cardiovascular Outcomes (IDACO)
IDACO
Database
Standardised questionnaires
Anthropometric measurements
CBP and ABP
Blood sample (cholesterol glucose etc)
Outcome of participants
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
CV prediction
IDACOdatabase
Cardiovascualr risk based on BP measured in outpatient
8
7
6
5
4
3
2
1
0
0 3 6 9 12 15
20
15
10
05
0
0 3 6 9 12 15
Follow-up (years) Follow-up (years)
CV
eve
nts
(
)
Adjusted for cohort sex age BMI smoking and drinking serum cholesterol CV disease and DM
Cardiovascular events Stroke
Stro
ke(
)
HT
Pre-HT
NT
Plt00001
p=0012
HT
Pre-HT
NT
p=0015
Plt00001
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
05 1 2 4 8 05 1 2 4 8
NT 2441 63 2441 13
NT with masked HT 198 14 198 5
Pre-HT with masked HT 900 90 900 31
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
Daytime BP thresholds ge13585 mmHg
212 (p=00058)
222 (plt00001)
275 (p=0026)
301 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
NT 2527 67 2527 14
NT with masked HT 112 10 112 4
Pre-HT with masked HT 672 74 672 27
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
05 1 2 4 8 05 1 2 4 8
24h BP thresholds ge13080 mmHg
258 (p=00032)
213 (plt00001)
418 (p=00047)
317 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
Home blood pressure and ABPM in detecting masked hypertension (same sample N=128 )
CV riskUpgraded 117Downgraded 148No change 734
Masked hypertensionHome BPM748ABPM 131
MH = masked hypertensionNR = normotensionSH = sustained hypertension
RISHO2014
Baseline to follow-up reproducibility of home blood pressure measurements in tertiles of the follow up duration
RISHO2014
100 120 140 160
-40
-20
0
20
40
CR=176
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=161
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=198
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=218
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=212
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=242
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
a) 1tertile
b) 2tertile
c) 3tertile
Bland and Altman method CR=coefficient of reproducibility twice of SD of the difference between repeated measurement
Observation 24y
43y
59y
Home Blood Pressure as a Predictor of Future Blood Pressure Stability in Borderline HypertensionThe Tecumseh StudyS D Nesbitt J V Amerena EGrant K A Jamerson H Lu A Weder Stevo Julius
JAMA 2016315(23)2564-2575
Characteristics of Colorectal Cancer Screening Strategiesa
Screening for Colorectal Cancer vs ABPM in PrehypertensionUS Preventive Services Task Force Recommendation Statement
PrehypertensionOutpatient BP
Home BPEvery year
ABPMif expected risk MH or
large CV risk
Conformation of MH
Medical treatment on time
Confirmation with ABPM
Treat or not to treat prehypertension this is the question now
bull lifestyle modification for those with prehypertension-the good news is that it works
Ideal cardiovascular health behaviors and factors prevent the development of hypertension inprehypertensive subjects
Gao J Sun H Liang X Gao M Zhao H Qi Y Wang Y Liu Y Li J Zhu Y Zhao Y Wang W Ma L Wu SClinical amp Experimental Hypertension (New York) 37(8)650-5 2015
bull BACKGROUND Seven ideal health metrics were defined by AHA to monitor cardiovascular health This study aimed to investigate the impact of ideal cardiovascular health behaviors and factors on the development of hypertension in prehypertensive subjects
METHODS Thirty-two thousand eight-hundred and eighty-seven participants with prehypertension were included in the study after excluding for preexisting stroke myocardial infarction or malignancy Cox proportional hazards regression was used to calculate hazard ratios and 95 confidence intervals [CI] for the development of hypertension
RESULTS During a follow-up of 522 months 15500 prehypertensive participants developed hypertension The cumulative incidence of hypertension decreased with the number of ideal health metrics increased It was 7861 7108 6315 5607 and 6162 in prehypertensive individuals carrying lt 1 2 3 4 and gt 5 ideal health behaviors or factors respectively After adjustment for age gender family history of hypertension alcohol consumption resting heart rate plasma triglyceride high-density lipoprotein cholesterol low-density lipoprotein cholesterol and high-sensitivity C-reactive protein the risk ratios of incident hypertension in the subjects who carried 2 3 4 and gt 5 ideal health metrics were 0833 (95CI 0789-0880) 0710 (95CI 0672-0749) 0604 (95CI 0568-0642) and 0581 (95CI 0524-0643) respectively in comparison to those with lt 1 ideal health metric A similar trend was also observed in male and female populations Poor health metrics including body mass index diet (salt intake) physical activity total cholesterol and smoking were predictors for the development of hypertension in prehypertensive individuals
CONCLUSION Ideal cardiovascular health behaviors and factors are protective factors to prevent the progression from prehypertension to hypertension
Treat or not to treat prehypertension this is the question now
bull ProfBakris
bull The argument has always been to use lifestyle modification for those with prehypertension-the good news is that it works but the bad news is that nobody does it
How does story continue
bull TROPHY study (candesartan) Julius S Nesbitt SD Egan BM et al Feasibility of treating prehypertension with an angiotensin-receptor blocker N Engl J Med2006354(16)1685-1697
bull PHARAO study (Ramipril) Luumlders S Schrader J Berger J et al The PHARAO study prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure a prospective randomized controlled prevention trial of the German Hypertension League J Hypertens 200826(7)1487-1496
bull Small studies no effect
TROPHY studyKaplan-Meier Curves of New Onset of Clinical
Hypertension in the Two Groups
0 1 2 3 4
Years in study
0
01
02
03
04
05
06
07
08
09
10
C
um
ula
tive
inci
den
ce
Candesartan
Placebo
Candesartan 391 356 309 191 128
Placebo 381 269 184 118 85
Numbers under the graph refer to hypertension-free individuals
2 YearsRR darr66AR darr 26
4 YearsRR darr158AR darr 96
P lt 00001
Julius S NesbittSD N Engl J Med 20063541-13
No effect
bull Lowering the tresholds for the initiation of pharmacologic therapy would have a tremendous economic effect on public health care system (Grassi N Eng J Med 2006)
bull The high-risk strategy identifes and treats those at greatest risk (eg 10y coronary heart disease risk gt20) While there benefits individual the population attributale risk remains significant since most events occur among those at lower risk levels (Egan Nesbitt Julius Therapevtic Advances in CV Disease)
Conclusion for our practice
bull Prehypertension is not an innocent stage and could be dangerous condition
bull It needs to be monitorised excluded masked hypertension
bull Regular blood pressure measurements HBPM ABPM telemonitoring
bull Life style modification versus pharmacological treatment
bull Subclinical organ damage assessmentbull Medical treatment as soon as it is needed
according present ESH guidelines
Mortality from ischemic heart disease and stroke increases with increasing blood pressrue
Prospective Studies Collaboration Lancet 20023601903-13
stroke
Ishemic heart disease
Prospective Studies Collaboration Lancet 20023601903-13
Framingham Heart Study (n=6859)
Cumulative Incidence of Cardiovascular Events in Women (Panel A) and Men (Panel B) without
Hypertension According to Blood-Pressure Category at the Base-Line Examination
Vasan Larson et all IMPACT OF HIGH-NORMAL BLOOD PRESSURE ON THE RISK OF CARDIOVASCULAR DISEASE N Engl J Med 2001
Vertical bars indicate 95 percent confidence intervals Optimal blood pressure is a systolic pressure of less than 120 mm Hg and a diastolic pressure of less than 80 mm Hg Normal blood pressure is a systolic pressure of 120 to 129 mm Hg or a diastolic pressure of 80 to 84 mm Hg High-normal blood pressure is a systolic pressure of 130 to 139 mm Hg or a diastolic pressure of 85 to 89 mm Hg If the systolic and diastolic pressure readings for a subject were in different categories the higher of the two categories was used
Prevalence of prehypertension ( 40)bull De Marco M de Simone G Roman MJ Chinali M Lee ET Russell M Howard BV Devereux RBCardiovascular and metabolic
predictors of progression of prehypertension into hypertension the Strong Heart Study Hypertension 2009 Nov54(5)974-80 Epub 2009 Aug 31Strong Heart Study 625 American Indian 45-74y
22 of prevalence of pht 53 among diabetics 33 among non-diabeticHigher BMI SBP DBP pp HR diabetes TG fibrinogen CRP lower HDL higher LVM
bull Zhang Y Lee ET Devereux RB Yeh J Best LG Fabsitz RR Howard BV Prehypertension diabetes and cardiovascular disease risk in a population based sample the Strong Heart Study
Hypertension 2006 Mar47(3)410-4 Epub 2006 Jan 30 Strong Heart Study1532 no diabetic and 1097 diabetics American Indian 55 +-8y
Prevalence of prehypert 594 in diabetics and 482 in non diabeticsIn all age groups from 45-49 to 70-74 diabetics had higher prevalence than non-diabetic and
Kaplan Meier plots showed that prehyperte had higher CV disease incidence and when diabetes was added it was even higher
Only prehypertension was lower than diabetes itself
bull Mainous AG 3rd Everett CJ Liszka H King DE Egan BMPrehypertension and mortality in a nationally representative cohortAm J Cardiol 2004 Dec 1594(12)1496-500NHAES IIstart NH2MS followed 9087 USA 30-74y
31prevalence of pht 37hypertension
bull Liszka HA Mainous AG III King DEEverett CJ Egan BM Prehypertension and cardiovascular morbidity Ann Fam Med 20053294-9NHAES 8986Usa 86white
33prevalence of pht47hypertension
World Hypertension Day Slovenija 2016
(n=2651)
Huang et all Neurology 2014
Prevalenca of prehypertension
Prevalence of prehypertension and hypertension stratified by sex and age
Hu L Huang X You C Li J Hong K et al (2017) Prevalence and Risk Factors of Prehypertension and Hypertension in Southern China PLOS ONE 12(1) e0170238 doi101371journalpone0170238httpjournalsplosorgplosonearticleid=101371journalpone0170238
PLOS 2017
Why is it important
bull Stage by itself or progression to hypertension
SBP (mm Hg) of Total CHD Deaths Pop RR
gt180 72 09
170-179 68 12
160-169 101 27
150-159 195 62
140-149 234 128
130-139 207 228
120-129 99 284
110-119 13 190
lt110 00 61
MRFIT Systolic BP And CHD Mortality Risk Pyramid For Men
Stage 1 429 190 51
Adapted from Stamler et al Arch Intern Med 1993153596
Stage 2 245 46 107
Pre-HTN 306 532 11
Normal 13 251 1
prehypertension was a major unsolved--but soluble--mass public health problem
Prehypertension and stroke risk
Noumerous abnormalities in borderline hypertension according to ProfJulius
bull High cardiac output fast heart rate
bull Abnormal vascular resistance
bull Low plasma volume high hematocrit
bull Several metabolic abnormalities
Age distribution (Slovenia 2009)
0
5
10
15
20
25
30
35
20-29 30-39 40-49 50-59 60-69 70-79 80-89 90-99
Age
Age distribution
Normal BP
New diagnose
HNBP
Hypertension
Risk Factors - Tecumseh BP Study
Normotensive
(n=822) Borderline
(n=124)
p
Cholesterol (mgdL) 176 190 0001
HDL (mgdL) 43 40 001
Triglycerides
(mgdL) 95 135 0001
Insulin (UdL) 12 18 0001
Glucose (mgdL) 92 95 001
Insulin-glucose ratio 0155 0200 0001
Percent overweight 136 301 lt0001
Julius S et al JAMA 1990 264 354-358
Prevalence of prehypertension and hypertension stratified by Visceral Adipose Index and Body Fat Percentage
Hu L Huang X You C Li J Hong K et al (2017) Prevalence and Risk Factors of Prehypertension and Hypertension in Southern China PLOS ONE 12(1) e0170238 doi101371journalpone0170238httpjournalsplosorgplosonearticleid=101371journalpone0170238
PLOS 2017
Framingham Study incidence of hypertension
Vasan LarsonLevy Lancet 2001
Flemish Study Belgiumincidence of hypertension
(781 women 675 men)
Zhang H Fagard R Staessen J J Hypertension 2006
1 summary
bull Prehypertensives are more obese have higher cholesterol levels blood glucose insuline resistance heart rate
bull Stage by itself and progression to hypertension
Letrsquos go for a drink
Definition of prehypertension
stage Outpatient BP
(mmHg)
Home BP
(mmHg)
ABMP (mmHg)
24-h Day-time Night-time
Normotension lt12080
Prehypertension 120-13980-89
Hypertension ge14090 gt13585 gt13080 gt13585 gt12070
BP Thresholds for Definition of Hypertension
High office BP
Normal home BP
ldquoWhite-coatrdquo hypertension
Normal office BP
Normal home BP
ldquoNormotensionrdquo
High office BP
High home BP
Sustained hypertension
Normal office BP
High home BP
Masked hypertension
14090 mmHg
lt13585mmHgHome BP
Office BP
Masked hypertension
0
40
80
120
160
200
0
40
80
120
160
200
12 14 16 18 20 22 0 2 4 6 8 10 12 14
Blo
od
pre
ssure
(mm
Hg)
H
eart
rate
(min
-1)
Time (hour)
Blood pressureHeart rate
Man 20 yearsDaytime 152 87 mm Hg
Night-time 130 71 mm HgNight-time BP Drop -15 -18
Home blood pressure consistently hypertensiveClinic blood pressure 11070 mm Hg target organs damage
12 cohorts
Copenhagen (Denmark)
Dublin (Ireland)
Jingning (China)
Krakoacutew (Poland)
Maracaibo (Venezuela)
Montevideo (Uruguay)
Noorderkempen (Belgium)
Novosibirsk (Russia)
Ohasama (Japan)
Padova (Italy)
Pilsen (Czechia)
Uppsala (Sweden)
To study risk stratification by ABPM in people stratified by CBP
categories The International Database on Ambulatory blood
pressure in relation to Cardiovascular Outcomes (IDACO)
IDACO
Database
Standardised questionnaires
Anthropometric measurements
CBP and ABP
Blood sample (cholesterol glucose etc)
Outcome of participants
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
CV prediction
IDACOdatabase
Cardiovascualr risk based on BP measured in outpatient
8
7
6
5
4
3
2
1
0
0 3 6 9 12 15
20
15
10
05
0
0 3 6 9 12 15
Follow-up (years) Follow-up (years)
CV
eve
nts
(
)
Adjusted for cohort sex age BMI smoking and drinking serum cholesterol CV disease and DM
Cardiovascular events Stroke
Stro
ke(
)
HT
Pre-HT
NT
Plt00001
p=0012
HT
Pre-HT
NT
p=0015
Plt00001
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
05 1 2 4 8 05 1 2 4 8
NT 2441 63 2441 13
NT with masked HT 198 14 198 5
Pre-HT with masked HT 900 90 900 31
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
Daytime BP thresholds ge13585 mmHg
212 (p=00058)
222 (plt00001)
275 (p=0026)
301 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
NT 2527 67 2527 14
NT with masked HT 112 10 112 4
Pre-HT with masked HT 672 74 672 27
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
05 1 2 4 8 05 1 2 4 8
24h BP thresholds ge13080 mmHg
258 (p=00032)
213 (plt00001)
418 (p=00047)
317 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
Home blood pressure and ABPM in detecting masked hypertension (same sample N=128 )
CV riskUpgraded 117Downgraded 148No change 734
Masked hypertensionHome BPM748ABPM 131
MH = masked hypertensionNR = normotensionSH = sustained hypertension
RISHO2014
Baseline to follow-up reproducibility of home blood pressure measurements in tertiles of the follow up duration
RISHO2014
100 120 140 160
-40
-20
0
20
40
CR=176
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=161
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=198
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=218
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=212
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=242
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
a) 1tertile
b) 2tertile
c) 3tertile
Bland and Altman method CR=coefficient of reproducibility twice of SD of the difference between repeated measurement
Observation 24y
43y
59y
Home Blood Pressure as a Predictor of Future Blood Pressure Stability in Borderline HypertensionThe Tecumseh StudyS D Nesbitt J V Amerena EGrant K A Jamerson H Lu A Weder Stevo Julius
JAMA 2016315(23)2564-2575
Characteristics of Colorectal Cancer Screening Strategiesa
Screening for Colorectal Cancer vs ABPM in PrehypertensionUS Preventive Services Task Force Recommendation Statement
PrehypertensionOutpatient BP
Home BPEvery year
ABPMif expected risk MH or
large CV risk
Conformation of MH
Medical treatment on time
Confirmation with ABPM
Treat or not to treat prehypertension this is the question now
bull lifestyle modification for those with prehypertension-the good news is that it works
Ideal cardiovascular health behaviors and factors prevent the development of hypertension inprehypertensive subjects
Gao J Sun H Liang X Gao M Zhao H Qi Y Wang Y Liu Y Li J Zhu Y Zhao Y Wang W Ma L Wu SClinical amp Experimental Hypertension (New York) 37(8)650-5 2015
bull BACKGROUND Seven ideal health metrics were defined by AHA to monitor cardiovascular health This study aimed to investigate the impact of ideal cardiovascular health behaviors and factors on the development of hypertension in prehypertensive subjects
METHODS Thirty-two thousand eight-hundred and eighty-seven participants with prehypertension were included in the study after excluding for preexisting stroke myocardial infarction or malignancy Cox proportional hazards regression was used to calculate hazard ratios and 95 confidence intervals [CI] for the development of hypertension
RESULTS During a follow-up of 522 months 15500 prehypertensive participants developed hypertension The cumulative incidence of hypertension decreased with the number of ideal health metrics increased It was 7861 7108 6315 5607 and 6162 in prehypertensive individuals carrying lt 1 2 3 4 and gt 5 ideal health behaviors or factors respectively After adjustment for age gender family history of hypertension alcohol consumption resting heart rate plasma triglyceride high-density lipoprotein cholesterol low-density lipoprotein cholesterol and high-sensitivity C-reactive protein the risk ratios of incident hypertension in the subjects who carried 2 3 4 and gt 5 ideal health metrics were 0833 (95CI 0789-0880) 0710 (95CI 0672-0749) 0604 (95CI 0568-0642) and 0581 (95CI 0524-0643) respectively in comparison to those with lt 1 ideal health metric A similar trend was also observed in male and female populations Poor health metrics including body mass index diet (salt intake) physical activity total cholesterol and smoking were predictors for the development of hypertension in prehypertensive individuals
CONCLUSION Ideal cardiovascular health behaviors and factors are protective factors to prevent the progression from prehypertension to hypertension
Treat or not to treat prehypertension this is the question now
bull ProfBakris
bull The argument has always been to use lifestyle modification for those with prehypertension-the good news is that it works but the bad news is that nobody does it
How does story continue
bull TROPHY study (candesartan) Julius S Nesbitt SD Egan BM et al Feasibility of treating prehypertension with an angiotensin-receptor blocker N Engl J Med2006354(16)1685-1697
bull PHARAO study (Ramipril) Luumlders S Schrader J Berger J et al The PHARAO study prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure a prospective randomized controlled prevention trial of the German Hypertension League J Hypertens 200826(7)1487-1496
bull Small studies no effect
TROPHY studyKaplan-Meier Curves of New Onset of Clinical
Hypertension in the Two Groups
0 1 2 3 4
Years in study
0
01
02
03
04
05
06
07
08
09
10
C
um
ula
tive
inci
den
ce
Candesartan
Placebo
Candesartan 391 356 309 191 128
Placebo 381 269 184 118 85
Numbers under the graph refer to hypertension-free individuals
2 YearsRR darr66AR darr 26
4 YearsRR darr158AR darr 96
P lt 00001
Julius S NesbittSD N Engl J Med 20063541-13
No effect
bull Lowering the tresholds for the initiation of pharmacologic therapy would have a tremendous economic effect on public health care system (Grassi N Eng J Med 2006)
bull The high-risk strategy identifes and treats those at greatest risk (eg 10y coronary heart disease risk gt20) While there benefits individual the population attributale risk remains significant since most events occur among those at lower risk levels (Egan Nesbitt Julius Therapevtic Advances in CV Disease)
Conclusion for our practice
bull Prehypertension is not an innocent stage and could be dangerous condition
bull It needs to be monitorised excluded masked hypertension
bull Regular blood pressure measurements HBPM ABPM telemonitoring
bull Life style modification versus pharmacological treatment
bull Subclinical organ damage assessmentbull Medical treatment as soon as it is needed
according present ESH guidelines
Framingham Heart Study (n=6859)
Cumulative Incidence of Cardiovascular Events in Women (Panel A) and Men (Panel B) without
Hypertension According to Blood-Pressure Category at the Base-Line Examination
Vasan Larson et all IMPACT OF HIGH-NORMAL BLOOD PRESSURE ON THE RISK OF CARDIOVASCULAR DISEASE N Engl J Med 2001
Vertical bars indicate 95 percent confidence intervals Optimal blood pressure is a systolic pressure of less than 120 mm Hg and a diastolic pressure of less than 80 mm Hg Normal blood pressure is a systolic pressure of 120 to 129 mm Hg or a diastolic pressure of 80 to 84 mm Hg High-normal blood pressure is a systolic pressure of 130 to 139 mm Hg or a diastolic pressure of 85 to 89 mm Hg If the systolic and diastolic pressure readings for a subject were in different categories the higher of the two categories was used
Prevalence of prehypertension ( 40)bull De Marco M de Simone G Roman MJ Chinali M Lee ET Russell M Howard BV Devereux RBCardiovascular and metabolic
predictors of progression of prehypertension into hypertension the Strong Heart Study Hypertension 2009 Nov54(5)974-80 Epub 2009 Aug 31Strong Heart Study 625 American Indian 45-74y
22 of prevalence of pht 53 among diabetics 33 among non-diabeticHigher BMI SBP DBP pp HR diabetes TG fibrinogen CRP lower HDL higher LVM
bull Zhang Y Lee ET Devereux RB Yeh J Best LG Fabsitz RR Howard BV Prehypertension diabetes and cardiovascular disease risk in a population based sample the Strong Heart Study
Hypertension 2006 Mar47(3)410-4 Epub 2006 Jan 30 Strong Heart Study1532 no diabetic and 1097 diabetics American Indian 55 +-8y
Prevalence of prehypert 594 in diabetics and 482 in non diabeticsIn all age groups from 45-49 to 70-74 diabetics had higher prevalence than non-diabetic and
Kaplan Meier plots showed that prehyperte had higher CV disease incidence and when diabetes was added it was even higher
Only prehypertension was lower than diabetes itself
bull Mainous AG 3rd Everett CJ Liszka H King DE Egan BMPrehypertension and mortality in a nationally representative cohortAm J Cardiol 2004 Dec 1594(12)1496-500NHAES IIstart NH2MS followed 9087 USA 30-74y
31prevalence of pht 37hypertension
bull Liszka HA Mainous AG III King DEEverett CJ Egan BM Prehypertension and cardiovascular morbidity Ann Fam Med 20053294-9NHAES 8986Usa 86white
33prevalence of pht47hypertension
World Hypertension Day Slovenija 2016
(n=2651)
Huang et all Neurology 2014
Prevalenca of prehypertension
Prevalence of prehypertension and hypertension stratified by sex and age
Hu L Huang X You C Li J Hong K et al (2017) Prevalence and Risk Factors of Prehypertension and Hypertension in Southern China PLOS ONE 12(1) e0170238 doi101371journalpone0170238httpjournalsplosorgplosonearticleid=101371journalpone0170238
PLOS 2017
Why is it important
bull Stage by itself or progression to hypertension
SBP (mm Hg) of Total CHD Deaths Pop RR
gt180 72 09
170-179 68 12
160-169 101 27
150-159 195 62
140-149 234 128
130-139 207 228
120-129 99 284
110-119 13 190
lt110 00 61
MRFIT Systolic BP And CHD Mortality Risk Pyramid For Men
Stage 1 429 190 51
Adapted from Stamler et al Arch Intern Med 1993153596
Stage 2 245 46 107
Pre-HTN 306 532 11
Normal 13 251 1
prehypertension was a major unsolved--but soluble--mass public health problem
Prehypertension and stroke risk
Noumerous abnormalities in borderline hypertension according to ProfJulius
bull High cardiac output fast heart rate
bull Abnormal vascular resistance
bull Low plasma volume high hematocrit
bull Several metabolic abnormalities
Age distribution (Slovenia 2009)
0
5
10
15
20
25
30
35
20-29 30-39 40-49 50-59 60-69 70-79 80-89 90-99
Age
Age distribution
Normal BP
New diagnose
HNBP
Hypertension
Risk Factors - Tecumseh BP Study
Normotensive
(n=822) Borderline
(n=124)
p
Cholesterol (mgdL) 176 190 0001
HDL (mgdL) 43 40 001
Triglycerides
(mgdL) 95 135 0001
Insulin (UdL) 12 18 0001
Glucose (mgdL) 92 95 001
Insulin-glucose ratio 0155 0200 0001
Percent overweight 136 301 lt0001
Julius S et al JAMA 1990 264 354-358
Prevalence of prehypertension and hypertension stratified by Visceral Adipose Index and Body Fat Percentage
Hu L Huang X You C Li J Hong K et al (2017) Prevalence and Risk Factors of Prehypertension and Hypertension in Southern China PLOS ONE 12(1) e0170238 doi101371journalpone0170238httpjournalsplosorgplosonearticleid=101371journalpone0170238
PLOS 2017
Framingham Study incidence of hypertension
Vasan LarsonLevy Lancet 2001
Flemish Study Belgiumincidence of hypertension
(781 women 675 men)
Zhang H Fagard R Staessen J J Hypertension 2006
1 summary
bull Prehypertensives are more obese have higher cholesterol levels blood glucose insuline resistance heart rate
bull Stage by itself and progression to hypertension
Letrsquos go for a drink
Definition of prehypertension
stage Outpatient BP
(mmHg)
Home BP
(mmHg)
ABMP (mmHg)
24-h Day-time Night-time
Normotension lt12080
Prehypertension 120-13980-89
Hypertension ge14090 gt13585 gt13080 gt13585 gt12070
BP Thresholds for Definition of Hypertension
High office BP
Normal home BP
ldquoWhite-coatrdquo hypertension
Normal office BP
Normal home BP
ldquoNormotensionrdquo
High office BP
High home BP
Sustained hypertension
Normal office BP
High home BP
Masked hypertension
14090 mmHg
lt13585mmHgHome BP
Office BP
Masked hypertension
0
40
80
120
160
200
0
40
80
120
160
200
12 14 16 18 20 22 0 2 4 6 8 10 12 14
Blo
od
pre
ssure
(mm
Hg)
H
eart
rate
(min
-1)
Time (hour)
Blood pressureHeart rate
Man 20 yearsDaytime 152 87 mm Hg
Night-time 130 71 mm HgNight-time BP Drop -15 -18
Home blood pressure consistently hypertensiveClinic blood pressure 11070 mm Hg target organs damage
12 cohorts
Copenhagen (Denmark)
Dublin (Ireland)
Jingning (China)
Krakoacutew (Poland)
Maracaibo (Venezuela)
Montevideo (Uruguay)
Noorderkempen (Belgium)
Novosibirsk (Russia)
Ohasama (Japan)
Padova (Italy)
Pilsen (Czechia)
Uppsala (Sweden)
To study risk stratification by ABPM in people stratified by CBP
categories The International Database on Ambulatory blood
pressure in relation to Cardiovascular Outcomes (IDACO)
IDACO
Database
Standardised questionnaires
Anthropometric measurements
CBP and ABP
Blood sample (cholesterol glucose etc)
Outcome of participants
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
CV prediction
IDACOdatabase
Cardiovascualr risk based on BP measured in outpatient
8
7
6
5
4
3
2
1
0
0 3 6 9 12 15
20
15
10
05
0
0 3 6 9 12 15
Follow-up (years) Follow-up (years)
CV
eve
nts
(
)
Adjusted for cohort sex age BMI smoking and drinking serum cholesterol CV disease and DM
Cardiovascular events Stroke
Stro
ke(
)
HT
Pre-HT
NT
Plt00001
p=0012
HT
Pre-HT
NT
p=0015
Plt00001
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
05 1 2 4 8 05 1 2 4 8
NT 2441 63 2441 13
NT with masked HT 198 14 198 5
Pre-HT with masked HT 900 90 900 31
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
Daytime BP thresholds ge13585 mmHg
212 (p=00058)
222 (plt00001)
275 (p=0026)
301 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
NT 2527 67 2527 14
NT with masked HT 112 10 112 4
Pre-HT with masked HT 672 74 672 27
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
05 1 2 4 8 05 1 2 4 8
24h BP thresholds ge13080 mmHg
258 (p=00032)
213 (plt00001)
418 (p=00047)
317 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
Home blood pressure and ABPM in detecting masked hypertension (same sample N=128 )
CV riskUpgraded 117Downgraded 148No change 734
Masked hypertensionHome BPM748ABPM 131
MH = masked hypertensionNR = normotensionSH = sustained hypertension
RISHO2014
Baseline to follow-up reproducibility of home blood pressure measurements in tertiles of the follow up duration
RISHO2014
100 120 140 160
-40
-20
0
20
40
CR=176
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=161
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=198
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=218
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=212
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=242
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
a) 1tertile
b) 2tertile
c) 3tertile
Bland and Altman method CR=coefficient of reproducibility twice of SD of the difference between repeated measurement
Observation 24y
43y
59y
Home Blood Pressure as a Predictor of Future Blood Pressure Stability in Borderline HypertensionThe Tecumseh StudyS D Nesbitt J V Amerena EGrant K A Jamerson H Lu A Weder Stevo Julius
JAMA 2016315(23)2564-2575
Characteristics of Colorectal Cancer Screening Strategiesa
Screening for Colorectal Cancer vs ABPM in PrehypertensionUS Preventive Services Task Force Recommendation Statement
PrehypertensionOutpatient BP
Home BPEvery year
ABPMif expected risk MH or
large CV risk
Conformation of MH
Medical treatment on time
Confirmation with ABPM
Treat or not to treat prehypertension this is the question now
bull lifestyle modification for those with prehypertension-the good news is that it works
Ideal cardiovascular health behaviors and factors prevent the development of hypertension inprehypertensive subjects
Gao J Sun H Liang X Gao M Zhao H Qi Y Wang Y Liu Y Li J Zhu Y Zhao Y Wang W Ma L Wu SClinical amp Experimental Hypertension (New York) 37(8)650-5 2015
bull BACKGROUND Seven ideal health metrics were defined by AHA to monitor cardiovascular health This study aimed to investigate the impact of ideal cardiovascular health behaviors and factors on the development of hypertension in prehypertensive subjects
METHODS Thirty-two thousand eight-hundred and eighty-seven participants with prehypertension were included in the study after excluding for preexisting stroke myocardial infarction or malignancy Cox proportional hazards regression was used to calculate hazard ratios and 95 confidence intervals [CI] for the development of hypertension
RESULTS During a follow-up of 522 months 15500 prehypertensive participants developed hypertension The cumulative incidence of hypertension decreased with the number of ideal health metrics increased It was 7861 7108 6315 5607 and 6162 in prehypertensive individuals carrying lt 1 2 3 4 and gt 5 ideal health behaviors or factors respectively After adjustment for age gender family history of hypertension alcohol consumption resting heart rate plasma triglyceride high-density lipoprotein cholesterol low-density lipoprotein cholesterol and high-sensitivity C-reactive protein the risk ratios of incident hypertension in the subjects who carried 2 3 4 and gt 5 ideal health metrics were 0833 (95CI 0789-0880) 0710 (95CI 0672-0749) 0604 (95CI 0568-0642) and 0581 (95CI 0524-0643) respectively in comparison to those with lt 1 ideal health metric A similar trend was also observed in male and female populations Poor health metrics including body mass index diet (salt intake) physical activity total cholesterol and smoking were predictors for the development of hypertension in prehypertensive individuals
CONCLUSION Ideal cardiovascular health behaviors and factors are protective factors to prevent the progression from prehypertension to hypertension
Treat or not to treat prehypertension this is the question now
bull ProfBakris
bull The argument has always been to use lifestyle modification for those with prehypertension-the good news is that it works but the bad news is that nobody does it
How does story continue
bull TROPHY study (candesartan) Julius S Nesbitt SD Egan BM et al Feasibility of treating prehypertension with an angiotensin-receptor blocker N Engl J Med2006354(16)1685-1697
bull PHARAO study (Ramipril) Luumlders S Schrader J Berger J et al The PHARAO study prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure a prospective randomized controlled prevention trial of the German Hypertension League J Hypertens 200826(7)1487-1496
bull Small studies no effect
TROPHY studyKaplan-Meier Curves of New Onset of Clinical
Hypertension in the Two Groups
0 1 2 3 4
Years in study
0
01
02
03
04
05
06
07
08
09
10
C
um
ula
tive
inci
den
ce
Candesartan
Placebo
Candesartan 391 356 309 191 128
Placebo 381 269 184 118 85
Numbers under the graph refer to hypertension-free individuals
2 YearsRR darr66AR darr 26
4 YearsRR darr158AR darr 96
P lt 00001
Julius S NesbittSD N Engl J Med 20063541-13
No effect
bull Lowering the tresholds for the initiation of pharmacologic therapy would have a tremendous economic effect on public health care system (Grassi N Eng J Med 2006)
bull The high-risk strategy identifes and treats those at greatest risk (eg 10y coronary heart disease risk gt20) While there benefits individual the population attributale risk remains significant since most events occur among those at lower risk levels (Egan Nesbitt Julius Therapevtic Advances in CV Disease)
Conclusion for our practice
bull Prehypertension is not an innocent stage and could be dangerous condition
bull It needs to be monitorised excluded masked hypertension
bull Regular blood pressure measurements HBPM ABPM telemonitoring
bull Life style modification versus pharmacological treatment
bull Subclinical organ damage assessmentbull Medical treatment as soon as it is needed
according present ESH guidelines
Prevalence of prehypertension ( 40)bull De Marco M de Simone G Roman MJ Chinali M Lee ET Russell M Howard BV Devereux RBCardiovascular and metabolic
predictors of progression of prehypertension into hypertension the Strong Heart Study Hypertension 2009 Nov54(5)974-80 Epub 2009 Aug 31Strong Heart Study 625 American Indian 45-74y
22 of prevalence of pht 53 among diabetics 33 among non-diabeticHigher BMI SBP DBP pp HR diabetes TG fibrinogen CRP lower HDL higher LVM
bull Zhang Y Lee ET Devereux RB Yeh J Best LG Fabsitz RR Howard BV Prehypertension diabetes and cardiovascular disease risk in a population based sample the Strong Heart Study
Hypertension 2006 Mar47(3)410-4 Epub 2006 Jan 30 Strong Heart Study1532 no diabetic and 1097 diabetics American Indian 55 +-8y
Prevalence of prehypert 594 in diabetics and 482 in non diabeticsIn all age groups from 45-49 to 70-74 diabetics had higher prevalence than non-diabetic and
Kaplan Meier plots showed that prehyperte had higher CV disease incidence and when diabetes was added it was even higher
Only prehypertension was lower than diabetes itself
bull Mainous AG 3rd Everett CJ Liszka H King DE Egan BMPrehypertension and mortality in a nationally representative cohortAm J Cardiol 2004 Dec 1594(12)1496-500NHAES IIstart NH2MS followed 9087 USA 30-74y
31prevalence of pht 37hypertension
bull Liszka HA Mainous AG III King DEEverett CJ Egan BM Prehypertension and cardiovascular morbidity Ann Fam Med 20053294-9NHAES 8986Usa 86white
33prevalence of pht47hypertension
World Hypertension Day Slovenija 2016
(n=2651)
Huang et all Neurology 2014
Prevalenca of prehypertension
Prevalence of prehypertension and hypertension stratified by sex and age
Hu L Huang X You C Li J Hong K et al (2017) Prevalence and Risk Factors of Prehypertension and Hypertension in Southern China PLOS ONE 12(1) e0170238 doi101371journalpone0170238httpjournalsplosorgplosonearticleid=101371journalpone0170238
PLOS 2017
Why is it important
bull Stage by itself or progression to hypertension
SBP (mm Hg) of Total CHD Deaths Pop RR
gt180 72 09
170-179 68 12
160-169 101 27
150-159 195 62
140-149 234 128
130-139 207 228
120-129 99 284
110-119 13 190
lt110 00 61
MRFIT Systolic BP And CHD Mortality Risk Pyramid For Men
Stage 1 429 190 51
Adapted from Stamler et al Arch Intern Med 1993153596
Stage 2 245 46 107
Pre-HTN 306 532 11
Normal 13 251 1
prehypertension was a major unsolved--but soluble--mass public health problem
Prehypertension and stroke risk
Noumerous abnormalities in borderline hypertension according to ProfJulius
bull High cardiac output fast heart rate
bull Abnormal vascular resistance
bull Low plasma volume high hematocrit
bull Several metabolic abnormalities
Age distribution (Slovenia 2009)
0
5
10
15
20
25
30
35
20-29 30-39 40-49 50-59 60-69 70-79 80-89 90-99
Age
Age distribution
Normal BP
New diagnose
HNBP
Hypertension
Risk Factors - Tecumseh BP Study
Normotensive
(n=822) Borderline
(n=124)
p
Cholesterol (mgdL) 176 190 0001
HDL (mgdL) 43 40 001
Triglycerides
(mgdL) 95 135 0001
Insulin (UdL) 12 18 0001
Glucose (mgdL) 92 95 001
Insulin-glucose ratio 0155 0200 0001
Percent overweight 136 301 lt0001
Julius S et al JAMA 1990 264 354-358
Prevalence of prehypertension and hypertension stratified by Visceral Adipose Index and Body Fat Percentage
Hu L Huang X You C Li J Hong K et al (2017) Prevalence and Risk Factors of Prehypertension and Hypertension in Southern China PLOS ONE 12(1) e0170238 doi101371journalpone0170238httpjournalsplosorgplosonearticleid=101371journalpone0170238
PLOS 2017
Framingham Study incidence of hypertension
Vasan LarsonLevy Lancet 2001
Flemish Study Belgiumincidence of hypertension
(781 women 675 men)
Zhang H Fagard R Staessen J J Hypertension 2006
1 summary
bull Prehypertensives are more obese have higher cholesterol levels blood glucose insuline resistance heart rate
bull Stage by itself and progression to hypertension
Letrsquos go for a drink
Definition of prehypertension
stage Outpatient BP
(mmHg)
Home BP
(mmHg)
ABMP (mmHg)
24-h Day-time Night-time
Normotension lt12080
Prehypertension 120-13980-89
Hypertension ge14090 gt13585 gt13080 gt13585 gt12070
BP Thresholds for Definition of Hypertension
High office BP
Normal home BP
ldquoWhite-coatrdquo hypertension
Normal office BP
Normal home BP
ldquoNormotensionrdquo
High office BP
High home BP
Sustained hypertension
Normal office BP
High home BP
Masked hypertension
14090 mmHg
lt13585mmHgHome BP
Office BP
Masked hypertension
0
40
80
120
160
200
0
40
80
120
160
200
12 14 16 18 20 22 0 2 4 6 8 10 12 14
Blo
od
pre
ssure
(mm
Hg)
H
eart
rate
(min
-1)
Time (hour)
Blood pressureHeart rate
Man 20 yearsDaytime 152 87 mm Hg
Night-time 130 71 mm HgNight-time BP Drop -15 -18
Home blood pressure consistently hypertensiveClinic blood pressure 11070 mm Hg target organs damage
12 cohorts
Copenhagen (Denmark)
Dublin (Ireland)
Jingning (China)
Krakoacutew (Poland)
Maracaibo (Venezuela)
Montevideo (Uruguay)
Noorderkempen (Belgium)
Novosibirsk (Russia)
Ohasama (Japan)
Padova (Italy)
Pilsen (Czechia)
Uppsala (Sweden)
To study risk stratification by ABPM in people stratified by CBP
categories The International Database on Ambulatory blood
pressure in relation to Cardiovascular Outcomes (IDACO)
IDACO
Database
Standardised questionnaires
Anthropometric measurements
CBP and ABP
Blood sample (cholesterol glucose etc)
Outcome of participants
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
CV prediction
IDACOdatabase
Cardiovascualr risk based on BP measured in outpatient
8
7
6
5
4
3
2
1
0
0 3 6 9 12 15
20
15
10
05
0
0 3 6 9 12 15
Follow-up (years) Follow-up (years)
CV
eve
nts
(
)
Adjusted for cohort sex age BMI smoking and drinking serum cholesterol CV disease and DM
Cardiovascular events Stroke
Stro
ke(
)
HT
Pre-HT
NT
Plt00001
p=0012
HT
Pre-HT
NT
p=0015
Plt00001
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
05 1 2 4 8 05 1 2 4 8
NT 2441 63 2441 13
NT with masked HT 198 14 198 5
Pre-HT with masked HT 900 90 900 31
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
Daytime BP thresholds ge13585 mmHg
212 (p=00058)
222 (plt00001)
275 (p=0026)
301 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
NT 2527 67 2527 14
NT with masked HT 112 10 112 4
Pre-HT with masked HT 672 74 672 27
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
05 1 2 4 8 05 1 2 4 8
24h BP thresholds ge13080 mmHg
258 (p=00032)
213 (plt00001)
418 (p=00047)
317 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
Home blood pressure and ABPM in detecting masked hypertension (same sample N=128 )
CV riskUpgraded 117Downgraded 148No change 734
Masked hypertensionHome BPM748ABPM 131
MH = masked hypertensionNR = normotensionSH = sustained hypertension
RISHO2014
Baseline to follow-up reproducibility of home blood pressure measurements in tertiles of the follow up duration
RISHO2014
100 120 140 160
-40
-20
0
20
40
CR=176
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=161
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=198
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=218
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=212
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=242
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
a) 1tertile
b) 2tertile
c) 3tertile
Bland and Altman method CR=coefficient of reproducibility twice of SD of the difference between repeated measurement
Observation 24y
43y
59y
Home Blood Pressure as a Predictor of Future Blood Pressure Stability in Borderline HypertensionThe Tecumseh StudyS D Nesbitt J V Amerena EGrant K A Jamerson H Lu A Weder Stevo Julius
JAMA 2016315(23)2564-2575
Characteristics of Colorectal Cancer Screening Strategiesa
Screening for Colorectal Cancer vs ABPM in PrehypertensionUS Preventive Services Task Force Recommendation Statement
PrehypertensionOutpatient BP
Home BPEvery year
ABPMif expected risk MH or
large CV risk
Conformation of MH
Medical treatment on time
Confirmation with ABPM
Treat or not to treat prehypertension this is the question now
bull lifestyle modification for those with prehypertension-the good news is that it works
Ideal cardiovascular health behaviors and factors prevent the development of hypertension inprehypertensive subjects
Gao J Sun H Liang X Gao M Zhao H Qi Y Wang Y Liu Y Li J Zhu Y Zhao Y Wang W Ma L Wu SClinical amp Experimental Hypertension (New York) 37(8)650-5 2015
bull BACKGROUND Seven ideal health metrics were defined by AHA to monitor cardiovascular health This study aimed to investigate the impact of ideal cardiovascular health behaviors and factors on the development of hypertension in prehypertensive subjects
METHODS Thirty-two thousand eight-hundred and eighty-seven participants with prehypertension were included in the study after excluding for preexisting stroke myocardial infarction or malignancy Cox proportional hazards regression was used to calculate hazard ratios and 95 confidence intervals [CI] for the development of hypertension
RESULTS During a follow-up of 522 months 15500 prehypertensive participants developed hypertension The cumulative incidence of hypertension decreased with the number of ideal health metrics increased It was 7861 7108 6315 5607 and 6162 in prehypertensive individuals carrying lt 1 2 3 4 and gt 5 ideal health behaviors or factors respectively After adjustment for age gender family history of hypertension alcohol consumption resting heart rate plasma triglyceride high-density lipoprotein cholesterol low-density lipoprotein cholesterol and high-sensitivity C-reactive protein the risk ratios of incident hypertension in the subjects who carried 2 3 4 and gt 5 ideal health metrics were 0833 (95CI 0789-0880) 0710 (95CI 0672-0749) 0604 (95CI 0568-0642) and 0581 (95CI 0524-0643) respectively in comparison to those with lt 1 ideal health metric A similar trend was also observed in male and female populations Poor health metrics including body mass index diet (salt intake) physical activity total cholesterol and smoking were predictors for the development of hypertension in prehypertensive individuals
CONCLUSION Ideal cardiovascular health behaviors and factors are protective factors to prevent the progression from prehypertension to hypertension
Treat or not to treat prehypertension this is the question now
bull ProfBakris
bull The argument has always been to use lifestyle modification for those with prehypertension-the good news is that it works but the bad news is that nobody does it
How does story continue
bull TROPHY study (candesartan) Julius S Nesbitt SD Egan BM et al Feasibility of treating prehypertension with an angiotensin-receptor blocker N Engl J Med2006354(16)1685-1697
bull PHARAO study (Ramipril) Luumlders S Schrader J Berger J et al The PHARAO study prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure a prospective randomized controlled prevention trial of the German Hypertension League J Hypertens 200826(7)1487-1496
bull Small studies no effect
TROPHY studyKaplan-Meier Curves of New Onset of Clinical
Hypertension in the Two Groups
0 1 2 3 4
Years in study
0
01
02
03
04
05
06
07
08
09
10
C
um
ula
tive
inci
den
ce
Candesartan
Placebo
Candesartan 391 356 309 191 128
Placebo 381 269 184 118 85
Numbers under the graph refer to hypertension-free individuals
2 YearsRR darr66AR darr 26
4 YearsRR darr158AR darr 96
P lt 00001
Julius S NesbittSD N Engl J Med 20063541-13
No effect
bull Lowering the tresholds for the initiation of pharmacologic therapy would have a tremendous economic effect on public health care system (Grassi N Eng J Med 2006)
bull The high-risk strategy identifes and treats those at greatest risk (eg 10y coronary heart disease risk gt20) While there benefits individual the population attributale risk remains significant since most events occur among those at lower risk levels (Egan Nesbitt Julius Therapevtic Advances in CV Disease)
Conclusion for our practice
bull Prehypertension is not an innocent stage and could be dangerous condition
bull It needs to be monitorised excluded masked hypertension
bull Regular blood pressure measurements HBPM ABPM telemonitoring
bull Life style modification versus pharmacological treatment
bull Subclinical organ damage assessmentbull Medical treatment as soon as it is needed
according present ESH guidelines
World Hypertension Day Slovenija 2016
(n=2651)
Huang et all Neurology 2014
Prevalenca of prehypertension
Prevalence of prehypertension and hypertension stratified by sex and age
Hu L Huang X You C Li J Hong K et al (2017) Prevalence and Risk Factors of Prehypertension and Hypertension in Southern China PLOS ONE 12(1) e0170238 doi101371journalpone0170238httpjournalsplosorgplosonearticleid=101371journalpone0170238
PLOS 2017
Why is it important
bull Stage by itself or progression to hypertension
SBP (mm Hg) of Total CHD Deaths Pop RR
gt180 72 09
170-179 68 12
160-169 101 27
150-159 195 62
140-149 234 128
130-139 207 228
120-129 99 284
110-119 13 190
lt110 00 61
MRFIT Systolic BP And CHD Mortality Risk Pyramid For Men
Stage 1 429 190 51
Adapted from Stamler et al Arch Intern Med 1993153596
Stage 2 245 46 107
Pre-HTN 306 532 11
Normal 13 251 1
prehypertension was a major unsolved--but soluble--mass public health problem
Prehypertension and stroke risk
Noumerous abnormalities in borderline hypertension according to ProfJulius
bull High cardiac output fast heart rate
bull Abnormal vascular resistance
bull Low plasma volume high hematocrit
bull Several metabolic abnormalities
Age distribution (Slovenia 2009)
0
5
10
15
20
25
30
35
20-29 30-39 40-49 50-59 60-69 70-79 80-89 90-99
Age
Age distribution
Normal BP
New diagnose
HNBP
Hypertension
Risk Factors - Tecumseh BP Study
Normotensive
(n=822) Borderline
(n=124)
p
Cholesterol (mgdL) 176 190 0001
HDL (mgdL) 43 40 001
Triglycerides
(mgdL) 95 135 0001
Insulin (UdL) 12 18 0001
Glucose (mgdL) 92 95 001
Insulin-glucose ratio 0155 0200 0001
Percent overweight 136 301 lt0001
Julius S et al JAMA 1990 264 354-358
Prevalence of prehypertension and hypertension stratified by Visceral Adipose Index and Body Fat Percentage
Hu L Huang X You C Li J Hong K et al (2017) Prevalence and Risk Factors of Prehypertension and Hypertension in Southern China PLOS ONE 12(1) e0170238 doi101371journalpone0170238httpjournalsplosorgplosonearticleid=101371journalpone0170238
PLOS 2017
Framingham Study incidence of hypertension
Vasan LarsonLevy Lancet 2001
Flemish Study Belgiumincidence of hypertension
(781 women 675 men)
Zhang H Fagard R Staessen J J Hypertension 2006
1 summary
bull Prehypertensives are more obese have higher cholesterol levels blood glucose insuline resistance heart rate
bull Stage by itself and progression to hypertension
Letrsquos go for a drink
Definition of prehypertension
stage Outpatient BP
(mmHg)
Home BP
(mmHg)
ABMP (mmHg)
24-h Day-time Night-time
Normotension lt12080
Prehypertension 120-13980-89
Hypertension ge14090 gt13585 gt13080 gt13585 gt12070
BP Thresholds for Definition of Hypertension
High office BP
Normal home BP
ldquoWhite-coatrdquo hypertension
Normal office BP
Normal home BP
ldquoNormotensionrdquo
High office BP
High home BP
Sustained hypertension
Normal office BP
High home BP
Masked hypertension
14090 mmHg
lt13585mmHgHome BP
Office BP
Masked hypertension
0
40
80
120
160
200
0
40
80
120
160
200
12 14 16 18 20 22 0 2 4 6 8 10 12 14
Blo
od
pre
ssure
(mm
Hg)
H
eart
rate
(min
-1)
Time (hour)
Blood pressureHeart rate
Man 20 yearsDaytime 152 87 mm Hg
Night-time 130 71 mm HgNight-time BP Drop -15 -18
Home blood pressure consistently hypertensiveClinic blood pressure 11070 mm Hg target organs damage
12 cohorts
Copenhagen (Denmark)
Dublin (Ireland)
Jingning (China)
Krakoacutew (Poland)
Maracaibo (Venezuela)
Montevideo (Uruguay)
Noorderkempen (Belgium)
Novosibirsk (Russia)
Ohasama (Japan)
Padova (Italy)
Pilsen (Czechia)
Uppsala (Sweden)
To study risk stratification by ABPM in people stratified by CBP
categories The International Database on Ambulatory blood
pressure in relation to Cardiovascular Outcomes (IDACO)
IDACO
Database
Standardised questionnaires
Anthropometric measurements
CBP and ABP
Blood sample (cholesterol glucose etc)
Outcome of participants
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
CV prediction
IDACOdatabase
Cardiovascualr risk based on BP measured in outpatient
8
7
6
5
4
3
2
1
0
0 3 6 9 12 15
20
15
10
05
0
0 3 6 9 12 15
Follow-up (years) Follow-up (years)
CV
eve
nts
(
)
Adjusted for cohort sex age BMI smoking and drinking serum cholesterol CV disease and DM
Cardiovascular events Stroke
Stro
ke(
)
HT
Pre-HT
NT
Plt00001
p=0012
HT
Pre-HT
NT
p=0015
Plt00001
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
05 1 2 4 8 05 1 2 4 8
NT 2441 63 2441 13
NT with masked HT 198 14 198 5
Pre-HT with masked HT 900 90 900 31
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
Daytime BP thresholds ge13585 mmHg
212 (p=00058)
222 (plt00001)
275 (p=0026)
301 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
NT 2527 67 2527 14
NT with masked HT 112 10 112 4
Pre-HT with masked HT 672 74 672 27
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
05 1 2 4 8 05 1 2 4 8
24h BP thresholds ge13080 mmHg
258 (p=00032)
213 (plt00001)
418 (p=00047)
317 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
Home blood pressure and ABPM in detecting masked hypertension (same sample N=128 )
CV riskUpgraded 117Downgraded 148No change 734
Masked hypertensionHome BPM748ABPM 131
MH = masked hypertensionNR = normotensionSH = sustained hypertension
RISHO2014
Baseline to follow-up reproducibility of home blood pressure measurements in tertiles of the follow up duration
RISHO2014
100 120 140 160
-40
-20
0
20
40
CR=176
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=161
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=198
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=218
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=212
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=242
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
a) 1tertile
b) 2tertile
c) 3tertile
Bland and Altman method CR=coefficient of reproducibility twice of SD of the difference between repeated measurement
Observation 24y
43y
59y
Home Blood Pressure as a Predictor of Future Blood Pressure Stability in Borderline HypertensionThe Tecumseh StudyS D Nesbitt J V Amerena EGrant K A Jamerson H Lu A Weder Stevo Julius
JAMA 2016315(23)2564-2575
Characteristics of Colorectal Cancer Screening Strategiesa
Screening for Colorectal Cancer vs ABPM in PrehypertensionUS Preventive Services Task Force Recommendation Statement
PrehypertensionOutpatient BP
Home BPEvery year
ABPMif expected risk MH or
large CV risk
Conformation of MH
Medical treatment on time
Confirmation with ABPM
Treat or not to treat prehypertension this is the question now
bull lifestyle modification for those with prehypertension-the good news is that it works
Ideal cardiovascular health behaviors and factors prevent the development of hypertension inprehypertensive subjects
Gao J Sun H Liang X Gao M Zhao H Qi Y Wang Y Liu Y Li J Zhu Y Zhao Y Wang W Ma L Wu SClinical amp Experimental Hypertension (New York) 37(8)650-5 2015
bull BACKGROUND Seven ideal health metrics were defined by AHA to monitor cardiovascular health This study aimed to investigate the impact of ideal cardiovascular health behaviors and factors on the development of hypertension in prehypertensive subjects
METHODS Thirty-two thousand eight-hundred and eighty-seven participants with prehypertension were included in the study after excluding for preexisting stroke myocardial infarction or malignancy Cox proportional hazards regression was used to calculate hazard ratios and 95 confidence intervals [CI] for the development of hypertension
RESULTS During a follow-up of 522 months 15500 prehypertensive participants developed hypertension The cumulative incidence of hypertension decreased with the number of ideal health metrics increased It was 7861 7108 6315 5607 and 6162 in prehypertensive individuals carrying lt 1 2 3 4 and gt 5 ideal health behaviors or factors respectively After adjustment for age gender family history of hypertension alcohol consumption resting heart rate plasma triglyceride high-density lipoprotein cholesterol low-density lipoprotein cholesterol and high-sensitivity C-reactive protein the risk ratios of incident hypertension in the subjects who carried 2 3 4 and gt 5 ideal health metrics were 0833 (95CI 0789-0880) 0710 (95CI 0672-0749) 0604 (95CI 0568-0642) and 0581 (95CI 0524-0643) respectively in comparison to those with lt 1 ideal health metric A similar trend was also observed in male and female populations Poor health metrics including body mass index diet (salt intake) physical activity total cholesterol and smoking were predictors for the development of hypertension in prehypertensive individuals
CONCLUSION Ideal cardiovascular health behaviors and factors are protective factors to prevent the progression from prehypertension to hypertension
Treat or not to treat prehypertension this is the question now
bull ProfBakris
bull The argument has always been to use lifestyle modification for those with prehypertension-the good news is that it works but the bad news is that nobody does it
How does story continue
bull TROPHY study (candesartan) Julius S Nesbitt SD Egan BM et al Feasibility of treating prehypertension with an angiotensin-receptor blocker N Engl J Med2006354(16)1685-1697
bull PHARAO study (Ramipril) Luumlders S Schrader J Berger J et al The PHARAO study prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure a prospective randomized controlled prevention trial of the German Hypertension League J Hypertens 200826(7)1487-1496
bull Small studies no effect
TROPHY studyKaplan-Meier Curves of New Onset of Clinical
Hypertension in the Two Groups
0 1 2 3 4
Years in study
0
01
02
03
04
05
06
07
08
09
10
C
um
ula
tive
inci
den
ce
Candesartan
Placebo
Candesartan 391 356 309 191 128
Placebo 381 269 184 118 85
Numbers under the graph refer to hypertension-free individuals
2 YearsRR darr66AR darr 26
4 YearsRR darr158AR darr 96
P lt 00001
Julius S NesbittSD N Engl J Med 20063541-13
No effect
bull Lowering the tresholds for the initiation of pharmacologic therapy would have a tremendous economic effect on public health care system (Grassi N Eng J Med 2006)
bull The high-risk strategy identifes and treats those at greatest risk (eg 10y coronary heart disease risk gt20) While there benefits individual the population attributale risk remains significant since most events occur among those at lower risk levels (Egan Nesbitt Julius Therapevtic Advances in CV Disease)
Conclusion for our practice
bull Prehypertension is not an innocent stage and could be dangerous condition
bull It needs to be monitorised excluded masked hypertension
bull Regular blood pressure measurements HBPM ABPM telemonitoring
bull Life style modification versus pharmacological treatment
bull Subclinical organ damage assessmentbull Medical treatment as soon as it is needed
according present ESH guidelines
Huang et all Neurology 2014
Prevalenca of prehypertension
Prevalence of prehypertension and hypertension stratified by sex and age
Hu L Huang X You C Li J Hong K et al (2017) Prevalence and Risk Factors of Prehypertension and Hypertension in Southern China PLOS ONE 12(1) e0170238 doi101371journalpone0170238httpjournalsplosorgplosonearticleid=101371journalpone0170238
PLOS 2017
Why is it important
bull Stage by itself or progression to hypertension
SBP (mm Hg) of Total CHD Deaths Pop RR
gt180 72 09
170-179 68 12
160-169 101 27
150-159 195 62
140-149 234 128
130-139 207 228
120-129 99 284
110-119 13 190
lt110 00 61
MRFIT Systolic BP And CHD Mortality Risk Pyramid For Men
Stage 1 429 190 51
Adapted from Stamler et al Arch Intern Med 1993153596
Stage 2 245 46 107
Pre-HTN 306 532 11
Normal 13 251 1
prehypertension was a major unsolved--but soluble--mass public health problem
Prehypertension and stroke risk
Noumerous abnormalities in borderline hypertension according to ProfJulius
bull High cardiac output fast heart rate
bull Abnormal vascular resistance
bull Low plasma volume high hematocrit
bull Several metabolic abnormalities
Age distribution (Slovenia 2009)
0
5
10
15
20
25
30
35
20-29 30-39 40-49 50-59 60-69 70-79 80-89 90-99
Age
Age distribution
Normal BP
New diagnose
HNBP
Hypertension
Risk Factors - Tecumseh BP Study
Normotensive
(n=822) Borderline
(n=124)
p
Cholesterol (mgdL) 176 190 0001
HDL (mgdL) 43 40 001
Triglycerides
(mgdL) 95 135 0001
Insulin (UdL) 12 18 0001
Glucose (mgdL) 92 95 001
Insulin-glucose ratio 0155 0200 0001
Percent overweight 136 301 lt0001
Julius S et al JAMA 1990 264 354-358
Prevalence of prehypertension and hypertension stratified by Visceral Adipose Index and Body Fat Percentage
Hu L Huang X You C Li J Hong K et al (2017) Prevalence and Risk Factors of Prehypertension and Hypertension in Southern China PLOS ONE 12(1) e0170238 doi101371journalpone0170238httpjournalsplosorgplosonearticleid=101371journalpone0170238
PLOS 2017
Framingham Study incidence of hypertension
Vasan LarsonLevy Lancet 2001
Flemish Study Belgiumincidence of hypertension
(781 women 675 men)
Zhang H Fagard R Staessen J J Hypertension 2006
1 summary
bull Prehypertensives are more obese have higher cholesterol levels blood glucose insuline resistance heart rate
bull Stage by itself and progression to hypertension
Letrsquos go for a drink
Definition of prehypertension
stage Outpatient BP
(mmHg)
Home BP
(mmHg)
ABMP (mmHg)
24-h Day-time Night-time
Normotension lt12080
Prehypertension 120-13980-89
Hypertension ge14090 gt13585 gt13080 gt13585 gt12070
BP Thresholds for Definition of Hypertension
High office BP
Normal home BP
ldquoWhite-coatrdquo hypertension
Normal office BP
Normal home BP
ldquoNormotensionrdquo
High office BP
High home BP
Sustained hypertension
Normal office BP
High home BP
Masked hypertension
14090 mmHg
lt13585mmHgHome BP
Office BP
Masked hypertension
0
40
80
120
160
200
0
40
80
120
160
200
12 14 16 18 20 22 0 2 4 6 8 10 12 14
Blo
od
pre
ssure
(mm
Hg)
H
eart
rate
(min
-1)
Time (hour)
Blood pressureHeart rate
Man 20 yearsDaytime 152 87 mm Hg
Night-time 130 71 mm HgNight-time BP Drop -15 -18
Home blood pressure consistently hypertensiveClinic blood pressure 11070 mm Hg target organs damage
12 cohorts
Copenhagen (Denmark)
Dublin (Ireland)
Jingning (China)
Krakoacutew (Poland)
Maracaibo (Venezuela)
Montevideo (Uruguay)
Noorderkempen (Belgium)
Novosibirsk (Russia)
Ohasama (Japan)
Padova (Italy)
Pilsen (Czechia)
Uppsala (Sweden)
To study risk stratification by ABPM in people stratified by CBP
categories The International Database on Ambulatory blood
pressure in relation to Cardiovascular Outcomes (IDACO)
IDACO
Database
Standardised questionnaires
Anthropometric measurements
CBP and ABP
Blood sample (cholesterol glucose etc)
Outcome of participants
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
CV prediction
IDACOdatabase
Cardiovascualr risk based on BP measured in outpatient
8
7
6
5
4
3
2
1
0
0 3 6 9 12 15
20
15
10
05
0
0 3 6 9 12 15
Follow-up (years) Follow-up (years)
CV
eve
nts
(
)
Adjusted for cohort sex age BMI smoking and drinking serum cholesterol CV disease and DM
Cardiovascular events Stroke
Stro
ke(
)
HT
Pre-HT
NT
Plt00001
p=0012
HT
Pre-HT
NT
p=0015
Plt00001
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
05 1 2 4 8 05 1 2 4 8
NT 2441 63 2441 13
NT with masked HT 198 14 198 5
Pre-HT with masked HT 900 90 900 31
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
Daytime BP thresholds ge13585 mmHg
212 (p=00058)
222 (plt00001)
275 (p=0026)
301 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
NT 2527 67 2527 14
NT with masked HT 112 10 112 4
Pre-HT with masked HT 672 74 672 27
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
05 1 2 4 8 05 1 2 4 8
24h BP thresholds ge13080 mmHg
258 (p=00032)
213 (plt00001)
418 (p=00047)
317 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
Home blood pressure and ABPM in detecting masked hypertension (same sample N=128 )
CV riskUpgraded 117Downgraded 148No change 734
Masked hypertensionHome BPM748ABPM 131
MH = masked hypertensionNR = normotensionSH = sustained hypertension
RISHO2014
Baseline to follow-up reproducibility of home blood pressure measurements in tertiles of the follow up duration
RISHO2014
100 120 140 160
-40
-20
0
20
40
CR=176
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=161
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=198
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=218
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=212
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=242
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
a) 1tertile
b) 2tertile
c) 3tertile
Bland and Altman method CR=coefficient of reproducibility twice of SD of the difference between repeated measurement
Observation 24y
43y
59y
Home Blood Pressure as a Predictor of Future Blood Pressure Stability in Borderline HypertensionThe Tecumseh StudyS D Nesbitt J V Amerena EGrant K A Jamerson H Lu A Weder Stevo Julius
JAMA 2016315(23)2564-2575
Characteristics of Colorectal Cancer Screening Strategiesa
Screening for Colorectal Cancer vs ABPM in PrehypertensionUS Preventive Services Task Force Recommendation Statement
PrehypertensionOutpatient BP
Home BPEvery year
ABPMif expected risk MH or
large CV risk
Conformation of MH
Medical treatment on time
Confirmation with ABPM
Treat or not to treat prehypertension this is the question now
bull lifestyle modification for those with prehypertension-the good news is that it works
Ideal cardiovascular health behaviors and factors prevent the development of hypertension inprehypertensive subjects
Gao J Sun H Liang X Gao M Zhao H Qi Y Wang Y Liu Y Li J Zhu Y Zhao Y Wang W Ma L Wu SClinical amp Experimental Hypertension (New York) 37(8)650-5 2015
bull BACKGROUND Seven ideal health metrics were defined by AHA to monitor cardiovascular health This study aimed to investigate the impact of ideal cardiovascular health behaviors and factors on the development of hypertension in prehypertensive subjects
METHODS Thirty-two thousand eight-hundred and eighty-seven participants with prehypertension were included in the study after excluding for preexisting stroke myocardial infarction or malignancy Cox proportional hazards regression was used to calculate hazard ratios and 95 confidence intervals [CI] for the development of hypertension
RESULTS During a follow-up of 522 months 15500 prehypertensive participants developed hypertension The cumulative incidence of hypertension decreased with the number of ideal health metrics increased It was 7861 7108 6315 5607 and 6162 in prehypertensive individuals carrying lt 1 2 3 4 and gt 5 ideal health behaviors or factors respectively After adjustment for age gender family history of hypertension alcohol consumption resting heart rate plasma triglyceride high-density lipoprotein cholesterol low-density lipoprotein cholesterol and high-sensitivity C-reactive protein the risk ratios of incident hypertension in the subjects who carried 2 3 4 and gt 5 ideal health metrics were 0833 (95CI 0789-0880) 0710 (95CI 0672-0749) 0604 (95CI 0568-0642) and 0581 (95CI 0524-0643) respectively in comparison to those with lt 1 ideal health metric A similar trend was also observed in male and female populations Poor health metrics including body mass index diet (salt intake) physical activity total cholesterol and smoking were predictors for the development of hypertension in prehypertensive individuals
CONCLUSION Ideal cardiovascular health behaviors and factors are protective factors to prevent the progression from prehypertension to hypertension
Treat or not to treat prehypertension this is the question now
bull ProfBakris
bull The argument has always been to use lifestyle modification for those with prehypertension-the good news is that it works but the bad news is that nobody does it
How does story continue
bull TROPHY study (candesartan) Julius S Nesbitt SD Egan BM et al Feasibility of treating prehypertension with an angiotensin-receptor blocker N Engl J Med2006354(16)1685-1697
bull PHARAO study (Ramipril) Luumlders S Schrader J Berger J et al The PHARAO study prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure a prospective randomized controlled prevention trial of the German Hypertension League J Hypertens 200826(7)1487-1496
bull Small studies no effect
TROPHY studyKaplan-Meier Curves of New Onset of Clinical
Hypertension in the Two Groups
0 1 2 3 4
Years in study
0
01
02
03
04
05
06
07
08
09
10
C
um
ula
tive
inci
den
ce
Candesartan
Placebo
Candesartan 391 356 309 191 128
Placebo 381 269 184 118 85
Numbers under the graph refer to hypertension-free individuals
2 YearsRR darr66AR darr 26
4 YearsRR darr158AR darr 96
P lt 00001
Julius S NesbittSD N Engl J Med 20063541-13
No effect
bull Lowering the tresholds for the initiation of pharmacologic therapy would have a tremendous economic effect on public health care system (Grassi N Eng J Med 2006)
bull The high-risk strategy identifes and treats those at greatest risk (eg 10y coronary heart disease risk gt20) While there benefits individual the population attributale risk remains significant since most events occur among those at lower risk levels (Egan Nesbitt Julius Therapevtic Advances in CV Disease)
Conclusion for our practice
bull Prehypertension is not an innocent stage and could be dangerous condition
bull It needs to be monitorised excluded masked hypertension
bull Regular blood pressure measurements HBPM ABPM telemonitoring
bull Life style modification versus pharmacological treatment
bull Subclinical organ damage assessmentbull Medical treatment as soon as it is needed
according present ESH guidelines
Prevalence of prehypertension and hypertension stratified by sex and age
Hu L Huang X You C Li J Hong K et al (2017) Prevalence and Risk Factors of Prehypertension and Hypertension in Southern China PLOS ONE 12(1) e0170238 doi101371journalpone0170238httpjournalsplosorgplosonearticleid=101371journalpone0170238
PLOS 2017
Why is it important
bull Stage by itself or progression to hypertension
SBP (mm Hg) of Total CHD Deaths Pop RR
gt180 72 09
170-179 68 12
160-169 101 27
150-159 195 62
140-149 234 128
130-139 207 228
120-129 99 284
110-119 13 190
lt110 00 61
MRFIT Systolic BP And CHD Mortality Risk Pyramid For Men
Stage 1 429 190 51
Adapted from Stamler et al Arch Intern Med 1993153596
Stage 2 245 46 107
Pre-HTN 306 532 11
Normal 13 251 1
prehypertension was a major unsolved--but soluble--mass public health problem
Prehypertension and stroke risk
Noumerous abnormalities in borderline hypertension according to ProfJulius
bull High cardiac output fast heart rate
bull Abnormal vascular resistance
bull Low plasma volume high hematocrit
bull Several metabolic abnormalities
Age distribution (Slovenia 2009)
0
5
10
15
20
25
30
35
20-29 30-39 40-49 50-59 60-69 70-79 80-89 90-99
Age
Age distribution
Normal BP
New diagnose
HNBP
Hypertension
Risk Factors - Tecumseh BP Study
Normotensive
(n=822) Borderline
(n=124)
p
Cholesterol (mgdL) 176 190 0001
HDL (mgdL) 43 40 001
Triglycerides
(mgdL) 95 135 0001
Insulin (UdL) 12 18 0001
Glucose (mgdL) 92 95 001
Insulin-glucose ratio 0155 0200 0001
Percent overweight 136 301 lt0001
Julius S et al JAMA 1990 264 354-358
Prevalence of prehypertension and hypertension stratified by Visceral Adipose Index and Body Fat Percentage
Hu L Huang X You C Li J Hong K et al (2017) Prevalence and Risk Factors of Prehypertension and Hypertension in Southern China PLOS ONE 12(1) e0170238 doi101371journalpone0170238httpjournalsplosorgplosonearticleid=101371journalpone0170238
PLOS 2017
Framingham Study incidence of hypertension
Vasan LarsonLevy Lancet 2001
Flemish Study Belgiumincidence of hypertension
(781 women 675 men)
Zhang H Fagard R Staessen J J Hypertension 2006
1 summary
bull Prehypertensives are more obese have higher cholesterol levels blood glucose insuline resistance heart rate
bull Stage by itself and progression to hypertension
Letrsquos go for a drink
Definition of prehypertension
stage Outpatient BP
(mmHg)
Home BP
(mmHg)
ABMP (mmHg)
24-h Day-time Night-time
Normotension lt12080
Prehypertension 120-13980-89
Hypertension ge14090 gt13585 gt13080 gt13585 gt12070
BP Thresholds for Definition of Hypertension
High office BP
Normal home BP
ldquoWhite-coatrdquo hypertension
Normal office BP
Normal home BP
ldquoNormotensionrdquo
High office BP
High home BP
Sustained hypertension
Normal office BP
High home BP
Masked hypertension
14090 mmHg
lt13585mmHgHome BP
Office BP
Masked hypertension
0
40
80
120
160
200
0
40
80
120
160
200
12 14 16 18 20 22 0 2 4 6 8 10 12 14
Blo
od
pre
ssure
(mm
Hg)
H
eart
rate
(min
-1)
Time (hour)
Blood pressureHeart rate
Man 20 yearsDaytime 152 87 mm Hg
Night-time 130 71 mm HgNight-time BP Drop -15 -18
Home blood pressure consistently hypertensiveClinic blood pressure 11070 mm Hg target organs damage
12 cohorts
Copenhagen (Denmark)
Dublin (Ireland)
Jingning (China)
Krakoacutew (Poland)
Maracaibo (Venezuela)
Montevideo (Uruguay)
Noorderkempen (Belgium)
Novosibirsk (Russia)
Ohasama (Japan)
Padova (Italy)
Pilsen (Czechia)
Uppsala (Sweden)
To study risk stratification by ABPM in people stratified by CBP
categories The International Database on Ambulatory blood
pressure in relation to Cardiovascular Outcomes (IDACO)
IDACO
Database
Standardised questionnaires
Anthropometric measurements
CBP and ABP
Blood sample (cholesterol glucose etc)
Outcome of participants
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
CV prediction
IDACOdatabase
Cardiovascualr risk based on BP measured in outpatient
8
7
6
5
4
3
2
1
0
0 3 6 9 12 15
20
15
10
05
0
0 3 6 9 12 15
Follow-up (years) Follow-up (years)
CV
eve
nts
(
)
Adjusted for cohort sex age BMI smoking and drinking serum cholesterol CV disease and DM
Cardiovascular events Stroke
Stro
ke(
)
HT
Pre-HT
NT
Plt00001
p=0012
HT
Pre-HT
NT
p=0015
Plt00001
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
05 1 2 4 8 05 1 2 4 8
NT 2441 63 2441 13
NT with masked HT 198 14 198 5
Pre-HT with masked HT 900 90 900 31
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
Daytime BP thresholds ge13585 mmHg
212 (p=00058)
222 (plt00001)
275 (p=0026)
301 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
NT 2527 67 2527 14
NT with masked HT 112 10 112 4
Pre-HT with masked HT 672 74 672 27
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
05 1 2 4 8 05 1 2 4 8
24h BP thresholds ge13080 mmHg
258 (p=00032)
213 (plt00001)
418 (p=00047)
317 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
Home blood pressure and ABPM in detecting masked hypertension (same sample N=128 )
CV riskUpgraded 117Downgraded 148No change 734
Masked hypertensionHome BPM748ABPM 131
MH = masked hypertensionNR = normotensionSH = sustained hypertension
RISHO2014
Baseline to follow-up reproducibility of home blood pressure measurements in tertiles of the follow up duration
RISHO2014
100 120 140 160
-40
-20
0
20
40
CR=176
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=161
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=198
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=218
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=212
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=242
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
a) 1tertile
b) 2tertile
c) 3tertile
Bland and Altman method CR=coefficient of reproducibility twice of SD of the difference between repeated measurement
Observation 24y
43y
59y
Home Blood Pressure as a Predictor of Future Blood Pressure Stability in Borderline HypertensionThe Tecumseh StudyS D Nesbitt J V Amerena EGrant K A Jamerson H Lu A Weder Stevo Julius
JAMA 2016315(23)2564-2575
Characteristics of Colorectal Cancer Screening Strategiesa
Screening for Colorectal Cancer vs ABPM in PrehypertensionUS Preventive Services Task Force Recommendation Statement
PrehypertensionOutpatient BP
Home BPEvery year
ABPMif expected risk MH or
large CV risk
Conformation of MH
Medical treatment on time
Confirmation with ABPM
Treat or not to treat prehypertension this is the question now
bull lifestyle modification for those with prehypertension-the good news is that it works
Ideal cardiovascular health behaviors and factors prevent the development of hypertension inprehypertensive subjects
Gao J Sun H Liang X Gao M Zhao H Qi Y Wang Y Liu Y Li J Zhu Y Zhao Y Wang W Ma L Wu SClinical amp Experimental Hypertension (New York) 37(8)650-5 2015
bull BACKGROUND Seven ideal health metrics were defined by AHA to monitor cardiovascular health This study aimed to investigate the impact of ideal cardiovascular health behaviors and factors on the development of hypertension in prehypertensive subjects
METHODS Thirty-two thousand eight-hundred and eighty-seven participants with prehypertension were included in the study after excluding for preexisting stroke myocardial infarction or malignancy Cox proportional hazards regression was used to calculate hazard ratios and 95 confidence intervals [CI] for the development of hypertension
RESULTS During a follow-up of 522 months 15500 prehypertensive participants developed hypertension The cumulative incidence of hypertension decreased with the number of ideal health metrics increased It was 7861 7108 6315 5607 and 6162 in prehypertensive individuals carrying lt 1 2 3 4 and gt 5 ideal health behaviors or factors respectively After adjustment for age gender family history of hypertension alcohol consumption resting heart rate plasma triglyceride high-density lipoprotein cholesterol low-density lipoprotein cholesterol and high-sensitivity C-reactive protein the risk ratios of incident hypertension in the subjects who carried 2 3 4 and gt 5 ideal health metrics were 0833 (95CI 0789-0880) 0710 (95CI 0672-0749) 0604 (95CI 0568-0642) and 0581 (95CI 0524-0643) respectively in comparison to those with lt 1 ideal health metric A similar trend was also observed in male and female populations Poor health metrics including body mass index diet (salt intake) physical activity total cholesterol and smoking were predictors for the development of hypertension in prehypertensive individuals
CONCLUSION Ideal cardiovascular health behaviors and factors are protective factors to prevent the progression from prehypertension to hypertension
Treat or not to treat prehypertension this is the question now
bull ProfBakris
bull The argument has always been to use lifestyle modification for those with prehypertension-the good news is that it works but the bad news is that nobody does it
How does story continue
bull TROPHY study (candesartan) Julius S Nesbitt SD Egan BM et al Feasibility of treating prehypertension with an angiotensin-receptor blocker N Engl J Med2006354(16)1685-1697
bull PHARAO study (Ramipril) Luumlders S Schrader J Berger J et al The PHARAO study prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure a prospective randomized controlled prevention trial of the German Hypertension League J Hypertens 200826(7)1487-1496
bull Small studies no effect
TROPHY studyKaplan-Meier Curves of New Onset of Clinical
Hypertension in the Two Groups
0 1 2 3 4
Years in study
0
01
02
03
04
05
06
07
08
09
10
C
um
ula
tive
inci
den
ce
Candesartan
Placebo
Candesartan 391 356 309 191 128
Placebo 381 269 184 118 85
Numbers under the graph refer to hypertension-free individuals
2 YearsRR darr66AR darr 26
4 YearsRR darr158AR darr 96
P lt 00001
Julius S NesbittSD N Engl J Med 20063541-13
No effect
bull Lowering the tresholds for the initiation of pharmacologic therapy would have a tremendous economic effect on public health care system (Grassi N Eng J Med 2006)
bull The high-risk strategy identifes and treats those at greatest risk (eg 10y coronary heart disease risk gt20) While there benefits individual the population attributale risk remains significant since most events occur among those at lower risk levels (Egan Nesbitt Julius Therapevtic Advances in CV Disease)
Conclusion for our practice
bull Prehypertension is not an innocent stage and could be dangerous condition
bull It needs to be monitorised excluded masked hypertension
bull Regular blood pressure measurements HBPM ABPM telemonitoring
bull Life style modification versus pharmacological treatment
bull Subclinical organ damage assessmentbull Medical treatment as soon as it is needed
according present ESH guidelines
Why is it important
bull Stage by itself or progression to hypertension
SBP (mm Hg) of Total CHD Deaths Pop RR
gt180 72 09
170-179 68 12
160-169 101 27
150-159 195 62
140-149 234 128
130-139 207 228
120-129 99 284
110-119 13 190
lt110 00 61
MRFIT Systolic BP And CHD Mortality Risk Pyramid For Men
Stage 1 429 190 51
Adapted from Stamler et al Arch Intern Med 1993153596
Stage 2 245 46 107
Pre-HTN 306 532 11
Normal 13 251 1
prehypertension was a major unsolved--but soluble--mass public health problem
Prehypertension and stroke risk
Noumerous abnormalities in borderline hypertension according to ProfJulius
bull High cardiac output fast heart rate
bull Abnormal vascular resistance
bull Low plasma volume high hematocrit
bull Several metabolic abnormalities
Age distribution (Slovenia 2009)
0
5
10
15
20
25
30
35
20-29 30-39 40-49 50-59 60-69 70-79 80-89 90-99
Age
Age distribution
Normal BP
New diagnose
HNBP
Hypertension
Risk Factors - Tecumseh BP Study
Normotensive
(n=822) Borderline
(n=124)
p
Cholesterol (mgdL) 176 190 0001
HDL (mgdL) 43 40 001
Triglycerides
(mgdL) 95 135 0001
Insulin (UdL) 12 18 0001
Glucose (mgdL) 92 95 001
Insulin-glucose ratio 0155 0200 0001
Percent overweight 136 301 lt0001
Julius S et al JAMA 1990 264 354-358
Prevalence of prehypertension and hypertension stratified by Visceral Adipose Index and Body Fat Percentage
Hu L Huang X You C Li J Hong K et al (2017) Prevalence and Risk Factors of Prehypertension and Hypertension in Southern China PLOS ONE 12(1) e0170238 doi101371journalpone0170238httpjournalsplosorgplosonearticleid=101371journalpone0170238
PLOS 2017
Framingham Study incidence of hypertension
Vasan LarsonLevy Lancet 2001
Flemish Study Belgiumincidence of hypertension
(781 women 675 men)
Zhang H Fagard R Staessen J J Hypertension 2006
1 summary
bull Prehypertensives are more obese have higher cholesterol levels blood glucose insuline resistance heart rate
bull Stage by itself and progression to hypertension
Letrsquos go for a drink
Definition of prehypertension
stage Outpatient BP
(mmHg)
Home BP
(mmHg)
ABMP (mmHg)
24-h Day-time Night-time
Normotension lt12080
Prehypertension 120-13980-89
Hypertension ge14090 gt13585 gt13080 gt13585 gt12070
BP Thresholds for Definition of Hypertension
High office BP
Normal home BP
ldquoWhite-coatrdquo hypertension
Normal office BP
Normal home BP
ldquoNormotensionrdquo
High office BP
High home BP
Sustained hypertension
Normal office BP
High home BP
Masked hypertension
14090 mmHg
lt13585mmHgHome BP
Office BP
Masked hypertension
0
40
80
120
160
200
0
40
80
120
160
200
12 14 16 18 20 22 0 2 4 6 8 10 12 14
Blo
od
pre
ssure
(mm
Hg)
H
eart
rate
(min
-1)
Time (hour)
Blood pressureHeart rate
Man 20 yearsDaytime 152 87 mm Hg
Night-time 130 71 mm HgNight-time BP Drop -15 -18
Home blood pressure consistently hypertensiveClinic blood pressure 11070 mm Hg target organs damage
12 cohorts
Copenhagen (Denmark)
Dublin (Ireland)
Jingning (China)
Krakoacutew (Poland)
Maracaibo (Venezuela)
Montevideo (Uruguay)
Noorderkempen (Belgium)
Novosibirsk (Russia)
Ohasama (Japan)
Padova (Italy)
Pilsen (Czechia)
Uppsala (Sweden)
To study risk stratification by ABPM in people stratified by CBP
categories The International Database on Ambulatory blood
pressure in relation to Cardiovascular Outcomes (IDACO)
IDACO
Database
Standardised questionnaires
Anthropometric measurements
CBP and ABP
Blood sample (cholesterol glucose etc)
Outcome of participants
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
CV prediction
IDACOdatabase
Cardiovascualr risk based on BP measured in outpatient
8
7
6
5
4
3
2
1
0
0 3 6 9 12 15
20
15
10
05
0
0 3 6 9 12 15
Follow-up (years) Follow-up (years)
CV
eve
nts
(
)
Adjusted for cohort sex age BMI smoking and drinking serum cholesterol CV disease and DM
Cardiovascular events Stroke
Stro
ke(
)
HT
Pre-HT
NT
Plt00001
p=0012
HT
Pre-HT
NT
p=0015
Plt00001
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
05 1 2 4 8 05 1 2 4 8
NT 2441 63 2441 13
NT with masked HT 198 14 198 5
Pre-HT with masked HT 900 90 900 31
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
Daytime BP thresholds ge13585 mmHg
212 (p=00058)
222 (plt00001)
275 (p=0026)
301 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
NT 2527 67 2527 14
NT with masked HT 112 10 112 4
Pre-HT with masked HT 672 74 672 27
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
05 1 2 4 8 05 1 2 4 8
24h BP thresholds ge13080 mmHg
258 (p=00032)
213 (plt00001)
418 (p=00047)
317 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
Home blood pressure and ABPM in detecting masked hypertension (same sample N=128 )
CV riskUpgraded 117Downgraded 148No change 734
Masked hypertensionHome BPM748ABPM 131
MH = masked hypertensionNR = normotensionSH = sustained hypertension
RISHO2014
Baseline to follow-up reproducibility of home blood pressure measurements in tertiles of the follow up duration
RISHO2014
100 120 140 160
-40
-20
0
20
40
CR=176
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=161
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=198
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=218
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=212
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=242
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
a) 1tertile
b) 2tertile
c) 3tertile
Bland and Altman method CR=coefficient of reproducibility twice of SD of the difference between repeated measurement
Observation 24y
43y
59y
Home Blood Pressure as a Predictor of Future Blood Pressure Stability in Borderline HypertensionThe Tecumseh StudyS D Nesbitt J V Amerena EGrant K A Jamerson H Lu A Weder Stevo Julius
JAMA 2016315(23)2564-2575
Characteristics of Colorectal Cancer Screening Strategiesa
Screening for Colorectal Cancer vs ABPM in PrehypertensionUS Preventive Services Task Force Recommendation Statement
PrehypertensionOutpatient BP
Home BPEvery year
ABPMif expected risk MH or
large CV risk
Conformation of MH
Medical treatment on time
Confirmation with ABPM
Treat or not to treat prehypertension this is the question now
bull lifestyle modification for those with prehypertension-the good news is that it works
Ideal cardiovascular health behaviors and factors prevent the development of hypertension inprehypertensive subjects
Gao J Sun H Liang X Gao M Zhao H Qi Y Wang Y Liu Y Li J Zhu Y Zhao Y Wang W Ma L Wu SClinical amp Experimental Hypertension (New York) 37(8)650-5 2015
bull BACKGROUND Seven ideal health metrics were defined by AHA to monitor cardiovascular health This study aimed to investigate the impact of ideal cardiovascular health behaviors and factors on the development of hypertension in prehypertensive subjects
METHODS Thirty-two thousand eight-hundred and eighty-seven participants with prehypertension were included in the study after excluding for preexisting stroke myocardial infarction or malignancy Cox proportional hazards regression was used to calculate hazard ratios and 95 confidence intervals [CI] for the development of hypertension
RESULTS During a follow-up of 522 months 15500 prehypertensive participants developed hypertension The cumulative incidence of hypertension decreased with the number of ideal health metrics increased It was 7861 7108 6315 5607 and 6162 in prehypertensive individuals carrying lt 1 2 3 4 and gt 5 ideal health behaviors or factors respectively After adjustment for age gender family history of hypertension alcohol consumption resting heart rate plasma triglyceride high-density lipoprotein cholesterol low-density lipoprotein cholesterol and high-sensitivity C-reactive protein the risk ratios of incident hypertension in the subjects who carried 2 3 4 and gt 5 ideal health metrics were 0833 (95CI 0789-0880) 0710 (95CI 0672-0749) 0604 (95CI 0568-0642) and 0581 (95CI 0524-0643) respectively in comparison to those with lt 1 ideal health metric A similar trend was also observed in male and female populations Poor health metrics including body mass index diet (salt intake) physical activity total cholesterol and smoking were predictors for the development of hypertension in prehypertensive individuals
CONCLUSION Ideal cardiovascular health behaviors and factors are protective factors to prevent the progression from prehypertension to hypertension
Treat or not to treat prehypertension this is the question now
bull ProfBakris
bull The argument has always been to use lifestyle modification for those with prehypertension-the good news is that it works but the bad news is that nobody does it
How does story continue
bull TROPHY study (candesartan) Julius S Nesbitt SD Egan BM et al Feasibility of treating prehypertension with an angiotensin-receptor blocker N Engl J Med2006354(16)1685-1697
bull PHARAO study (Ramipril) Luumlders S Schrader J Berger J et al The PHARAO study prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure a prospective randomized controlled prevention trial of the German Hypertension League J Hypertens 200826(7)1487-1496
bull Small studies no effect
TROPHY studyKaplan-Meier Curves of New Onset of Clinical
Hypertension in the Two Groups
0 1 2 3 4
Years in study
0
01
02
03
04
05
06
07
08
09
10
C
um
ula
tive
inci
den
ce
Candesartan
Placebo
Candesartan 391 356 309 191 128
Placebo 381 269 184 118 85
Numbers under the graph refer to hypertension-free individuals
2 YearsRR darr66AR darr 26
4 YearsRR darr158AR darr 96
P lt 00001
Julius S NesbittSD N Engl J Med 20063541-13
No effect
bull Lowering the tresholds for the initiation of pharmacologic therapy would have a tremendous economic effect on public health care system (Grassi N Eng J Med 2006)
bull The high-risk strategy identifes and treats those at greatest risk (eg 10y coronary heart disease risk gt20) While there benefits individual the population attributale risk remains significant since most events occur among those at lower risk levels (Egan Nesbitt Julius Therapevtic Advances in CV Disease)
Conclusion for our practice
bull Prehypertension is not an innocent stage and could be dangerous condition
bull It needs to be monitorised excluded masked hypertension
bull Regular blood pressure measurements HBPM ABPM telemonitoring
bull Life style modification versus pharmacological treatment
bull Subclinical organ damage assessmentbull Medical treatment as soon as it is needed
according present ESH guidelines
SBP (mm Hg) of Total CHD Deaths Pop RR
gt180 72 09
170-179 68 12
160-169 101 27
150-159 195 62
140-149 234 128
130-139 207 228
120-129 99 284
110-119 13 190
lt110 00 61
MRFIT Systolic BP And CHD Mortality Risk Pyramid For Men
Stage 1 429 190 51
Adapted from Stamler et al Arch Intern Med 1993153596
Stage 2 245 46 107
Pre-HTN 306 532 11
Normal 13 251 1
prehypertension was a major unsolved--but soluble--mass public health problem
Prehypertension and stroke risk
Noumerous abnormalities in borderline hypertension according to ProfJulius
bull High cardiac output fast heart rate
bull Abnormal vascular resistance
bull Low plasma volume high hematocrit
bull Several metabolic abnormalities
Age distribution (Slovenia 2009)
0
5
10
15
20
25
30
35
20-29 30-39 40-49 50-59 60-69 70-79 80-89 90-99
Age
Age distribution
Normal BP
New diagnose
HNBP
Hypertension
Risk Factors - Tecumseh BP Study
Normotensive
(n=822) Borderline
(n=124)
p
Cholesterol (mgdL) 176 190 0001
HDL (mgdL) 43 40 001
Triglycerides
(mgdL) 95 135 0001
Insulin (UdL) 12 18 0001
Glucose (mgdL) 92 95 001
Insulin-glucose ratio 0155 0200 0001
Percent overweight 136 301 lt0001
Julius S et al JAMA 1990 264 354-358
Prevalence of prehypertension and hypertension stratified by Visceral Adipose Index and Body Fat Percentage
Hu L Huang X You C Li J Hong K et al (2017) Prevalence and Risk Factors of Prehypertension and Hypertension in Southern China PLOS ONE 12(1) e0170238 doi101371journalpone0170238httpjournalsplosorgplosonearticleid=101371journalpone0170238
PLOS 2017
Framingham Study incidence of hypertension
Vasan LarsonLevy Lancet 2001
Flemish Study Belgiumincidence of hypertension
(781 women 675 men)
Zhang H Fagard R Staessen J J Hypertension 2006
1 summary
bull Prehypertensives are more obese have higher cholesterol levels blood glucose insuline resistance heart rate
bull Stage by itself and progression to hypertension
Letrsquos go for a drink
Definition of prehypertension
stage Outpatient BP
(mmHg)
Home BP
(mmHg)
ABMP (mmHg)
24-h Day-time Night-time
Normotension lt12080
Prehypertension 120-13980-89
Hypertension ge14090 gt13585 gt13080 gt13585 gt12070
BP Thresholds for Definition of Hypertension
High office BP
Normal home BP
ldquoWhite-coatrdquo hypertension
Normal office BP
Normal home BP
ldquoNormotensionrdquo
High office BP
High home BP
Sustained hypertension
Normal office BP
High home BP
Masked hypertension
14090 mmHg
lt13585mmHgHome BP
Office BP
Masked hypertension
0
40
80
120
160
200
0
40
80
120
160
200
12 14 16 18 20 22 0 2 4 6 8 10 12 14
Blo
od
pre
ssure
(mm
Hg)
H
eart
rate
(min
-1)
Time (hour)
Blood pressureHeart rate
Man 20 yearsDaytime 152 87 mm Hg
Night-time 130 71 mm HgNight-time BP Drop -15 -18
Home blood pressure consistently hypertensiveClinic blood pressure 11070 mm Hg target organs damage
12 cohorts
Copenhagen (Denmark)
Dublin (Ireland)
Jingning (China)
Krakoacutew (Poland)
Maracaibo (Venezuela)
Montevideo (Uruguay)
Noorderkempen (Belgium)
Novosibirsk (Russia)
Ohasama (Japan)
Padova (Italy)
Pilsen (Czechia)
Uppsala (Sweden)
To study risk stratification by ABPM in people stratified by CBP
categories The International Database on Ambulatory blood
pressure in relation to Cardiovascular Outcomes (IDACO)
IDACO
Database
Standardised questionnaires
Anthropometric measurements
CBP and ABP
Blood sample (cholesterol glucose etc)
Outcome of participants
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
CV prediction
IDACOdatabase
Cardiovascualr risk based on BP measured in outpatient
8
7
6
5
4
3
2
1
0
0 3 6 9 12 15
20
15
10
05
0
0 3 6 9 12 15
Follow-up (years) Follow-up (years)
CV
eve
nts
(
)
Adjusted for cohort sex age BMI smoking and drinking serum cholesterol CV disease and DM
Cardiovascular events Stroke
Stro
ke(
)
HT
Pre-HT
NT
Plt00001
p=0012
HT
Pre-HT
NT
p=0015
Plt00001
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
05 1 2 4 8 05 1 2 4 8
NT 2441 63 2441 13
NT with masked HT 198 14 198 5
Pre-HT with masked HT 900 90 900 31
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
Daytime BP thresholds ge13585 mmHg
212 (p=00058)
222 (plt00001)
275 (p=0026)
301 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
NT 2527 67 2527 14
NT with masked HT 112 10 112 4
Pre-HT with masked HT 672 74 672 27
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
05 1 2 4 8 05 1 2 4 8
24h BP thresholds ge13080 mmHg
258 (p=00032)
213 (plt00001)
418 (p=00047)
317 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
Home blood pressure and ABPM in detecting masked hypertension (same sample N=128 )
CV riskUpgraded 117Downgraded 148No change 734
Masked hypertensionHome BPM748ABPM 131
MH = masked hypertensionNR = normotensionSH = sustained hypertension
RISHO2014
Baseline to follow-up reproducibility of home blood pressure measurements in tertiles of the follow up duration
RISHO2014
100 120 140 160
-40
-20
0
20
40
CR=176
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=161
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=198
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=218
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=212
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=242
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
a) 1tertile
b) 2tertile
c) 3tertile
Bland and Altman method CR=coefficient of reproducibility twice of SD of the difference between repeated measurement
Observation 24y
43y
59y
Home Blood Pressure as a Predictor of Future Blood Pressure Stability in Borderline HypertensionThe Tecumseh StudyS D Nesbitt J V Amerena EGrant K A Jamerson H Lu A Weder Stevo Julius
JAMA 2016315(23)2564-2575
Characteristics of Colorectal Cancer Screening Strategiesa
Screening for Colorectal Cancer vs ABPM in PrehypertensionUS Preventive Services Task Force Recommendation Statement
PrehypertensionOutpatient BP
Home BPEvery year
ABPMif expected risk MH or
large CV risk
Conformation of MH
Medical treatment on time
Confirmation with ABPM
Treat or not to treat prehypertension this is the question now
bull lifestyle modification for those with prehypertension-the good news is that it works
Ideal cardiovascular health behaviors and factors prevent the development of hypertension inprehypertensive subjects
Gao J Sun H Liang X Gao M Zhao H Qi Y Wang Y Liu Y Li J Zhu Y Zhao Y Wang W Ma L Wu SClinical amp Experimental Hypertension (New York) 37(8)650-5 2015
bull BACKGROUND Seven ideal health metrics were defined by AHA to monitor cardiovascular health This study aimed to investigate the impact of ideal cardiovascular health behaviors and factors on the development of hypertension in prehypertensive subjects
METHODS Thirty-two thousand eight-hundred and eighty-seven participants with prehypertension were included in the study after excluding for preexisting stroke myocardial infarction or malignancy Cox proportional hazards regression was used to calculate hazard ratios and 95 confidence intervals [CI] for the development of hypertension
RESULTS During a follow-up of 522 months 15500 prehypertensive participants developed hypertension The cumulative incidence of hypertension decreased with the number of ideal health metrics increased It was 7861 7108 6315 5607 and 6162 in prehypertensive individuals carrying lt 1 2 3 4 and gt 5 ideal health behaviors or factors respectively After adjustment for age gender family history of hypertension alcohol consumption resting heart rate plasma triglyceride high-density lipoprotein cholesterol low-density lipoprotein cholesterol and high-sensitivity C-reactive protein the risk ratios of incident hypertension in the subjects who carried 2 3 4 and gt 5 ideal health metrics were 0833 (95CI 0789-0880) 0710 (95CI 0672-0749) 0604 (95CI 0568-0642) and 0581 (95CI 0524-0643) respectively in comparison to those with lt 1 ideal health metric A similar trend was also observed in male and female populations Poor health metrics including body mass index diet (salt intake) physical activity total cholesterol and smoking were predictors for the development of hypertension in prehypertensive individuals
CONCLUSION Ideal cardiovascular health behaviors and factors are protective factors to prevent the progression from prehypertension to hypertension
Treat or not to treat prehypertension this is the question now
bull ProfBakris
bull The argument has always been to use lifestyle modification for those with prehypertension-the good news is that it works but the bad news is that nobody does it
How does story continue
bull TROPHY study (candesartan) Julius S Nesbitt SD Egan BM et al Feasibility of treating prehypertension with an angiotensin-receptor blocker N Engl J Med2006354(16)1685-1697
bull PHARAO study (Ramipril) Luumlders S Schrader J Berger J et al The PHARAO study prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure a prospective randomized controlled prevention trial of the German Hypertension League J Hypertens 200826(7)1487-1496
bull Small studies no effect
TROPHY studyKaplan-Meier Curves of New Onset of Clinical
Hypertension in the Two Groups
0 1 2 3 4
Years in study
0
01
02
03
04
05
06
07
08
09
10
C
um
ula
tive
inci
den
ce
Candesartan
Placebo
Candesartan 391 356 309 191 128
Placebo 381 269 184 118 85
Numbers under the graph refer to hypertension-free individuals
2 YearsRR darr66AR darr 26
4 YearsRR darr158AR darr 96
P lt 00001
Julius S NesbittSD N Engl J Med 20063541-13
No effect
bull Lowering the tresholds for the initiation of pharmacologic therapy would have a tremendous economic effect on public health care system (Grassi N Eng J Med 2006)
bull The high-risk strategy identifes and treats those at greatest risk (eg 10y coronary heart disease risk gt20) While there benefits individual the population attributale risk remains significant since most events occur among those at lower risk levels (Egan Nesbitt Julius Therapevtic Advances in CV Disease)
Conclusion for our practice
bull Prehypertension is not an innocent stage and could be dangerous condition
bull It needs to be monitorised excluded masked hypertension
bull Regular blood pressure measurements HBPM ABPM telemonitoring
bull Life style modification versus pharmacological treatment
bull Subclinical organ damage assessmentbull Medical treatment as soon as it is needed
according present ESH guidelines
Prehypertension and stroke risk
Noumerous abnormalities in borderline hypertension according to ProfJulius
bull High cardiac output fast heart rate
bull Abnormal vascular resistance
bull Low plasma volume high hematocrit
bull Several metabolic abnormalities
Age distribution (Slovenia 2009)
0
5
10
15
20
25
30
35
20-29 30-39 40-49 50-59 60-69 70-79 80-89 90-99
Age
Age distribution
Normal BP
New diagnose
HNBP
Hypertension
Risk Factors - Tecumseh BP Study
Normotensive
(n=822) Borderline
(n=124)
p
Cholesterol (mgdL) 176 190 0001
HDL (mgdL) 43 40 001
Triglycerides
(mgdL) 95 135 0001
Insulin (UdL) 12 18 0001
Glucose (mgdL) 92 95 001
Insulin-glucose ratio 0155 0200 0001
Percent overweight 136 301 lt0001
Julius S et al JAMA 1990 264 354-358
Prevalence of prehypertension and hypertension stratified by Visceral Adipose Index and Body Fat Percentage
Hu L Huang X You C Li J Hong K et al (2017) Prevalence and Risk Factors of Prehypertension and Hypertension in Southern China PLOS ONE 12(1) e0170238 doi101371journalpone0170238httpjournalsplosorgplosonearticleid=101371journalpone0170238
PLOS 2017
Framingham Study incidence of hypertension
Vasan LarsonLevy Lancet 2001
Flemish Study Belgiumincidence of hypertension
(781 women 675 men)
Zhang H Fagard R Staessen J J Hypertension 2006
1 summary
bull Prehypertensives are more obese have higher cholesterol levels blood glucose insuline resistance heart rate
bull Stage by itself and progression to hypertension
Letrsquos go for a drink
Definition of prehypertension
stage Outpatient BP
(mmHg)
Home BP
(mmHg)
ABMP (mmHg)
24-h Day-time Night-time
Normotension lt12080
Prehypertension 120-13980-89
Hypertension ge14090 gt13585 gt13080 gt13585 gt12070
BP Thresholds for Definition of Hypertension
High office BP
Normal home BP
ldquoWhite-coatrdquo hypertension
Normal office BP
Normal home BP
ldquoNormotensionrdquo
High office BP
High home BP
Sustained hypertension
Normal office BP
High home BP
Masked hypertension
14090 mmHg
lt13585mmHgHome BP
Office BP
Masked hypertension
0
40
80
120
160
200
0
40
80
120
160
200
12 14 16 18 20 22 0 2 4 6 8 10 12 14
Blo
od
pre
ssure
(mm
Hg)
H
eart
rate
(min
-1)
Time (hour)
Blood pressureHeart rate
Man 20 yearsDaytime 152 87 mm Hg
Night-time 130 71 mm HgNight-time BP Drop -15 -18
Home blood pressure consistently hypertensiveClinic blood pressure 11070 mm Hg target organs damage
12 cohorts
Copenhagen (Denmark)
Dublin (Ireland)
Jingning (China)
Krakoacutew (Poland)
Maracaibo (Venezuela)
Montevideo (Uruguay)
Noorderkempen (Belgium)
Novosibirsk (Russia)
Ohasama (Japan)
Padova (Italy)
Pilsen (Czechia)
Uppsala (Sweden)
To study risk stratification by ABPM in people stratified by CBP
categories The International Database on Ambulatory blood
pressure in relation to Cardiovascular Outcomes (IDACO)
IDACO
Database
Standardised questionnaires
Anthropometric measurements
CBP and ABP
Blood sample (cholesterol glucose etc)
Outcome of participants
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
CV prediction
IDACOdatabase
Cardiovascualr risk based on BP measured in outpatient
8
7
6
5
4
3
2
1
0
0 3 6 9 12 15
20
15
10
05
0
0 3 6 9 12 15
Follow-up (years) Follow-up (years)
CV
eve
nts
(
)
Adjusted for cohort sex age BMI smoking and drinking serum cholesterol CV disease and DM
Cardiovascular events Stroke
Stro
ke(
)
HT
Pre-HT
NT
Plt00001
p=0012
HT
Pre-HT
NT
p=0015
Plt00001
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
05 1 2 4 8 05 1 2 4 8
NT 2441 63 2441 13
NT with masked HT 198 14 198 5
Pre-HT with masked HT 900 90 900 31
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
Daytime BP thresholds ge13585 mmHg
212 (p=00058)
222 (plt00001)
275 (p=0026)
301 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
NT 2527 67 2527 14
NT with masked HT 112 10 112 4
Pre-HT with masked HT 672 74 672 27
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
05 1 2 4 8 05 1 2 4 8
24h BP thresholds ge13080 mmHg
258 (p=00032)
213 (plt00001)
418 (p=00047)
317 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
Home blood pressure and ABPM in detecting masked hypertension (same sample N=128 )
CV riskUpgraded 117Downgraded 148No change 734
Masked hypertensionHome BPM748ABPM 131
MH = masked hypertensionNR = normotensionSH = sustained hypertension
RISHO2014
Baseline to follow-up reproducibility of home blood pressure measurements in tertiles of the follow up duration
RISHO2014
100 120 140 160
-40
-20
0
20
40
CR=176
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=161
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=198
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=218
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=212
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=242
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
a) 1tertile
b) 2tertile
c) 3tertile
Bland and Altman method CR=coefficient of reproducibility twice of SD of the difference between repeated measurement
Observation 24y
43y
59y
Home Blood Pressure as a Predictor of Future Blood Pressure Stability in Borderline HypertensionThe Tecumseh StudyS D Nesbitt J V Amerena EGrant K A Jamerson H Lu A Weder Stevo Julius
JAMA 2016315(23)2564-2575
Characteristics of Colorectal Cancer Screening Strategiesa
Screening for Colorectal Cancer vs ABPM in PrehypertensionUS Preventive Services Task Force Recommendation Statement
PrehypertensionOutpatient BP
Home BPEvery year
ABPMif expected risk MH or
large CV risk
Conformation of MH
Medical treatment on time
Confirmation with ABPM
Treat or not to treat prehypertension this is the question now
bull lifestyle modification for those with prehypertension-the good news is that it works
Ideal cardiovascular health behaviors and factors prevent the development of hypertension inprehypertensive subjects
Gao J Sun H Liang X Gao M Zhao H Qi Y Wang Y Liu Y Li J Zhu Y Zhao Y Wang W Ma L Wu SClinical amp Experimental Hypertension (New York) 37(8)650-5 2015
bull BACKGROUND Seven ideal health metrics were defined by AHA to monitor cardiovascular health This study aimed to investigate the impact of ideal cardiovascular health behaviors and factors on the development of hypertension in prehypertensive subjects
METHODS Thirty-two thousand eight-hundred and eighty-seven participants with prehypertension were included in the study after excluding for preexisting stroke myocardial infarction or malignancy Cox proportional hazards regression was used to calculate hazard ratios and 95 confidence intervals [CI] for the development of hypertension
RESULTS During a follow-up of 522 months 15500 prehypertensive participants developed hypertension The cumulative incidence of hypertension decreased with the number of ideal health metrics increased It was 7861 7108 6315 5607 and 6162 in prehypertensive individuals carrying lt 1 2 3 4 and gt 5 ideal health behaviors or factors respectively After adjustment for age gender family history of hypertension alcohol consumption resting heart rate plasma triglyceride high-density lipoprotein cholesterol low-density lipoprotein cholesterol and high-sensitivity C-reactive protein the risk ratios of incident hypertension in the subjects who carried 2 3 4 and gt 5 ideal health metrics were 0833 (95CI 0789-0880) 0710 (95CI 0672-0749) 0604 (95CI 0568-0642) and 0581 (95CI 0524-0643) respectively in comparison to those with lt 1 ideal health metric A similar trend was also observed in male and female populations Poor health metrics including body mass index diet (salt intake) physical activity total cholesterol and smoking were predictors for the development of hypertension in prehypertensive individuals
CONCLUSION Ideal cardiovascular health behaviors and factors are protective factors to prevent the progression from prehypertension to hypertension
Treat or not to treat prehypertension this is the question now
bull ProfBakris
bull The argument has always been to use lifestyle modification for those with prehypertension-the good news is that it works but the bad news is that nobody does it
How does story continue
bull TROPHY study (candesartan) Julius S Nesbitt SD Egan BM et al Feasibility of treating prehypertension with an angiotensin-receptor blocker N Engl J Med2006354(16)1685-1697
bull PHARAO study (Ramipril) Luumlders S Schrader J Berger J et al The PHARAO study prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure a prospective randomized controlled prevention trial of the German Hypertension League J Hypertens 200826(7)1487-1496
bull Small studies no effect
TROPHY studyKaplan-Meier Curves of New Onset of Clinical
Hypertension in the Two Groups
0 1 2 3 4
Years in study
0
01
02
03
04
05
06
07
08
09
10
C
um
ula
tive
inci
den
ce
Candesartan
Placebo
Candesartan 391 356 309 191 128
Placebo 381 269 184 118 85
Numbers under the graph refer to hypertension-free individuals
2 YearsRR darr66AR darr 26
4 YearsRR darr158AR darr 96
P lt 00001
Julius S NesbittSD N Engl J Med 20063541-13
No effect
bull Lowering the tresholds for the initiation of pharmacologic therapy would have a tremendous economic effect on public health care system (Grassi N Eng J Med 2006)
bull The high-risk strategy identifes and treats those at greatest risk (eg 10y coronary heart disease risk gt20) While there benefits individual the population attributale risk remains significant since most events occur among those at lower risk levels (Egan Nesbitt Julius Therapevtic Advances in CV Disease)
Conclusion for our practice
bull Prehypertension is not an innocent stage and could be dangerous condition
bull It needs to be monitorised excluded masked hypertension
bull Regular blood pressure measurements HBPM ABPM telemonitoring
bull Life style modification versus pharmacological treatment
bull Subclinical organ damage assessmentbull Medical treatment as soon as it is needed
according present ESH guidelines
Noumerous abnormalities in borderline hypertension according to ProfJulius
bull High cardiac output fast heart rate
bull Abnormal vascular resistance
bull Low plasma volume high hematocrit
bull Several metabolic abnormalities
Age distribution (Slovenia 2009)
0
5
10
15
20
25
30
35
20-29 30-39 40-49 50-59 60-69 70-79 80-89 90-99
Age
Age distribution
Normal BP
New diagnose
HNBP
Hypertension
Risk Factors - Tecumseh BP Study
Normotensive
(n=822) Borderline
(n=124)
p
Cholesterol (mgdL) 176 190 0001
HDL (mgdL) 43 40 001
Triglycerides
(mgdL) 95 135 0001
Insulin (UdL) 12 18 0001
Glucose (mgdL) 92 95 001
Insulin-glucose ratio 0155 0200 0001
Percent overweight 136 301 lt0001
Julius S et al JAMA 1990 264 354-358
Prevalence of prehypertension and hypertension stratified by Visceral Adipose Index and Body Fat Percentage
Hu L Huang X You C Li J Hong K et al (2017) Prevalence and Risk Factors of Prehypertension and Hypertension in Southern China PLOS ONE 12(1) e0170238 doi101371journalpone0170238httpjournalsplosorgplosonearticleid=101371journalpone0170238
PLOS 2017
Framingham Study incidence of hypertension
Vasan LarsonLevy Lancet 2001
Flemish Study Belgiumincidence of hypertension
(781 women 675 men)
Zhang H Fagard R Staessen J J Hypertension 2006
1 summary
bull Prehypertensives are more obese have higher cholesterol levels blood glucose insuline resistance heart rate
bull Stage by itself and progression to hypertension
Letrsquos go for a drink
Definition of prehypertension
stage Outpatient BP
(mmHg)
Home BP
(mmHg)
ABMP (mmHg)
24-h Day-time Night-time
Normotension lt12080
Prehypertension 120-13980-89
Hypertension ge14090 gt13585 gt13080 gt13585 gt12070
BP Thresholds for Definition of Hypertension
High office BP
Normal home BP
ldquoWhite-coatrdquo hypertension
Normal office BP
Normal home BP
ldquoNormotensionrdquo
High office BP
High home BP
Sustained hypertension
Normal office BP
High home BP
Masked hypertension
14090 mmHg
lt13585mmHgHome BP
Office BP
Masked hypertension
0
40
80
120
160
200
0
40
80
120
160
200
12 14 16 18 20 22 0 2 4 6 8 10 12 14
Blo
od
pre
ssure
(mm
Hg)
H
eart
rate
(min
-1)
Time (hour)
Blood pressureHeart rate
Man 20 yearsDaytime 152 87 mm Hg
Night-time 130 71 mm HgNight-time BP Drop -15 -18
Home blood pressure consistently hypertensiveClinic blood pressure 11070 mm Hg target organs damage
12 cohorts
Copenhagen (Denmark)
Dublin (Ireland)
Jingning (China)
Krakoacutew (Poland)
Maracaibo (Venezuela)
Montevideo (Uruguay)
Noorderkempen (Belgium)
Novosibirsk (Russia)
Ohasama (Japan)
Padova (Italy)
Pilsen (Czechia)
Uppsala (Sweden)
To study risk stratification by ABPM in people stratified by CBP
categories The International Database on Ambulatory blood
pressure in relation to Cardiovascular Outcomes (IDACO)
IDACO
Database
Standardised questionnaires
Anthropometric measurements
CBP and ABP
Blood sample (cholesterol glucose etc)
Outcome of participants
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
CV prediction
IDACOdatabase
Cardiovascualr risk based on BP measured in outpatient
8
7
6
5
4
3
2
1
0
0 3 6 9 12 15
20
15
10
05
0
0 3 6 9 12 15
Follow-up (years) Follow-up (years)
CV
eve
nts
(
)
Adjusted for cohort sex age BMI smoking and drinking serum cholesterol CV disease and DM
Cardiovascular events Stroke
Stro
ke(
)
HT
Pre-HT
NT
Plt00001
p=0012
HT
Pre-HT
NT
p=0015
Plt00001
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
05 1 2 4 8 05 1 2 4 8
NT 2441 63 2441 13
NT with masked HT 198 14 198 5
Pre-HT with masked HT 900 90 900 31
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
Daytime BP thresholds ge13585 mmHg
212 (p=00058)
222 (plt00001)
275 (p=0026)
301 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
NT 2527 67 2527 14
NT with masked HT 112 10 112 4
Pre-HT with masked HT 672 74 672 27
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
05 1 2 4 8 05 1 2 4 8
24h BP thresholds ge13080 mmHg
258 (p=00032)
213 (plt00001)
418 (p=00047)
317 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
Home blood pressure and ABPM in detecting masked hypertension (same sample N=128 )
CV riskUpgraded 117Downgraded 148No change 734
Masked hypertensionHome BPM748ABPM 131
MH = masked hypertensionNR = normotensionSH = sustained hypertension
RISHO2014
Baseline to follow-up reproducibility of home blood pressure measurements in tertiles of the follow up duration
RISHO2014
100 120 140 160
-40
-20
0
20
40
CR=176
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=161
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=198
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=218
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=212
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=242
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
a) 1tertile
b) 2tertile
c) 3tertile
Bland and Altman method CR=coefficient of reproducibility twice of SD of the difference between repeated measurement
Observation 24y
43y
59y
Home Blood Pressure as a Predictor of Future Blood Pressure Stability in Borderline HypertensionThe Tecumseh StudyS D Nesbitt J V Amerena EGrant K A Jamerson H Lu A Weder Stevo Julius
JAMA 2016315(23)2564-2575
Characteristics of Colorectal Cancer Screening Strategiesa
Screening for Colorectal Cancer vs ABPM in PrehypertensionUS Preventive Services Task Force Recommendation Statement
PrehypertensionOutpatient BP
Home BPEvery year
ABPMif expected risk MH or
large CV risk
Conformation of MH
Medical treatment on time
Confirmation with ABPM
Treat or not to treat prehypertension this is the question now
bull lifestyle modification for those with prehypertension-the good news is that it works
Ideal cardiovascular health behaviors and factors prevent the development of hypertension inprehypertensive subjects
Gao J Sun H Liang X Gao M Zhao H Qi Y Wang Y Liu Y Li J Zhu Y Zhao Y Wang W Ma L Wu SClinical amp Experimental Hypertension (New York) 37(8)650-5 2015
bull BACKGROUND Seven ideal health metrics were defined by AHA to monitor cardiovascular health This study aimed to investigate the impact of ideal cardiovascular health behaviors and factors on the development of hypertension in prehypertensive subjects
METHODS Thirty-two thousand eight-hundred and eighty-seven participants with prehypertension were included in the study after excluding for preexisting stroke myocardial infarction or malignancy Cox proportional hazards regression was used to calculate hazard ratios and 95 confidence intervals [CI] for the development of hypertension
RESULTS During a follow-up of 522 months 15500 prehypertensive participants developed hypertension The cumulative incidence of hypertension decreased with the number of ideal health metrics increased It was 7861 7108 6315 5607 and 6162 in prehypertensive individuals carrying lt 1 2 3 4 and gt 5 ideal health behaviors or factors respectively After adjustment for age gender family history of hypertension alcohol consumption resting heart rate plasma triglyceride high-density lipoprotein cholesterol low-density lipoprotein cholesterol and high-sensitivity C-reactive protein the risk ratios of incident hypertension in the subjects who carried 2 3 4 and gt 5 ideal health metrics were 0833 (95CI 0789-0880) 0710 (95CI 0672-0749) 0604 (95CI 0568-0642) and 0581 (95CI 0524-0643) respectively in comparison to those with lt 1 ideal health metric A similar trend was also observed in male and female populations Poor health metrics including body mass index diet (salt intake) physical activity total cholesterol and smoking were predictors for the development of hypertension in prehypertensive individuals
CONCLUSION Ideal cardiovascular health behaviors and factors are protective factors to prevent the progression from prehypertension to hypertension
Treat or not to treat prehypertension this is the question now
bull ProfBakris
bull The argument has always been to use lifestyle modification for those with prehypertension-the good news is that it works but the bad news is that nobody does it
How does story continue
bull TROPHY study (candesartan) Julius S Nesbitt SD Egan BM et al Feasibility of treating prehypertension with an angiotensin-receptor blocker N Engl J Med2006354(16)1685-1697
bull PHARAO study (Ramipril) Luumlders S Schrader J Berger J et al The PHARAO study prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure a prospective randomized controlled prevention trial of the German Hypertension League J Hypertens 200826(7)1487-1496
bull Small studies no effect
TROPHY studyKaplan-Meier Curves of New Onset of Clinical
Hypertension in the Two Groups
0 1 2 3 4
Years in study
0
01
02
03
04
05
06
07
08
09
10
C
um
ula
tive
inci
den
ce
Candesartan
Placebo
Candesartan 391 356 309 191 128
Placebo 381 269 184 118 85
Numbers under the graph refer to hypertension-free individuals
2 YearsRR darr66AR darr 26
4 YearsRR darr158AR darr 96
P lt 00001
Julius S NesbittSD N Engl J Med 20063541-13
No effect
bull Lowering the tresholds for the initiation of pharmacologic therapy would have a tremendous economic effect on public health care system (Grassi N Eng J Med 2006)
bull The high-risk strategy identifes and treats those at greatest risk (eg 10y coronary heart disease risk gt20) While there benefits individual the population attributale risk remains significant since most events occur among those at lower risk levels (Egan Nesbitt Julius Therapevtic Advances in CV Disease)
Conclusion for our practice
bull Prehypertension is not an innocent stage and could be dangerous condition
bull It needs to be monitorised excluded masked hypertension
bull Regular blood pressure measurements HBPM ABPM telemonitoring
bull Life style modification versus pharmacological treatment
bull Subclinical organ damage assessmentbull Medical treatment as soon as it is needed
according present ESH guidelines
Age distribution (Slovenia 2009)
0
5
10
15
20
25
30
35
20-29 30-39 40-49 50-59 60-69 70-79 80-89 90-99
Age
Age distribution
Normal BP
New diagnose
HNBP
Hypertension
Risk Factors - Tecumseh BP Study
Normotensive
(n=822) Borderline
(n=124)
p
Cholesterol (mgdL) 176 190 0001
HDL (mgdL) 43 40 001
Triglycerides
(mgdL) 95 135 0001
Insulin (UdL) 12 18 0001
Glucose (mgdL) 92 95 001
Insulin-glucose ratio 0155 0200 0001
Percent overweight 136 301 lt0001
Julius S et al JAMA 1990 264 354-358
Prevalence of prehypertension and hypertension stratified by Visceral Adipose Index and Body Fat Percentage
Hu L Huang X You C Li J Hong K et al (2017) Prevalence and Risk Factors of Prehypertension and Hypertension in Southern China PLOS ONE 12(1) e0170238 doi101371journalpone0170238httpjournalsplosorgplosonearticleid=101371journalpone0170238
PLOS 2017
Framingham Study incidence of hypertension
Vasan LarsonLevy Lancet 2001
Flemish Study Belgiumincidence of hypertension
(781 women 675 men)
Zhang H Fagard R Staessen J J Hypertension 2006
1 summary
bull Prehypertensives are more obese have higher cholesterol levels blood glucose insuline resistance heart rate
bull Stage by itself and progression to hypertension
Letrsquos go for a drink
Definition of prehypertension
stage Outpatient BP
(mmHg)
Home BP
(mmHg)
ABMP (mmHg)
24-h Day-time Night-time
Normotension lt12080
Prehypertension 120-13980-89
Hypertension ge14090 gt13585 gt13080 gt13585 gt12070
BP Thresholds for Definition of Hypertension
High office BP
Normal home BP
ldquoWhite-coatrdquo hypertension
Normal office BP
Normal home BP
ldquoNormotensionrdquo
High office BP
High home BP
Sustained hypertension
Normal office BP
High home BP
Masked hypertension
14090 mmHg
lt13585mmHgHome BP
Office BP
Masked hypertension
0
40
80
120
160
200
0
40
80
120
160
200
12 14 16 18 20 22 0 2 4 6 8 10 12 14
Blo
od
pre
ssure
(mm
Hg)
H
eart
rate
(min
-1)
Time (hour)
Blood pressureHeart rate
Man 20 yearsDaytime 152 87 mm Hg
Night-time 130 71 mm HgNight-time BP Drop -15 -18
Home blood pressure consistently hypertensiveClinic blood pressure 11070 mm Hg target organs damage
12 cohorts
Copenhagen (Denmark)
Dublin (Ireland)
Jingning (China)
Krakoacutew (Poland)
Maracaibo (Venezuela)
Montevideo (Uruguay)
Noorderkempen (Belgium)
Novosibirsk (Russia)
Ohasama (Japan)
Padova (Italy)
Pilsen (Czechia)
Uppsala (Sweden)
To study risk stratification by ABPM in people stratified by CBP
categories The International Database on Ambulatory blood
pressure in relation to Cardiovascular Outcomes (IDACO)
IDACO
Database
Standardised questionnaires
Anthropometric measurements
CBP and ABP
Blood sample (cholesterol glucose etc)
Outcome of participants
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
CV prediction
IDACOdatabase
Cardiovascualr risk based on BP measured in outpatient
8
7
6
5
4
3
2
1
0
0 3 6 9 12 15
20
15
10
05
0
0 3 6 9 12 15
Follow-up (years) Follow-up (years)
CV
eve
nts
(
)
Adjusted for cohort sex age BMI smoking and drinking serum cholesterol CV disease and DM
Cardiovascular events Stroke
Stro
ke(
)
HT
Pre-HT
NT
Plt00001
p=0012
HT
Pre-HT
NT
p=0015
Plt00001
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
05 1 2 4 8 05 1 2 4 8
NT 2441 63 2441 13
NT with masked HT 198 14 198 5
Pre-HT with masked HT 900 90 900 31
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
Daytime BP thresholds ge13585 mmHg
212 (p=00058)
222 (plt00001)
275 (p=0026)
301 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
NT 2527 67 2527 14
NT with masked HT 112 10 112 4
Pre-HT with masked HT 672 74 672 27
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
05 1 2 4 8 05 1 2 4 8
24h BP thresholds ge13080 mmHg
258 (p=00032)
213 (plt00001)
418 (p=00047)
317 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
Home blood pressure and ABPM in detecting masked hypertension (same sample N=128 )
CV riskUpgraded 117Downgraded 148No change 734
Masked hypertensionHome BPM748ABPM 131
MH = masked hypertensionNR = normotensionSH = sustained hypertension
RISHO2014
Baseline to follow-up reproducibility of home blood pressure measurements in tertiles of the follow up duration
RISHO2014
100 120 140 160
-40
-20
0
20
40
CR=176
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=161
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=198
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=218
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=212
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=242
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
a) 1tertile
b) 2tertile
c) 3tertile
Bland and Altman method CR=coefficient of reproducibility twice of SD of the difference between repeated measurement
Observation 24y
43y
59y
Home Blood Pressure as a Predictor of Future Blood Pressure Stability in Borderline HypertensionThe Tecumseh StudyS D Nesbitt J V Amerena EGrant K A Jamerson H Lu A Weder Stevo Julius
JAMA 2016315(23)2564-2575
Characteristics of Colorectal Cancer Screening Strategiesa
Screening for Colorectal Cancer vs ABPM in PrehypertensionUS Preventive Services Task Force Recommendation Statement
PrehypertensionOutpatient BP
Home BPEvery year
ABPMif expected risk MH or
large CV risk
Conformation of MH
Medical treatment on time
Confirmation with ABPM
Treat or not to treat prehypertension this is the question now
bull lifestyle modification for those with prehypertension-the good news is that it works
Ideal cardiovascular health behaviors and factors prevent the development of hypertension inprehypertensive subjects
Gao J Sun H Liang X Gao M Zhao H Qi Y Wang Y Liu Y Li J Zhu Y Zhao Y Wang W Ma L Wu SClinical amp Experimental Hypertension (New York) 37(8)650-5 2015
bull BACKGROUND Seven ideal health metrics were defined by AHA to monitor cardiovascular health This study aimed to investigate the impact of ideal cardiovascular health behaviors and factors on the development of hypertension in prehypertensive subjects
METHODS Thirty-two thousand eight-hundred and eighty-seven participants with prehypertension were included in the study after excluding for preexisting stroke myocardial infarction or malignancy Cox proportional hazards regression was used to calculate hazard ratios and 95 confidence intervals [CI] for the development of hypertension
RESULTS During a follow-up of 522 months 15500 prehypertensive participants developed hypertension The cumulative incidence of hypertension decreased with the number of ideal health metrics increased It was 7861 7108 6315 5607 and 6162 in prehypertensive individuals carrying lt 1 2 3 4 and gt 5 ideal health behaviors or factors respectively After adjustment for age gender family history of hypertension alcohol consumption resting heart rate plasma triglyceride high-density lipoprotein cholesterol low-density lipoprotein cholesterol and high-sensitivity C-reactive protein the risk ratios of incident hypertension in the subjects who carried 2 3 4 and gt 5 ideal health metrics were 0833 (95CI 0789-0880) 0710 (95CI 0672-0749) 0604 (95CI 0568-0642) and 0581 (95CI 0524-0643) respectively in comparison to those with lt 1 ideal health metric A similar trend was also observed in male and female populations Poor health metrics including body mass index diet (salt intake) physical activity total cholesterol and smoking were predictors for the development of hypertension in prehypertensive individuals
CONCLUSION Ideal cardiovascular health behaviors and factors are protective factors to prevent the progression from prehypertension to hypertension
Treat or not to treat prehypertension this is the question now
bull ProfBakris
bull The argument has always been to use lifestyle modification for those with prehypertension-the good news is that it works but the bad news is that nobody does it
How does story continue
bull TROPHY study (candesartan) Julius S Nesbitt SD Egan BM et al Feasibility of treating prehypertension with an angiotensin-receptor blocker N Engl J Med2006354(16)1685-1697
bull PHARAO study (Ramipril) Luumlders S Schrader J Berger J et al The PHARAO study prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure a prospective randomized controlled prevention trial of the German Hypertension League J Hypertens 200826(7)1487-1496
bull Small studies no effect
TROPHY studyKaplan-Meier Curves of New Onset of Clinical
Hypertension in the Two Groups
0 1 2 3 4
Years in study
0
01
02
03
04
05
06
07
08
09
10
C
um
ula
tive
inci
den
ce
Candesartan
Placebo
Candesartan 391 356 309 191 128
Placebo 381 269 184 118 85
Numbers under the graph refer to hypertension-free individuals
2 YearsRR darr66AR darr 26
4 YearsRR darr158AR darr 96
P lt 00001
Julius S NesbittSD N Engl J Med 20063541-13
No effect
bull Lowering the tresholds for the initiation of pharmacologic therapy would have a tremendous economic effect on public health care system (Grassi N Eng J Med 2006)
bull The high-risk strategy identifes and treats those at greatest risk (eg 10y coronary heart disease risk gt20) While there benefits individual the population attributale risk remains significant since most events occur among those at lower risk levels (Egan Nesbitt Julius Therapevtic Advances in CV Disease)
Conclusion for our practice
bull Prehypertension is not an innocent stage and could be dangerous condition
bull It needs to be monitorised excluded masked hypertension
bull Regular blood pressure measurements HBPM ABPM telemonitoring
bull Life style modification versus pharmacological treatment
bull Subclinical organ damage assessmentbull Medical treatment as soon as it is needed
according present ESH guidelines
Risk Factors - Tecumseh BP Study
Normotensive
(n=822) Borderline
(n=124)
p
Cholesterol (mgdL) 176 190 0001
HDL (mgdL) 43 40 001
Triglycerides
(mgdL) 95 135 0001
Insulin (UdL) 12 18 0001
Glucose (mgdL) 92 95 001
Insulin-glucose ratio 0155 0200 0001
Percent overweight 136 301 lt0001
Julius S et al JAMA 1990 264 354-358
Prevalence of prehypertension and hypertension stratified by Visceral Adipose Index and Body Fat Percentage
Hu L Huang X You C Li J Hong K et al (2017) Prevalence and Risk Factors of Prehypertension and Hypertension in Southern China PLOS ONE 12(1) e0170238 doi101371journalpone0170238httpjournalsplosorgplosonearticleid=101371journalpone0170238
PLOS 2017
Framingham Study incidence of hypertension
Vasan LarsonLevy Lancet 2001
Flemish Study Belgiumincidence of hypertension
(781 women 675 men)
Zhang H Fagard R Staessen J J Hypertension 2006
1 summary
bull Prehypertensives are more obese have higher cholesterol levels blood glucose insuline resistance heart rate
bull Stage by itself and progression to hypertension
Letrsquos go for a drink
Definition of prehypertension
stage Outpatient BP
(mmHg)
Home BP
(mmHg)
ABMP (mmHg)
24-h Day-time Night-time
Normotension lt12080
Prehypertension 120-13980-89
Hypertension ge14090 gt13585 gt13080 gt13585 gt12070
BP Thresholds for Definition of Hypertension
High office BP
Normal home BP
ldquoWhite-coatrdquo hypertension
Normal office BP
Normal home BP
ldquoNormotensionrdquo
High office BP
High home BP
Sustained hypertension
Normal office BP
High home BP
Masked hypertension
14090 mmHg
lt13585mmHgHome BP
Office BP
Masked hypertension
0
40
80
120
160
200
0
40
80
120
160
200
12 14 16 18 20 22 0 2 4 6 8 10 12 14
Blo
od
pre
ssure
(mm
Hg)
H
eart
rate
(min
-1)
Time (hour)
Blood pressureHeart rate
Man 20 yearsDaytime 152 87 mm Hg
Night-time 130 71 mm HgNight-time BP Drop -15 -18
Home blood pressure consistently hypertensiveClinic blood pressure 11070 mm Hg target organs damage
12 cohorts
Copenhagen (Denmark)
Dublin (Ireland)
Jingning (China)
Krakoacutew (Poland)
Maracaibo (Venezuela)
Montevideo (Uruguay)
Noorderkempen (Belgium)
Novosibirsk (Russia)
Ohasama (Japan)
Padova (Italy)
Pilsen (Czechia)
Uppsala (Sweden)
To study risk stratification by ABPM in people stratified by CBP
categories The International Database on Ambulatory blood
pressure in relation to Cardiovascular Outcomes (IDACO)
IDACO
Database
Standardised questionnaires
Anthropometric measurements
CBP and ABP
Blood sample (cholesterol glucose etc)
Outcome of participants
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
CV prediction
IDACOdatabase
Cardiovascualr risk based on BP measured in outpatient
8
7
6
5
4
3
2
1
0
0 3 6 9 12 15
20
15
10
05
0
0 3 6 9 12 15
Follow-up (years) Follow-up (years)
CV
eve
nts
(
)
Adjusted for cohort sex age BMI smoking and drinking serum cholesterol CV disease and DM
Cardiovascular events Stroke
Stro
ke(
)
HT
Pre-HT
NT
Plt00001
p=0012
HT
Pre-HT
NT
p=0015
Plt00001
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
05 1 2 4 8 05 1 2 4 8
NT 2441 63 2441 13
NT with masked HT 198 14 198 5
Pre-HT with masked HT 900 90 900 31
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
Daytime BP thresholds ge13585 mmHg
212 (p=00058)
222 (plt00001)
275 (p=0026)
301 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
NT 2527 67 2527 14
NT with masked HT 112 10 112 4
Pre-HT with masked HT 672 74 672 27
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
05 1 2 4 8 05 1 2 4 8
24h BP thresholds ge13080 mmHg
258 (p=00032)
213 (plt00001)
418 (p=00047)
317 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
Home blood pressure and ABPM in detecting masked hypertension (same sample N=128 )
CV riskUpgraded 117Downgraded 148No change 734
Masked hypertensionHome BPM748ABPM 131
MH = masked hypertensionNR = normotensionSH = sustained hypertension
RISHO2014
Baseline to follow-up reproducibility of home blood pressure measurements in tertiles of the follow up duration
RISHO2014
100 120 140 160
-40
-20
0
20
40
CR=176
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=161
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=198
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=218
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=212
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=242
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
a) 1tertile
b) 2tertile
c) 3tertile
Bland and Altman method CR=coefficient of reproducibility twice of SD of the difference between repeated measurement
Observation 24y
43y
59y
Home Blood Pressure as a Predictor of Future Blood Pressure Stability in Borderline HypertensionThe Tecumseh StudyS D Nesbitt J V Amerena EGrant K A Jamerson H Lu A Weder Stevo Julius
JAMA 2016315(23)2564-2575
Characteristics of Colorectal Cancer Screening Strategiesa
Screening for Colorectal Cancer vs ABPM in PrehypertensionUS Preventive Services Task Force Recommendation Statement
PrehypertensionOutpatient BP
Home BPEvery year
ABPMif expected risk MH or
large CV risk
Conformation of MH
Medical treatment on time
Confirmation with ABPM
Treat or not to treat prehypertension this is the question now
bull lifestyle modification for those with prehypertension-the good news is that it works
Ideal cardiovascular health behaviors and factors prevent the development of hypertension inprehypertensive subjects
Gao J Sun H Liang X Gao M Zhao H Qi Y Wang Y Liu Y Li J Zhu Y Zhao Y Wang W Ma L Wu SClinical amp Experimental Hypertension (New York) 37(8)650-5 2015
bull BACKGROUND Seven ideal health metrics were defined by AHA to monitor cardiovascular health This study aimed to investigate the impact of ideal cardiovascular health behaviors and factors on the development of hypertension in prehypertensive subjects
METHODS Thirty-two thousand eight-hundred and eighty-seven participants with prehypertension were included in the study after excluding for preexisting stroke myocardial infarction or malignancy Cox proportional hazards regression was used to calculate hazard ratios and 95 confidence intervals [CI] for the development of hypertension
RESULTS During a follow-up of 522 months 15500 prehypertensive participants developed hypertension The cumulative incidence of hypertension decreased with the number of ideal health metrics increased It was 7861 7108 6315 5607 and 6162 in prehypertensive individuals carrying lt 1 2 3 4 and gt 5 ideal health behaviors or factors respectively After adjustment for age gender family history of hypertension alcohol consumption resting heart rate plasma triglyceride high-density lipoprotein cholesterol low-density lipoprotein cholesterol and high-sensitivity C-reactive protein the risk ratios of incident hypertension in the subjects who carried 2 3 4 and gt 5 ideal health metrics were 0833 (95CI 0789-0880) 0710 (95CI 0672-0749) 0604 (95CI 0568-0642) and 0581 (95CI 0524-0643) respectively in comparison to those with lt 1 ideal health metric A similar trend was also observed in male and female populations Poor health metrics including body mass index diet (salt intake) physical activity total cholesterol and smoking were predictors for the development of hypertension in prehypertensive individuals
CONCLUSION Ideal cardiovascular health behaviors and factors are protective factors to prevent the progression from prehypertension to hypertension
Treat or not to treat prehypertension this is the question now
bull ProfBakris
bull The argument has always been to use lifestyle modification for those with prehypertension-the good news is that it works but the bad news is that nobody does it
How does story continue
bull TROPHY study (candesartan) Julius S Nesbitt SD Egan BM et al Feasibility of treating prehypertension with an angiotensin-receptor blocker N Engl J Med2006354(16)1685-1697
bull PHARAO study (Ramipril) Luumlders S Schrader J Berger J et al The PHARAO study prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure a prospective randomized controlled prevention trial of the German Hypertension League J Hypertens 200826(7)1487-1496
bull Small studies no effect
TROPHY studyKaplan-Meier Curves of New Onset of Clinical
Hypertension in the Two Groups
0 1 2 3 4
Years in study
0
01
02
03
04
05
06
07
08
09
10
C
um
ula
tive
inci
den
ce
Candesartan
Placebo
Candesartan 391 356 309 191 128
Placebo 381 269 184 118 85
Numbers under the graph refer to hypertension-free individuals
2 YearsRR darr66AR darr 26
4 YearsRR darr158AR darr 96
P lt 00001
Julius S NesbittSD N Engl J Med 20063541-13
No effect
bull Lowering the tresholds for the initiation of pharmacologic therapy would have a tremendous economic effect on public health care system (Grassi N Eng J Med 2006)
bull The high-risk strategy identifes and treats those at greatest risk (eg 10y coronary heart disease risk gt20) While there benefits individual the population attributale risk remains significant since most events occur among those at lower risk levels (Egan Nesbitt Julius Therapevtic Advances in CV Disease)
Conclusion for our practice
bull Prehypertension is not an innocent stage and could be dangerous condition
bull It needs to be monitorised excluded masked hypertension
bull Regular blood pressure measurements HBPM ABPM telemonitoring
bull Life style modification versus pharmacological treatment
bull Subclinical organ damage assessmentbull Medical treatment as soon as it is needed
according present ESH guidelines
Prevalence of prehypertension and hypertension stratified by Visceral Adipose Index and Body Fat Percentage
Hu L Huang X You C Li J Hong K et al (2017) Prevalence and Risk Factors of Prehypertension and Hypertension in Southern China PLOS ONE 12(1) e0170238 doi101371journalpone0170238httpjournalsplosorgplosonearticleid=101371journalpone0170238
PLOS 2017
Framingham Study incidence of hypertension
Vasan LarsonLevy Lancet 2001
Flemish Study Belgiumincidence of hypertension
(781 women 675 men)
Zhang H Fagard R Staessen J J Hypertension 2006
1 summary
bull Prehypertensives are more obese have higher cholesterol levels blood glucose insuline resistance heart rate
bull Stage by itself and progression to hypertension
Letrsquos go for a drink
Definition of prehypertension
stage Outpatient BP
(mmHg)
Home BP
(mmHg)
ABMP (mmHg)
24-h Day-time Night-time
Normotension lt12080
Prehypertension 120-13980-89
Hypertension ge14090 gt13585 gt13080 gt13585 gt12070
BP Thresholds for Definition of Hypertension
High office BP
Normal home BP
ldquoWhite-coatrdquo hypertension
Normal office BP
Normal home BP
ldquoNormotensionrdquo
High office BP
High home BP
Sustained hypertension
Normal office BP
High home BP
Masked hypertension
14090 mmHg
lt13585mmHgHome BP
Office BP
Masked hypertension
0
40
80
120
160
200
0
40
80
120
160
200
12 14 16 18 20 22 0 2 4 6 8 10 12 14
Blo
od
pre
ssure
(mm
Hg)
H
eart
rate
(min
-1)
Time (hour)
Blood pressureHeart rate
Man 20 yearsDaytime 152 87 mm Hg
Night-time 130 71 mm HgNight-time BP Drop -15 -18
Home blood pressure consistently hypertensiveClinic blood pressure 11070 mm Hg target organs damage
12 cohorts
Copenhagen (Denmark)
Dublin (Ireland)
Jingning (China)
Krakoacutew (Poland)
Maracaibo (Venezuela)
Montevideo (Uruguay)
Noorderkempen (Belgium)
Novosibirsk (Russia)
Ohasama (Japan)
Padova (Italy)
Pilsen (Czechia)
Uppsala (Sweden)
To study risk stratification by ABPM in people stratified by CBP
categories The International Database on Ambulatory blood
pressure in relation to Cardiovascular Outcomes (IDACO)
IDACO
Database
Standardised questionnaires
Anthropometric measurements
CBP and ABP
Blood sample (cholesterol glucose etc)
Outcome of participants
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
CV prediction
IDACOdatabase
Cardiovascualr risk based on BP measured in outpatient
8
7
6
5
4
3
2
1
0
0 3 6 9 12 15
20
15
10
05
0
0 3 6 9 12 15
Follow-up (years) Follow-up (years)
CV
eve
nts
(
)
Adjusted for cohort sex age BMI smoking and drinking serum cholesterol CV disease and DM
Cardiovascular events Stroke
Stro
ke(
)
HT
Pre-HT
NT
Plt00001
p=0012
HT
Pre-HT
NT
p=0015
Plt00001
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
05 1 2 4 8 05 1 2 4 8
NT 2441 63 2441 13
NT with masked HT 198 14 198 5
Pre-HT with masked HT 900 90 900 31
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
Daytime BP thresholds ge13585 mmHg
212 (p=00058)
222 (plt00001)
275 (p=0026)
301 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
NT 2527 67 2527 14
NT with masked HT 112 10 112 4
Pre-HT with masked HT 672 74 672 27
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
05 1 2 4 8 05 1 2 4 8
24h BP thresholds ge13080 mmHg
258 (p=00032)
213 (plt00001)
418 (p=00047)
317 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
Home blood pressure and ABPM in detecting masked hypertension (same sample N=128 )
CV riskUpgraded 117Downgraded 148No change 734
Masked hypertensionHome BPM748ABPM 131
MH = masked hypertensionNR = normotensionSH = sustained hypertension
RISHO2014
Baseline to follow-up reproducibility of home blood pressure measurements in tertiles of the follow up duration
RISHO2014
100 120 140 160
-40
-20
0
20
40
CR=176
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=161
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=198
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=218
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=212
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=242
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
a) 1tertile
b) 2tertile
c) 3tertile
Bland and Altman method CR=coefficient of reproducibility twice of SD of the difference between repeated measurement
Observation 24y
43y
59y
Home Blood Pressure as a Predictor of Future Blood Pressure Stability in Borderline HypertensionThe Tecumseh StudyS D Nesbitt J V Amerena EGrant K A Jamerson H Lu A Weder Stevo Julius
JAMA 2016315(23)2564-2575
Characteristics of Colorectal Cancer Screening Strategiesa
Screening for Colorectal Cancer vs ABPM in PrehypertensionUS Preventive Services Task Force Recommendation Statement
PrehypertensionOutpatient BP
Home BPEvery year
ABPMif expected risk MH or
large CV risk
Conformation of MH
Medical treatment on time
Confirmation with ABPM
Treat or not to treat prehypertension this is the question now
bull lifestyle modification for those with prehypertension-the good news is that it works
Ideal cardiovascular health behaviors and factors prevent the development of hypertension inprehypertensive subjects
Gao J Sun H Liang X Gao M Zhao H Qi Y Wang Y Liu Y Li J Zhu Y Zhao Y Wang W Ma L Wu SClinical amp Experimental Hypertension (New York) 37(8)650-5 2015
bull BACKGROUND Seven ideal health metrics were defined by AHA to monitor cardiovascular health This study aimed to investigate the impact of ideal cardiovascular health behaviors and factors on the development of hypertension in prehypertensive subjects
METHODS Thirty-two thousand eight-hundred and eighty-seven participants with prehypertension were included in the study after excluding for preexisting stroke myocardial infarction or malignancy Cox proportional hazards regression was used to calculate hazard ratios and 95 confidence intervals [CI] for the development of hypertension
RESULTS During a follow-up of 522 months 15500 prehypertensive participants developed hypertension The cumulative incidence of hypertension decreased with the number of ideal health metrics increased It was 7861 7108 6315 5607 and 6162 in prehypertensive individuals carrying lt 1 2 3 4 and gt 5 ideal health behaviors or factors respectively After adjustment for age gender family history of hypertension alcohol consumption resting heart rate plasma triglyceride high-density lipoprotein cholesterol low-density lipoprotein cholesterol and high-sensitivity C-reactive protein the risk ratios of incident hypertension in the subjects who carried 2 3 4 and gt 5 ideal health metrics were 0833 (95CI 0789-0880) 0710 (95CI 0672-0749) 0604 (95CI 0568-0642) and 0581 (95CI 0524-0643) respectively in comparison to those with lt 1 ideal health metric A similar trend was also observed in male and female populations Poor health metrics including body mass index diet (salt intake) physical activity total cholesterol and smoking were predictors for the development of hypertension in prehypertensive individuals
CONCLUSION Ideal cardiovascular health behaviors and factors are protective factors to prevent the progression from prehypertension to hypertension
Treat or not to treat prehypertension this is the question now
bull ProfBakris
bull The argument has always been to use lifestyle modification for those with prehypertension-the good news is that it works but the bad news is that nobody does it
How does story continue
bull TROPHY study (candesartan) Julius S Nesbitt SD Egan BM et al Feasibility of treating prehypertension with an angiotensin-receptor blocker N Engl J Med2006354(16)1685-1697
bull PHARAO study (Ramipril) Luumlders S Schrader J Berger J et al The PHARAO study prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure a prospective randomized controlled prevention trial of the German Hypertension League J Hypertens 200826(7)1487-1496
bull Small studies no effect
TROPHY studyKaplan-Meier Curves of New Onset of Clinical
Hypertension in the Two Groups
0 1 2 3 4
Years in study
0
01
02
03
04
05
06
07
08
09
10
C
um
ula
tive
inci
den
ce
Candesartan
Placebo
Candesartan 391 356 309 191 128
Placebo 381 269 184 118 85
Numbers under the graph refer to hypertension-free individuals
2 YearsRR darr66AR darr 26
4 YearsRR darr158AR darr 96
P lt 00001
Julius S NesbittSD N Engl J Med 20063541-13
No effect
bull Lowering the tresholds for the initiation of pharmacologic therapy would have a tremendous economic effect on public health care system (Grassi N Eng J Med 2006)
bull The high-risk strategy identifes and treats those at greatest risk (eg 10y coronary heart disease risk gt20) While there benefits individual the population attributale risk remains significant since most events occur among those at lower risk levels (Egan Nesbitt Julius Therapevtic Advances in CV Disease)
Conclusion for our practice
bull Prehypertension is not an innocent stage and could be dangerous condition
bull It needs to be monitorised excluded masked hypertension
bull Regular blood pressure measurements HBPM ABPM telemonitoring
bull Life style modification versus pharmacological treatment
bull Subclinical organ damage assessmentbull Medical treatment as soon as it is needed
according present ESH guidelines
Framingham Study incidence of hypertension
Vasan LarsonLevy Lancet 2001
Flemish Study Belgiumincidence of hypertension
(781 women 675 men)
Zhang H Fagard R Staessen J J Hypertension 2006
1 summary
bull Prehypertensives are more obese have higher cholesterol levels blood glucose insuline resistance heart rate
bull Stage by itself and progression to hypertension
Letrsquos go for a drink
Definition of prehypertension
stage Outpatient BP
(mmHg)
Home BP
(mmHg)
ABMP (mmHg)
24-h Day-time Night-time
Normotension lt12080
Prehypertension 120-13980-89
Hypertension ge14090 gt13585 gt13080 gt13585 gt12070
BP Thresholds for Definition of Hypertension
High office BP
Normal home BP
ldquoWhite-coatrdquo hypertension
Normal office BP
Normal home BP
ldquoNormotensionrdquo
High office BP
High home BP
Sustained hypertension
Normal office BP
High home BP
Masked hypertension
14090 mmHg
lt13585mmHgHome BP
Office BP
Masked hypertension
0
40
80
120
160
200
0
40
80
120
160
200
12 14 16 18 20 22 0 2 4 6 8 10 12 14
Blo
od
pre
ssure
(mm
Hg)
H
eart
rate
(min
-1)
Time (hour)
Blood pressureHeart rate
Man 20 yearsDaytime 152 87 mm Hg
Night-time 130 71 mm HgNight-time BP Drop -15 -18
Home blood pressure consistently hypertensiveClinic blood pressure 11070 mm Hg target organs damage
12 cohorts
Copenhagen (Denmark)
Dublin (Ireland)
Jingning (China)
Krakoacutew (Poland)
Maracaibo (Venezuela)
Montevideo (Uruguay)
Noorderkempen (Belgium)
Novosibirsk (Russia)
Ohasama (Japan)
Padova (Italy)
Pilsen (Czechia)
Uppsala (Sweden)
To study risk stratification by ABPM in people stratified by CBP
categories The International Database on Ambulatory blood
pressure in relation to Cardiovascular Outcomes (IDACO)
IDACO
Database
Standardised questionnaires
Anthropometric measurements
CBP and ABP
Blood sample (cholesterol glucose etc)
Outcome of participants
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
CV prediction
IDACOdatabase
Cardiovascualr risk based on BP measured in outpatient
8
7
6
5
4
3
2
1
0
0 3 6 9 12 15
20
15
10
05
0
0 3 6 9 12 15
Follow-up (years) Follow-up (years)
CV
eve
nts
(
)
Adjusted for cohort sex age BMI smoking and drinking serum cholesterol CV disease and DM
Cardiovascular events Stroke
Stro
ke(
)
HT
Pre-HT
NT
Plt00001
p=0012
HT
Pre-HT
NT
p=0015
Plt00001
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
05 1 2 4 8 05 1 2 4 8
NT 2441 63 2441 13
NT with masked HT 198 14 198 5
Pre-HT with masked HT 900 90 900 31
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
Daytime BP thresholds ge13585 mmHg
212 (p=00058)
222 (plt00001)
275 (p=0026)
301 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
NT 2527 67 2527 14
NT with masked HT 112 10 112 4
Pre-HT with masked HT 672 74 672 27
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
05 1 2 4 8 05 1 2 4 8
24h BP thresholds ge13080 mmHg
258 (p=00032)
213 (plt00001)
418 (p=00047)
317 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
Home blood pressure and ABPM in detecting masked hypertension (same sample N=128 )
CV riskUpgraded 117Downgraded 148No change 734
Masked hypertensionHome BPM748ABPM 131
MH = masked hypertensionNR = normotensionSH = sustained hypertension
RISHO2014
Baseline to follow-up reproducibility of home blood pressure measurements in tertiles of the follow up duration
RISHO2014
100 120 140 160
-40
-20
0
20
40
CR=176
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=161
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=198
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=218
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=212
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=242
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
a) 1tertile
b) 2tertile
c) 3tertile
Bland and Altman method CR=coefficient of reproducibility twice of SD of the difference between repeated measurement
Observation 24y
43y
59y
Home Blood Pressure as a Predictor of Future Blood Pressure Stability in Borderline HypertensionThe Tecumseh StudyS D Nesbitt J V Amerena EGrant K A Jamerson H Lu A Weder Stevo Julius
JAMA 2016315(23)2564-2575
Characteristics of Colorectal Cancer Screening Strategiesa
Screening for Colorectal Cancer vs ABPM in PrehypertensionUS Preventive Services Task Force Recommendation Statement
PrehypertensionOutpatient BP
Home BPEvery year
ABPMif expected risk MH or
large CV risk
Conformation of MH
Medical treatment on time
Confirmation with ABPM
Treat or not to treat prehypertension this is the question now
bull lifestyle modification for those with prehypertension-the good news is that it works
Ideal cardiovascular health behaviors and factors prevent the development of hypertension inprehypertensive subjects
Gao J Sun H Liang X Gao M Zhao H Qi Y Wang Y Liu Y Li J Zhu Y Zhao Y Wang W Ma L Wu SClinical amp Experimental Hypertension (New York) 37(8)650-5 2015
bull BACKGROUND Seven ideal health metrics were defined by AHA to monitor cardiovascular health This study aimed to investigate the impact of ideal cardiovascular health behaviors and factors on the development of hypertension in prehypertensive subjects
METHODS Thirty-two thousand eight-hundred and eighty-seven participants with prehypertension were included in the study after excluding for preexisting stroke myocardial infarction or malignancy Cox proportional hazards regression was used to calculate hazard ratios and 95 confidence intervals [CI] for the development of hypertension
RESULTS During a follow-up of 522 months 15500 prehypertensive participants developed hypertension The cumulative incidence of hypertension decreased with the number of ideal health metrics increased It was 7861 7108 6315 5607 and 6162 in prehypertensive individuals carrying lt 1 2 3 4 and gt 5 ideal health behaviors or factors respectively After adjustment for age gender family history of hypertension alcohol consumption resting heart rate plasma triglyceride high-density lipoprotein cholesterol low-density lipoprotein cholesterol and high-sensitivity C-reactive protein the risk ratios of incident hypertension in the subjects who carried 2 3 4 and gt 5 ideal health metrics were 0833 (95CI 0789-0880) 0710 (95CI 0672-0749) 0604 (95CI 0568-0642) and 0581 (95CI 0524-0643) respectively in comparison to those with lt 1 ideal health metric A similar trend was also observed in male and female populations Poor health metrics including body mass index diet (salt intake) physical activity total cholesterol and smoking were predictors for the development of hypertension in prehypertensive individuals
CONCLUSION Ideal cardiovascular health behaviors and factors are protective factors to prevent the progression from prehypertension to hypertension
Treat or not to treat prehypertension this is the question now
bull ProfBakris
bull The argument has always been to use lifestyle modification for those with prehypertension-the good news is that it works but the bad news is that nobody does it
How does story continue
bull TROPHY study (candesartan) Julius S Nesbitt SD Egan BM et al Feasibility of treating prehypertension with an angiotensin-receptor blocker N Engl J Med2006354(16)1685-1697
bull PHARAO study (Ramipril) Luumlders S Schrader J Berger J et al The PHARAO study prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure a prospective randomized controlled prevention trial of the German Hypertension League J Hypertens 200826(7)1487-1496
bull Small studies no effect
TROPHY studyKaplan-Meier Curves of New Onset of Clinical
Hypertension in the Two Groups
0 1 2 3 4
Years in study
0
01
02
03
04
05
06
07
08
09
10
C
um
ula
tive
inci
den
ce
Candesartan
Placebo
Candesartan 391 356 309 191 128
Placebo 381 269 184 118 85
Numbers under the graph refer to hypertension-free individuals
2 YearsRR darr66AR darr 26
4 YearsRR darr158AR darr 96
P lt 00001
Julius S NesbittSD N Engl J Med 20063541-13
No effect
bull Lowering the tresholds for the initiation of pharmacologic therapy would have a tremendous economic effect on public health care system (Grassi N Eng J Med 2006)
bull The high-risk strategy identifes and treats those at greatest risk (eg 10y coronary heart disease risk gt20) While there benefits individual the population attributale risk remains significant since most events occur among those at lower risk levels (Egan Nesbitt Julius Therapevtic Advances in CV Disease)
Conclusion for our practice
bull Prehypertension is not an innocent stage and could be dangerous condition
bull It needs to be monitorised excluded masked hypertension
bull Regular blood pressure measurements HBPM ABPM telemonitoring
bull Life style modification versus pharmacological treatment
bull Subclinical organ damage assessmentbull Medical treatment as soon as it is needed
according present ESH guidelines
Flemish Study Belgiumincidence of hypertension
(781 women 675 men)
Zhang H Fagard R Staessen J J Hypertension 2006
1 summary
bull Prehypertensives are more obese have higher cholesterol levels blood glucose insuline resistance heart rate
bull Stage by itself and progression to hypertension
Letrsquos go for a drink
Definition of prehypertension
stage Outpatient BP
(mmHg)
Home BP
(mmHg)
ABMP (mmHg)
24-h Day-time Night-time
Normotension lt12080
Prehypertension 120-13980-89
Hypertension ge14090 gt13585 gt13080 gt13585 gt12070
BP Thresholds for Definition of Hypertension
High office BP
Normal home BP
ldquoWhite-coatrdquo hypertension
Normal office BP
Normal home BP
ldquoNormotensionrdquo
High office BP
High home BP
Sustained hypertension
Normal office BP
High home BP
Masked hypertension
14090 mmHg
lt13585mmHgHome BP
Office BP
Masked hypertension
0
40
80
120
160
200
0
40
80
120
160
200
12 14 16 18 20 22 0 2 4 6 8 10 12 14
Blo
od
pre
ssure
(mm
Hg)
H
eart
rate
(min
-1)
Time (hour)
Blood pressureHeart rate
Man 20 yearsDaytime 152 87 mm Hg
Night-time 130 71 mm HgNight-time BP Drop -15 -18
Home blood pressure consistently hypertensiveClinic blood pressure 11070 mm Hg target organs damage
12 cohorts
Copenhagen (Denmark)
Dublin (Ireland)
Jingning (China)
Krakoacutew (Poland)
Maracaibo (Venezuela)
Montevideo (Uruguay)
Noorderkempen (Belgium)
Novosibirsk (Russia)
Ohasama (Japan)
Padova (Italy)
Pilsen (Czechia)
Uppsala (Sweden)
To study risk stratification by ABPM in people stratified by CBP
categories The International Database on Ambulatory blood
pressure in relation to Cardiovascular Outcomes (IDACO)
IDACO
Database
Standardised questionnaires
Anthropometric measurements
CBP and ABP
Blood sample (cholesterol glucose etc)
Outcome of participants
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
CV prediction
IDACOdatabase
Cardiovascualr risk based on BP measured in outpatient
8
7
6
5
4
3
2
1
0
0 3 6 9 12 15
20
15
10
05
0
0 3 6 9 12 15
Follow-up (years) Follow-up (years)
CV
eve
nts
(
)
Adjusted for cohort sex age BMI smoking and drinking serum cholesterol CV disease and DM
Cardiovascular events Stroke
Stro
ke(
)
HT
Pre-HT
NT
Plt00001
p=0012
HT
Pre-HT
NT
p=0015
Plt00001
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
05 1 2 4 8 05 1 2 4 8
NT 2441 63 2441 13
NT with masked HT 198 14 198 5
Pre-HT with masked HT 900 90 900 31
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
Daytime BP thresholds ge13585 mmHg
212 (p=00058)
222 (plt00001)
275 (p=0026)
301 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
NT 2527 67 2527 14
NT with masked HT 112 10 112 4
Pre-HT with masked HT 672 74 672 27
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
05 1 2 4 8 05 1 2 4 8
24h BP thresholds ge13080 mmHg
258 (p=00032)
213 (plt00001)
418 (p=00047)
317 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
Home blood pressure and ABPM in detecting masked hypertension (same sample N=128 )
CV riskUpgraded 117Downgraded 148No change 734
Masked hypertensionHome BPM748ABPM 131
MH = masked hypertensionNR = normotensionSH = sustained hypertension
RISHO2014
Baseline to follow-up reproducibility of home blood pressure measurements in tertiles of the follow up duration
RISHO2014
100 120 140 160
-40
-20
0
20
40
CR=176
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=161
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=198
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=218
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=212
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=242
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
a) 1tertile
b) 2tertile
c) 3tertile
Bland and Altman method CR=coefficient of reproducibility twice of SD of the difference between repeated measurement
Observation 24y
43y
59y
Home Blood Pressure as a Predictor of Future Blood Pressure Stability in Borderline HypertensionThe Tecumseh StudyS D Nesbitt J V Amerena EGrant K A Jamerson H Lu A Weder Stevo Julius
JAMA 2016315(23)2564-2575
Characteristics of Colorectal Cancer Screening Strategiesa
Screening for Colorectal Cancer vs ABPM in PrehypertensionUS Preventive Services Task Force Recommendation Statement
PrehypertensionOutpatient BP
Home BPEvery year
ABPMif expected risk MH or
large CV risk
Conformation of MH
Medical treatment on time
Confirmation with ABPM
Treat or not to treat prehypertension this is the question now
bull lifestyle modification for those with prehypertension-the good news is that it works
Ideal cardiovascular health behaviors and factors prevent the development of hypertension inprehypertensive subjects
Gao J Sun H Liang X Gao M Zhao H Qi Y Wang Y Liu Y Li J Zhu Y Zhao Y Wang W Ma L Wu SClinical amp Experimental Hypertension (New York) 37(8)650-5 2015
bull BACKGROUND Seven ideal health metrics were defined by AHA to monitor cardiovascular health This study aimed to investigate the impact of ideal cardiovascular health behaviors and factors on the development of hypertension in prehypertensive subjects
METHODS Thirty-two thousand eight-hundred and eighty-seven participants with prehypertension were included in the study after excluding for preexisting stroke myocardial infarction or malignancy Cox proportional hazards regression was used to calculate hazard ratios and 95 confidence intervals [CI] for the development of hypertension
RESULTS During a follow-up of 522 months 15500 prehypertensive participants developed hypertension The cumulative incidence of hypertension decreased with the number of ideal health metrics increased It was 7861 7108 6315 5607 and 6162 in prehypertensive individuals carrying lt 1 2 3 4 and gt 5 ideal health behaviors or factors respectively After adjustment for age gender family history of hypertension alcohol consumption resting heart rate plasma triglyceride high-density lipoprotein cholesterol low-density lipoprotein cholesterol and high-sensitivity C-reactive protein the risk ratios of incident hypertension in the subjects who carried 2 3 4 and gt 5 ideal health metrics were 0833 (95CI 0789-0880) 0710 (95CI 0672-0749) 0604 (95CI 0568-0642) and 0581 (95CI 0524-0643) respectively in comparison to those with lt 1 ideal health metric A similar trend was also observed in male and female populations Poor health metrics including body mass index diet (salt intake) physical activity total cholesterol and smoking were predictors for the development of hypertension in prehypertensive individuals
CONCLUSION Ideal cardiovascular health behaviors and factors are protective factors to prevent the progression from prehypertension to hypertension
Treat or not to treat prehypertension this is the question now
bull ProfBakris
bull The argument has always been to use lifestyle modification for those with prehypertension-the good news is that it works but the bad news is that nobody does it
How does story continue
bull TROPHY study (candesartan) Julius S Nesbitt SD Egan BM et al Feasibility of treating prehypertension with an angiotensin-receptor blocker N Engl J Med2006354(16)1685-1697
bull PHARAO study (Ramipril) Luumlders S Schrader J Berger J et al The PHARAO study prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure a prospective randomized controlled prevention trial of the German Hypertension League J Hypertens 200826(7)1487-1496
bull Small studies no effect
TROPHY studyKaplan-Meier Curves of New Onset of Clinical
Hypertension in the Two Groups
0 1 2 3 4
Years in study
0
01
02
03
04
05
06
07
08
09
10
C
um
ula
tive
inci
den
ce
Candesartan
Placebo
Candesartan 391 356 309 191 128
Placebo 381 269 184 118 85
Numbers under the graph refer to hypertension-free individuals
2 YearsRR darr66AR darr 26
4 YearsRR darr158AR darr 96
P lt 00001
Julius S NesbittSD N Engl J Med 20063541-13
No effect
bull Lowering the tresholds for the initiation of pharmacologic therapy would have a tremendous economic effect on public health care system (Grassi N Eng J Med 2006)
bull The high-risk strategy identifes and treats those at greatest risk (eg 10y coronary heart disease risk gt20) While there benefits individual the population attributale risk remains significant since most events occur among those at lower risk levels (Egan Nesbitt Julius Therapevtic Advances in CV Disease)
Conclusion for our practice
bull Prehypertension is not an innocent stage and could be dangerous condition
bull It needs to be monitorised excluded masked hypertension
bull Regular blood pressure measurements HBPM ABPM telemonitoring
bull Life style modification versus pharmacological treatment
bull Subclinical organ damage assessmentbull Medical treatment as soon as it is needed
according present ESH guidelines
1 summary
bull Prehypertensives are more obese have higher cholesterol levels blood glucose insuline resistance heart rate
bull Stage by itself and progression to hypertension
Letrsquos go for a drink
Definition of prehypertension
stage Outpatient BP
(mmHg)
Home BP
(mmHg)
ABMP (mmHg)
24-h Day-time Night-time
Normotension lt12080
Prehypertension 120-13980-89
Hypertension ge14090 gt13585 gt13080 gt13585 gt12070
BP Thresholds for Definition of Hypertension
High office BP
Normal home BP
ldquoWhite-coatrdquo hypertension
Normal office BP
Normal home BP
ldquoNormotensionrdquo
High office BP
High home BP
Sustained hypertension
Normal office BP
High home BP
Masked hypertension
14090 mmHg
lt13585mmHgHome BP
Office BP
Masked hypertension
0
40
80
120
160
200
0
40
80
120
160
200
12 14 16 18 20 22 0 2 4 6 8 10 12 14
Blo
od
pre
ssure
(mm
Hg)
H
eart
rate
(min
-1)
Time (hour)
Blood pressureHeart rate
Man 20 yearsDaytime 152 87 mm Hg
Night-time 130 71 mm HgNight-time BP Drop -15 -18
Home blood pressure consistently hypertensiveClinic blood pressure 11070 mm Hg target organs damage
12 cohorts
Copenhagen (Denmark)
Dublin (Ireland)
Jingning (China)
Krakoacutew (Poland)
Maracaibo (Venezuela)
Montevideo (Uruguay)
Noorderkempen (Belgium)
Novosibirsk (Russia)
Ohasama (Japan)
Padova (Italy)
Pilsen (Czechia)
Uppsala (Sweden)
To study risk stratification by ABPM in people stratified by CBP
categories The International Database on Ambulatory blood
pressure in relation to Cardiovascular Outcomes (IDACO)
IDACO
Database
Standardised questionnaires
Anthropometric measurements
CBP and ABP
Blood sample (cholesterol glucose etc)
Outcome of participants
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
CV prediction
IDACOdatabase
Cardiovascualr risk based on BP measured in outpatient
8
7
6
5
4
3
2
1
0
0 3 6 9 12 15
20
15
10
05
0
0 3 6 9 12 15
Follow-up (years) Follow-up (years)
CV
eve
nts
(
)
Adjusted for cohort sex age BMI smoking and drinking serum cholesterol CV disease and DM
Cardiovascular events Stroke
Stro
ke(
)
HT
Pre-HT
NT
Plt00001
p=0012
HT
Pre-HT
NT
p=0015
Plt00001
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
05 1 2 4 8 05 1 2 4 8
NT 2441 63 2441 13
NT with masked HT 198 14 198 5
Pre-HT with masked HT 900 90 900 31
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
Daytime BP thresholds ge13585 mmHg
212 (p=00058)
222 (plt00001)
275 (p=0026)
301 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
NT 2527 67 2527 14
NT with masked HT 112 10 112 4
Pre-HT with masked HT 672 74 672 27
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
05 1 2 4 8 05 1 2 4 8
24h BP thresholds ge13080 mmHg
258 (p=00032)
213 (plt00001)
418 (p=00047)
317 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
Home blood pressure and ABPM in detecting masked hypertension (same sample N=128 )
CV riskUpgraded 117Downgraded 148No change 734
Masked hypertensionHome BPM748ABPM 131
MH = masked hypertensionNR = normotensionSH = sustained hypertension
RISHO2014
Baseline to follow-up reproducibility of home blood pressure measurements in tertiles of the follow up duration
RISHO2014
100 120 140 160
-40
-20
0
20
40
CR=176
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=161
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=198
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=218
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=212
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=242
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
a) 1tertile
b) 2tertile
c) 3tertile
Bland and Altman method CR=coefficient of reproducibility twice of SD of the difference between repeated measurement
Observation 24y
43y
59y
Home Blood Pressure as a Predictor of Future Blood Pressure Stability in Borderline HypertensionThe Tecumseh StudyS D Nesbitt J V Amerena EGrant K A Jamerson H Lu A Weder Stevo Julius
JAMA 2016315(23)2564-2575
Characteristics of Colorectal Cancer Screening Strategiesa
Screening for Colorectal Cancer vs ABPM in PrehypertensionUS Preventive Services Task Force Recommendation Statement
PrehypertensionOutpatient BP
Home BPEvery year
ABPMif expected risk MH or
large CV risk
Conformation of MH
Medical treatment on time
Confirmation with ABPM
Treat or not to treat prehypertension this is the question now
bull lifestyle modification for those with prehypertension-the good news is that it works
Ideal cardiovascular health behaviors and factors prevent the development of hypertension inprehypertensive subjects
Gao J Sun H Liang X Gao M Zhao H Qi Y Wang Y Liu Y Li J Zhu Y Zhao Y Wang W Ma L Wu SClinical amp Experimental Hypertension (New York) 37(8)650-5 2015
bull BACKGROUND Seven ideal health metrics were defined by AHA to monitor cardiovascular health This study aimed to investigate the impact of ideal cardiovascular health behaviors and factors on the development of hypertension in prehypertensive subjects
METHODS Thirty-two thousand eight-hundred and eighty-seven participants with prehypertension were included in the study after excluding for preexisting stroke myocardial infarction or malignancy Cox proportional hazards regression was used to calculate hazard ratios and 95 confidence intervals [CI] for the development of hypertension
RESULTS During a follow-up of 522 months 15500 prehypertensive participants developed hypertension The cumulative incidence of hypertension decreased with the number of ideal health metrics increased It was 7861 7108 6315 5607 and 6162 in prehypertensive individuals carrying lt 1 2 3 4 and gt 5 ideal health behaviors or factors respectively After adjustment for age gender family history of hypertension alcohol consumption resting heart rate plasma triglyceride high-density lipoprotein cholesterol low-density lipoprotein cholesterol and high-sensitivity C-reactive protein the risk ratios of incident hypertension in the subjects who carried 2 3 4 and gt 5 ideal health metrics were 0833 (95CI 0789-0880) 0710 (95CI 0672-0749) 0604 (95CI 0568-0642) and 0581 (95CI 0524-0643) respectively in comparison to those with lt 1 ideal health metric A similar trend was also observed in male and female populations Poor health metrics including body mass index diet (salt intake) physical activity total cholesterol and smoking were predictors for the development of hypertension in prehypertensive individuals
CONCLUSION Ideal cardiovascular health behaviors and factors are protective factors to prevent the progression from prehypertension to hypertension
Treat or not to treat prehypertension this is the question now
bull ProfBakris
bull The argument has always been to use lifestyle modification for those with prehypertension-the good news is that it works but the bad news is that nobody does it
How does story continue
bull TROPHY study (candesartan) Julius S Nesbitt SD Egan BM et al Feasibility of treating prehypertension with an angiotensin-receptor blocker N Engl J Med2006354(16)1685-1697
bull PHARAO study (Ramipril) Luumlders S Schrader J Berger J et al The PHARAO study prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure a prospective randomized controlled prevention trial of the German Hypertension League J Hypertens 200826(7)1487-1496
bull Small studies no effect
TROPHY studyKaplan-Meier Curves of New Onset of Clinical
Hypertension in the Two Groups
0 1 2 3 4
Years in study
0
01
02
03
04
05
06
07
08
09
10
C
um
ula
tive
inci
den
ce
Candesartan
Placebo
Candesartan 391 356 309 191 128
Placebo 381 269 184 118 85
Numbers under the graph refer to hypertension-free individuals
2 YearsRR darr66AR darr 26
4 YearsRR darr158AR darr 96
P lt 00001
Julius S NesbittSD N Engl J Med 20063541-13
No effect
bull Lowering the tresholds for the initiation of pharmacologic therapy would have a tremendous economic effect on public health care system (Grassi N Eng J Med 2006)
bull The high-risk strategy identifes and treats those at greatest risk (eg 10y coronary heart disease risk gt20) While there benefits individual the population attributale risk remains significant since most events occur among those at lower risk levels (Egan Nesbitt Julius Therapevtic Advances in CV Disease)
Conclusion for our practice
bull Prehypertension is not an innocent stage and could be dangerous condition
bull It needs to be monitorised excluded masked hypertension
bull Regular blood pressure measurements HBPM ABPM telemonitoring
bull Life style modification versus pharmacological treatment
bull Subclinical organ damage assessmentbull Medical treatment as soon as it is needed
according present ESH guidelines
Letrsquos go for a drink
Definition of prehypertension
stage Outpatient BP
(mmHg)
Home BP
(mmHg)
ABMP (mmHg)
24-h Day-time Night-time
Normotension lt12080
Prehypertension 120-13980-89
Hypertension ge14090 gt13585 gt13080 gt13585 gt12070
BP Thresholds for Definition of Hypertension
High office BP
Normal home BP
ldquoWhite-coatrdquo hypertension
Normal office BP
Normal home BP
ldquoNormotensionrdquo
High office BP
High home BP
Sustained hypertension
Normal office BP
High home BP
Masked hypertension
14090 mmHg
lt13585mmHgHome BP
Office BP
Masked hypertension
0
40
80
120
160
200
0
40
80
120
160
200
12 14 16 18 20 22 0 2 4 6 8 10 12 14
Blo
od
pre
ssure
(mm
Hg)
H
eart
rate
(min
-1)
Time (hour)
Blood pressureHeart rate
Man 20 yearsDaytime 152 87 mm Hg
Night-time 130 71 mm HgNight-time BP Drop -15 -18
Home blood pressure consistently hypertensiveClinic blood pressure 11070 mm Hg target organs damage
12 cohorts
Copenhagen (Denmark)
Dublin (Ireland)
Jingning (China)
Krakoacutew (Poland)
Maracaibo (Venezuela)
Montevideo (Uruguay)
Noorderkempen (Belgium)
Novosibirsk (Russia)
Ohasama (Japan)
Padova (Italy)
Pilsen (Czechia)
Uppsala (Sweden)
To study risk stratification by ABPM in people stratified by CBP
categories The International Database on Ambulatory blood
pressure in relation to Cardiovascular Outcomes (IDACO)
IDACO
Database
Standardised questionnaires
Anthropometric measurements
CBP and ABP
Blood sample (cholesterol glucose etc)
Outcome of participants
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
CV prediction
IDACOdatabase
Cardiovascualr risk based on BP measured in outpatient
8
7
6
5
4
3
2
1
0
0 3 6 9 12 15
20
15
10
05
0
0 3 6 9 12 15
Follow-up (years) Follow-up (years)
CV
eve
nts
(
)
Adjusted for cohort sex age BMI smoking and drinking serum cholesterol CV disease and DM
Cardiovascular events Stroke
Stro
ke(
)
HT
Pre-HT
NT
Plt00001
p=0012
HT
Pre-HT
NT
p=0015
Plt00001
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
05 1 2 4 8 05 1 2 4 8
NT 2441 63 2441 13
NT with masked HT 198 14 198 5
Pre-HT with masked HT 900 90 900 31
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
Daytime BP thresholds ge13585 mmHg
212 (p=00058)
222 (plt00001)
275 (p=0026)
301 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
NT 2527 67 2527 14
NT with masked HT 112 10 112 4
Pre-HT with masked HT 672 74 672 27
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
05 1 2 4 8 05 1 2 4 8
24h BP thresholds ge13080 mmHg
258 (p=00032)
213 (plt00001)
418 (p=00047)
317 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
Home blood pressure and ABPM in detecting masked hypertension (same sample N=128 )
CV riskUpgraded 117Downgraded 148No change 734
Masked hypertensionHome BPM748ABPM 131
MH = masked hypertensionNR = normotensionSH = sustained hypertension
RISHO2014
Baseline to follow-up reproducibility of home blood pressure measurements in tertiles of the follow up duration
RISHO2014
100 120 140 160
-40
-20
0
20
40
CR=176
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=161
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=198
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=218
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=212
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=242
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
a) 1tertile
b) 2tertile
c) 3tertile
Bland and Altman method CR=coefficient of reproducibility twice of SD of the difference between repeated measurement
Observation 24y
43y
59y
Home Blood Pressure as a Predictor of Future Blood Pressure Stability in Borderline HypertensionThe Tecumseh StudyS D Nesbitt J V Amerena EGrant K A Jamerson H Lu A Weder Stevo Julius
JAMA 2016315(23)2564-2575
Characteristics of Colorectal Cancer Screening Strategiesa
Screening for Colorectal Cancer vs ABPM in PrehypertensionUS Preventive Services Task Force Recommendation Statement
PrehypertensionOutpatient BP
Home BPEvery year
ABPMif expected risk MH or
large CV risk
Conformation of MH
Medical treatment on time
Confirmation with ABPM
Treat or not to treat prehypertension this is the question now
bull lifestyle modification for those with prehypertension-the good news is that it works
Ideal cardiovascular health behaviors and factors prevent the development of hypertension inprehypertensive subjects
Gao J Sun H Liang X Gao M Zhao H Qi Y Wang Y Liu Y Li J Zhu Y Zhao Y Wang W Ma L Wu SClinical amp Experimental Hypertension (New York) 37(8)650-5 2015
bull BACKGROUND Seven ideal health metrics were defined by AHA to monitor cardiovascular health This study aimed to investigate the impact of ideal cardiovascular health behaviors and factors on the development of hypertension in prehypertensive subjects
METHODS Thirty-two thousand eight-hundred and eighty-seven participants with prehypertension were included in the study after excluding for preexisting stroke myocardial infarction or malignancy Cox proportional hazards regression was used to calculate hazard ratios and 95 confidence intervals [CI] for the development of hypertension
RESULTS During a follow-up of 522 months 15500 prehypertensive participants developed hypertension The cumulative incidence of hypertension decreased with the number of ideal health metrics increased It was 7861 7108 6315 5607 and 6162 in prehypertensive individuals carrying lt 1 2 3 4 and gt 5 ideal health behaviors or factors respectively After adjustment for age gender family history of hypertension alcohol consumption resting heart rate plasma triglyceride high-density lipoprotein cholesterol low-density lipoprotein cholesterol and high-sensitivity C-reactive protein the risk ratios of incident hypertension in the subjects who carried 2 3 4 and gt 5 ideal health metrics were 0833 (95CI 0789-0880) 0710 (95CI 0672-0749) 0604 (95CI 0568-0642) and 0581 (95CI 0524-0643) respectively in comparison to those with lt 1 ideal health metric A similar trend was also observed in male and female populations Poor health metrics including body mass index diet (salt intake) physical activity total cholesterol and smoking were predictors for the development of hypertension in prehypertensive individuals
CONCLUSION Ideal cardiovascular health behaviors and factors are protective factors to prevent the progression from prehypertension to hypertension
Treat or not to treat prehypertension this is the question now
bull ProfBakris
bull The argument has always been to use lifestyle modification for those with prehypertension-the good news is that it works but the bad news is that nobody does it
How does story continue
bull TROPHY study (candesartan) Julius S Nesbitt SD Egan BM et al Feasibility of treating prehypertension with an angiotensin-receptor blocker N Engl J Med2006354(16)1685-1697
bull PHARAO study (Ramipril) Luumlders S Schrader J Berger J et al The PHARAO study prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure a prospective randomized controlled prevention trial of the German Hypertension League J Hypertens 200826(7)1487-1496
bull Small studies no effect
TROPHY studyKaplan-Meier Curves of New Onset of Clinical
Hypertension in the Two Groups
0 1 2 3 4
Years in study
0
01
02
03
04
05
06
07
08
09
10
C
um
ula
tive
inci
den
ce
Candesartan
Placebo
Candesartan 391 356 309 191 128
Placebo 381 269 184 118 85
Numbers under the graph refer to hypertension-free individuals
2 YearsRR darr66AR darr 26
4 YearsRR darr158AR darr 96
P lt 00001
Julius S NesbittSD N Engl J Med 20063541-13
No effect
bull Lowering the tresholds for the initiation of pharmacologic therapy would have a tremendous economic effect on public health care system (Grassi N Eng J Med 2006)
bull The high-risk strategy identifes and treats those at greatest risk (eg 10y coronary heart disease risk gt20) While there benefits individual the population attributale risk remains significant since most events occur among those at lower risk levels (Egan Nesbitt Julius Therapevtic Advances in CV Disease)
Conclusion for our practice
bull Prehypertension is not an innocent stage and could be dangerous condition
bull It needs to be monitorised excluded masked hypertension
bull Regular blood pressure measurements HBPM ABPM telemonitoring
bull Life style modification versus pharmacological treatment
bull Subclinical organ damage assessmentbull Medical treatment as soon as it is needed
according present ESH guidelines
Definition of prehypertension
stage Outpatient BP
(mmHg)
Home BP
(mmHg)
ABMP (mmHg)
24-h Day-time Night-time
Normotension lt12080
Prehypertension 120-13980-89
Hypertension ge14090 gt13585 gt13080 gt13585 gt12070
BP Thresholds for Definition of Hypertension
High office BP
Normal home BP
ldquoWhite-coatrdquo hypertension
Normal office BP
Normal home BP
ldquoNormotensionrdquo
High office BP
High home BP
Sustained hypertension
Normal office BP
High home BP
Masked hypertension
14090 mmHg
lt13585mmHgHome BP
Office BP
Masked hypertension
0
40
80
120
160
200
0
40
80
120
160
200
12 14 16 18 20 22 0 2 4 6 8 10 12 14
Blo
od
pre
ssure
(mm
Hg)
H
eart
rate
(min
-1)
Time (hour)
Blood pressureHeart rate
Man 20 yearsDaytime 152 87 mm Hg
Night-time 130 71 mm HgNight-time BP Drop -15 -18
Home blood pressure consistently hypertensiveClinic blood pressure 11070 mm Hg target organs damage
12 cohorts
Copenhagen (Denmark)
Dublin (Ireland)
Jingning (China)
Krakoacutew (Poland)
Maracaibo (Venezuela)
Montevideo (Uruguay)
Noorderkempen (Belgium)
Novosibirsk (Russia)
Ohasama (Japan)
Padova (Italy)
Pilsen (Czechia)
Uppsala (Sweden)
To study risk stratification by ABPM in people stratified by CBP
categories The International Database on Ambulatory blood
pressure in relation to Cardiovascular Outcomes (IDACO)
IDACO
Database
Standardised questionnaires
Anthropometric measurements
CBP and ABP
Blood sample (cholesterol glucose etc)
Outcome of participants
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
CV prediction
IDACOdatabase
Cardiovascualr risk based on BP measured in outpatient
8
7
6
5
4
3
2
1
0
0 3 6 9 12 15
20
15
10
05
0
0 3 6 9 12 15
Follow-up (years) Follow-up (years)
CV
eve
nts
(
)
Adjusted for cohort sex age BMI smoking and drinking serum cholesterol CV disease and DM
Cardiovascular events Stroke
Stro
ke(
)
HT
Pre-HT
NT
Plt00001
p=0012
HT
Pre-HT
NT
p=0015
Plt00001
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
05 1 2 4 8 05 1 2 4 8
NT 2441 63 2441 13
NT with masked HT 198 14 198 5
Pre-HT with masked HT 900 90 900 31
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
Daytime BP thresholds ge13585 mmHg
212 (p=00058)
222 (plt00001)
275 (p=0026)
301 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
NT 2527 67 2527 14
NT with masked HT 112 10 112 4
Pre-HT with masked HT 672 74 672 27
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
05 1 2 4 8 05 1 2 4 8
24h BP thresholds ge13080 mmHg
258 (p=00032)
213 (plt00001)
418 (p=00047)
317 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
Home blood pressure and ABPM in detecting masked hypertension (same sample N=128 )
CV riskUpgraded 117Downgraded 148No change 734
Masked hypertensionHome BPM748ABPM 131
MH = masked hypertensionNR = normotensionSH = sustained hypertension
RISHO2014
Baseline to follow-up reproducibility of home blood pressure measurements in tertiles of the follow up duration
RISHO2014
100 120 140 160
-40
-20
0
20
40
CR=176
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=161
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=198
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=218
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=212
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=242
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
a) 1tertile
b) 2tertile
c) 3tertile
Bland and Altman method CR=coefficient of reproducibility twice of SD of the difference between repeated measurement
Observation 24y
43y
59y
Home Blood Pressure as a Predictor of Future Blood Pressure Stability in Borderline HypertensionThe Tecumseh StudyS D Nesbitt J V Amerena EGrant K A Jamerson H Lu A Weder Stevo Julius
JAMA 2016315(23)2564-2575
Characteristics of Colorectal Cancer Screening Strategiesa
Screening for Colorectal Cancer vs ABPM in PrehypertensionUS Preventive Services Task Force Recommendation Statement
PrehypertensionOutpatient BP
Home BPEvery year
ABPMif expected risk MH or
large CV risk
Conformation of MH
Medical treatment on time
Confirmation with ABPM
Treat or not to treat prehypertension this is the question now
bull lifestyle modification for those with prehypertension-the good news is that it works
Ideal cardiovascular health behaviors and factors prevent the development of hypertension inprehypertensive subjects
Gao J Sun H Liang X Gao M Zhao H Qi Y Wang Y Liu Y Li J Zhu Y Zhao Y Wang W Ma L Wu SClinical amp Experimental Hypertension (New York) 37(8)650-5 2015
bull BACKGROUND Seven ideal health metrics were defined by AHA to monitor cardiovascular health This study aimed to investigate the impact of ideal cardiovascular health behaviors and factors on the development of hypertension in prehypertensive subjects
METHODS Thirty-two thousand eight-hundred and eighty-seven participants with prehypertension were included in the study after excluding for preexisting stroke myocardial infarction or malignancy Cox proportional hazards regression was used to calculate hazard ratios and 95 confidence intervals [CI] for the development of hypertension
RESULTS During a follow-up of 522 months 15500 prehypertensive participants developed hypertension The cumulative incidence of hypertension decreased with the number of ideal health metrics increased It was 7861 7108 6315 5607 and 6162 in prehypertensive individuals carrying lt 1 2 3 4 and gt 5 ideal health behaviors or factors respectively After adjustment for age gender family history of hypertension alcohol consumption resting heart rate plasma triglyceride high-density lipoprotein cholesterol low-density lipoprotein cholesterol and high-sensitivity C-reactive protein the risk ratios of incident hypertension in the subjects who carried 2 3 4 and gt 5 ideal health metrics were 0833 (95CI 0789-0880) 0710 (95CI 0672-0749) 0604 (95CI 0568-0642) and 0581 (95CI 0524-0643) respectively in comparison to those with lt 1 ideal health metric A similar trend was also observed in male and female populations Poor health metrics including body mass index diet (salt intake) physical activity total cholesterol and smoking were predictors for the development of hypertension in prehypertensive individuals
CONCLUSION Ideal cardiovascular health behaviors and factors are protective factors to prevent the progression from prehypertension to hypertension
Treat or not to treat prehypertension this is the question now
bull ProfBakris
bull The argument has always been to use lifestyle modification for those with prehypertension-the good news is that it works but the bad news is that nobody does it
How does story continue
bull TROPHY study (candesartan) Julius S Nesbitt SD Egan BM et al Feasibility of treating prehypertension with an angiotensin-receptor blocker N Engl J Med2006354(16)1685-1697
bull PHARAO study (Ramipril) Luumlders S Schrader J Berger J et al The PHARAO study prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure a prospective randomized controlled prevention trial of the German Hypertension League J Hypertens 200826(7)1487-1496
bull Small studies no effect
TROPHY studyKaplan-Meier Curves of New Onset of Clinical
Hypertension in the Two Groups
0 1 2 3 4
Years in study
0
01
02
03
04
05
06
07
08
09
10
C
um
ula
tive
inci
den
ce
Candesartan
Placebo
Candesartan 391 356 309 191 128
Placebo 381 269 184 118 85
Numbers under the graph refer to hypertension-free individuals
2 YearsRR darr66AR darr 26
4 YearsRR darr158AR darr 96
P lt 00001
Julius S NesbittSD N Engl J Med 20063541-13
No effect
bull Lowering the tresholds for the initiation of pharmacologic therapy would have a tremendous economic effect on public health care system (Grassi N Eng J Med 2006)
bull The high-risk strategy identifes and treats those at greatest risk (eg 10y coronary heart disease risk gt20) While there benefits individual the population attributale risk remains significant since most events occur among those at lower risk levels (Egan Nesbitt Julius Therapevtic Advances in CV Disease)
Conclusion for our practice
bull Prehypertension is not an innocent stage and could be dangerous condition
bull It needs to be monitorised excluded masked hypertension
bull Regular blood pressure measurements HBPM ABPM telemonitoring
bull Life style modification versus pharmacological treatment
bull Subclinical organ damage assessmentbull Medical treatment as soon as it is needed
according present ESH guidelines
BP Thresholds for Definition of Hypertension
High office BP
Normal home BP
ldquoWhite-coatrdquo hypertension
Normal office BP
Normal home BP
ldquoNormotensionrdquo
High office BP
High home BP
Sustained hypertension
Normal office BP
High home BP
Masked hypertension
14090 mmHg
lt13585mmHgHome BP
Office BP
Masked hypertension
0
40
80
120
160
200
0
40
80
120
160
200
12 14 16 18 20 22 0 2 4 6 8 10 12 14
Blo
od
pre
ssure
(mm
Hg)
H
eart
rate
(min
-1)
Time (hour)
Blood pressureHeart rate
Man 20 yearsDaytime 152 87 mm Hg
Night-time 130 71 mm HgNight-time BP Drop -15 -18
Home blood pressure consistently hypertensiveClinic blood pressure 11070 mm Hg target organs damage
12 cohorts
Copenhagen (Denmark)
Dublin (Ireland)
Jingning (China)
Krakoacutew (Poland)
Maracaibo (Venezuela)
Montevideo (Uruguay)
Noorderkempen (Belgium)
Novosibirsk (Russia)
Ohasama (Japan)
Padova (Italy)
Pilsen (Czechia)
Uppsala (Sweden)
To study risk stratification by ABPM in people stratified by CBP
categories The International Database on Ambulatory blood
pressure in relation to Cardiovascular Outcomes (IDACO)
IDACO
Database
Standardised questionnaires
Anthropometric measurements
CBP and ABP
Blood sample (cholesterol glucose etc)
Outcome of participants
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
CV prediction
IDACOdatabase
Cardiovascualr risk based on BP measured in outpatient
8
7
6
5
4
3
2
1
0
0 3 6 9 12 15
20
15
10
05
0
0 3 6 9 12 15
Follow-up (years) Follow-up (years)
CV
eve
nts
(
)
Adjusted for cohort sex age BMI smoking and drinking serum cholesterol CV disease and DM
Cardiovascular events Stroke
Stro
ke(
)
HT
Pre-HT
NT
Plt00001
p=0012
HT
Pre-HT
NT
p=0015
Plt00001
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
05 1 2 4 8 05 1 2 4 8
NT 2441 63 2441 13
NT with masked HT 198 14 198 5
Pre-HT with masked HT 900 90 900 31
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
Daytime BP thresholds ge13585 mmHg
212 (p=00058)
222 (plt00001)
275 (p=0026)
301 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
NT 2527 67 2527 14
NT with masked HT 112 10 112 4
Pre-HT with masked HT 672 74 672 27
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
05 1 2 4 8 05 1 2 4 8
24h BP thresholds ge13080 mmHg
258 (p=00032)
213 (plt00001)
418 (p=00047)
317 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
Home blood pressure and ABPM in detecting masked hypertension (same sample N=128 )
CV riskUpgraded 117Downgraded 148No change 734
Masked hypertensionHome BPM748ABPM 131
MH = masked hypertensionNR = normotensionSH = sustained hypertension
RISHO2014
Baseline to follow-up reproducibility of home blood pressure measurements in tertiles of the follow up duration
RISHO2014
100 120 140 160
-40
-20
0
20
40
CR=176
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=161
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=198
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=218
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=212
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=242
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
a) 1tertile
b) 2tertile
c) 3tertile
Bland and Altman method CR=coefficient of reproducibility twice of SD of the difference between repeated measurement
Observation 24y
43y
59y
Home Blood Pressure as a Predictor of Future Blood Pressure Stability in Borderline HypertensionThe Tecumseh StudyS D Nesbitt J V Amerena EGrant K A Jamerson H Lu A Weder Stevo Julius
JAMA 2016315(23)2564-2575
Characteristics of Colorectal Cancer Screening Strategiesa
Screening for Colorectal Cancer vs ABPM in PrehypertensionUS Preventive Services Task Force Recommendation Statement
PrehypertensionOutpatient BP
Home BPEvery year
ABPMif expected risk MH or
large CV risk
Conformation of MH
Medical treatment on time
Confirmation with ABPM
Treat or not to treat prehypertension this is the question now
bull lifestyle modification for those with prehypertension-the good news is that it works
Ideal cardiovascular health behaviors and factors prevent the development of hypertension inprehypertensive subjects
Gao J Sun H Liang X Gao M Zhao H Qi Y Wang Y Liu Y Li J Zhu Y Zhao Y Wang W Ma L Wu SClinical amp Experimental Hypertension (New York) 37(8)650-5 2015
bull BACKGROUND Seven ideal health metrics were defined by AHA to monitor cardiovascular health This study aimed to investigate the impact of ideal cardiovascular health behaviors and factors on the development of hypertension in prehypertensive subjects
METHODS Thirty-two thousand eight-hundred and eighty-seven participants with prehypertension were included in the study after excluding for preexisting stroke myocardial infarction or malignancy Cox proportional hazards regression was used to calculate hazard ratios and 95 confidence intervals [CI] for the development of hypertension
RESULTS During a follow-up of 522 months 15500 prehypertensive participants developed hypertension The cumulative incidence of hypertension decreased with the number of ideal health metrics increased It was 7861 7108 6315 5607 and 6162 in prehypertensive individuals carrying lt 1 2 3 4 and gt 5 ideal health behaviors or factors respectively After adjustment for age gender family history of hypertension alcohol consumption resting heart rate plasma triglyceride high-density lipoprotein cholesterol low-density lipoprotein cholesterol and high-sensitivity C-reactive protein the risk ratios of incident hypertension in the subjects who carried 2 3 4 and gt 5 ideal health metrics were 0833 (95CI 0789-0880) 0710 (95CI 0672-0749) 0604 (95CI 0568-0642) and 0581 (95CI 0524-0643) respectively in comparison to those with lt 1 ideal health metric A similar trend was also observed in male and female populations Poor health metrics including body mass index diet (salt intake) physical activity total cholesterol and smoking were predictors for the development of hypertension in prehypertensive individuals
CONCLUSION Ideal cardiovascular health behaviors and factors are protective factors to prevent the progression from prehypertension to hypertension
Treat or not to treat prehypertension this is the question now
bull ProfBakris
bull The argument has always been to use lifestyle modification for those with prehypertension-the good news is that it works but the bad news is that nobody does it
How does story continue
bull TROPHY study (candesartan) Julius S Nesbitt SD Egan BM et al Feasibility of treating prehypertension with an angiotensin-receptor blocker N Engl J Med2006354(16)1685-1697
bull PHARAO study (Ramipril) Luumlders S Schrader J Berger J et al The PHARAO study prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure a prospective randomized controlled prevention trial of the German Hypertension League J Hypertens 200826(7)1487-1496
bull Small studies no effect
TROPHY studyKaplan-Meier Curves of New Onset of Clinical
Hypertension in the Two Groups
0 1 2 3 4
Years in study
0
01
02
03
04
05
06
07
08
09
10
C
um
ula
tive
inci
den
ce
Candesartan
Placebo
Candesartan 391 356 309 191 128
Placebo 381 269 184 118 85
Numbers under the graph refer to hypertension-free individuals
2 YearsRR darr66AR darr 26
4 YearsRR darr158AR darr 96
P lt 00001
Julius S NesbittSD N Engl J Med 20063541-13
No effect
bull Lowering the tresholds for the initiation of pharmacologic therapy would have a tremendous economic effect on public health care system (Grassi N Eng J Med 2006)
bull The high-risk strategy identifes and treats those at greatest risk (eg 10y coronary heart disease risk gt20) While there benefits individual the population attributale risk remains significant since most events occur among those at lower risk levels (Egan Nesbitt Julius Therapevtic Advances in CV Disease)
Conclusion for our practice
bull Prehypertension is not an innocent stage and could be dangerous condition
bull It needs to be monitorised excluded masked hypertension
bull Regular blood pressure measurements HBPM ABPM telemonitoring
bull Life style modification versus pharmacological treatment
bull Subclinical organ damage assessmentbull Medical treatment as soon as it is needed
according present ESH guidelines
Masked hypertension
0
40
80
120
160
200
0
40
80
120
160
200
12 14 16 18 20 22 0 2 4 6 8 10 12 14
Blo
od
pre
ssure
(mm
Hg)
H
eart
rate
(min
-1)
Time (hour)
Blood pressureHeart rate
Man 20 yearsDaytime 152 87 mm Hg
Night-time 130 71 mm HgNight-time BP Drop -15 -18
Home blood pressure consistently hypertensiveClinic blood pressure 11070 mm Hg target organs damage
12 cohorts
Copenhagen (Denmark)
Dublin (Ireland)
Jingning (China)
Krakoacutew (Poland)
Maracaibo (Venezuela)
Montevideo (Uruguay)
Noorderkempen (Belgium)
Novosibirsk (Russia)
Ohasama (Japan)
Padova (Italy)
Pilsen (Czechia)
Uppsala (Sweden)
To study risk stratification by ABPM in people stratified by CBP
categories The International Database on Ambulatory blood
pressure in relation to Cardiovascular Outcomes (IDACO)
IDACO
Database
Standardised questionnaires
Anthropometric measurements
CBP and ABP
Blood sample (cholesterol glucose etc)
Outcome of participants
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
CV prediction
IDACOdatabase
Cardiovascualr risk based on BP measured in outpatient
8
7
6
5
4
3
2
1
0
0 3 6 9 12 15
20
15
10
05
0
0 3 6 9 12 15
Follow-up (years) Follow-up (years)
CV
eve
nts
(
)
Adjusted for cohort sex age BMI smoking and drinking serum cholesterol CV disease and DM
Cardiovascular events Stroke
Stro
ke(
)
HT
Pre-HT
NT
Plt00001
p=0012
HT
Pre-HT
NT
p=0015
Plt00001
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
05 1 2 4 8 05 1 2 4 8
NT 2441 63 2441 13
NT with masked HT 198 14 198 5
Pre-HT with masked HT 900 90 900 31
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
Daytime BP thresholds ge13585 mmHg
212 (p=00058)
222 (plt00001)
275 (p=0026)
301 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
NT 2527 67 2527 14
NT with masked HT 112 10 112 4
Pre-HT with masked HT 672 74 672 27
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
05 1 2 4 8 05 1 2 4 8
24h BP thresholds ge13080 mmHg
258 (p=00032)
213 (plt00001)
418 (p=00047)
317 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
Home blood pressure and ABPM in detecting masked hypertension (same sample N=128 )
CV riskUpgraded 117Downgraded 148No change 734
Masked hypertensionHome BPM748ABPM 131
MH = masked hypertensionNR = normotensionSH = sustained hypertension
RISHO2014
Baseline to follow-up reproducibility of home blood pressure measurements in tertiles of the follow up duration
RISHO2014
100 120 140 160
-40
-20
0
20
40
CR=176
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=161
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=198
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=218
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=212
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=242
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
a) 1tertile
b) 2tertile
c) 3tertile
Bland and Altman method CR=coefficient of reproducibility twice of SD of the difference between repeated measurement
Observation 24y
43y
59y
Home Blood Pressure as a Predictor of Future Blood Pressure Stability in Borderline HypertensionThe Tecumseh StudyS D Nesbitt J V Amerena EGrant K A Jamerson H Lu A Weder Stevo Julius
JAMA 2016315(23)2564-2575
Characteristics of Colorectal Cancer Screening Strategiesa
Screening for Colorectal Cancer vs ABPM in PrehypertensionUS Preventive Services Task Force Recommendation Statement
PrehypertensionOutpatient BP
Home BPEvery year
ABPMif expected risk MH or
large CV risk
Conformation of MH
Medical treatment on time
Confirmation with ABPM
Treat or not to treat prehypertension this is the question now
bull lifestyle modification for those with prehypertension-the good news is that it works
Ideal cardiovascular health behaviors and factors prevent the development of hypertension inprehypertensive subjects
Gao J Sun H Liang X Gao M Zhao H Qi Y Wang Y Liu Y Li J Zhu Y Zhao Y Wang W Ma L Wu SClinical amp Experimental Hypertension (New York) 37(8)650-5 2015
bull BACKGROUND Seven ideal health metrics were defined by AHA to monitor cardiovascular health This study aimed to investigate the impact of ideal cardiovascular health behaviors and factors on the development of hypertension in prehypertensive subjects
METHODS Thirty-two thousand eight-hundred and eighty-seven participants with prehypertension were included in the study after excluding for preexisting stroke myocardial infarction or malignancy Cox proportional hazards regression was used to calculate hazard ratios and 95 confidence intervals [CI] for the development of hypertension
RESULTS During a follow-up of 522 months 15500 prehypertensive participants developed hypertension The cumulative incidence of hypertension decreased with the number of ideal health metrics increased It was 7861 7108 6315 5607 and 6162 in prehypertensive individuals carrying lt 1 2 3 4 and gt 5 ideal health behaviors or factors respectively After adjustment for age gender family history of hypertension alcohol consumption resting heart rate plasma triglyceride high-density lipoprotein cholesterol low-density lipoprotein cholesterol and high-sensitivity C-reactive protein the risk ratios of incident hypertension in the subjects who carried 2 3 4 and gt 5 ideal health metrics were 0833 (95CI 0789-0880) 0710 (95CI 0672-0749) 0604 (95CI 0568-0642) and 0581 (95CI 0524-0643) respectively in comparison to those with lt 1 ideal health metric A similar trend was also observed in male and female populations Poor health metrics including body mass index diet (salt intake) physical activity total cholesterol and smoking were predictors for the development of hypertension in prehypertensive individuals
CONCLUSION Ideal cardiovascular health behaviors and factors are protective factors to prevent the progression from prehypertension to hypertension
Treat or not to treat prehypertension this is the question now
bull ProfBakris
bull The argument has always been to use lifestyle modification for those with prehypertension-the good news is that it works but the bad news is that nobody does it
How does story continue
bull TROPHY study (candesartan) Julius S Nesbitt SD Egan BM et al Feasibility of treating prehypertension with an angiotensin-receptor blocker N Engl J Med2006354(16)1685-1697
bull PHARAO study (Ramipril) Luumlders S Schrader J Berger J et al The PHARAO study prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure a prospective randomized controlled prevention trial of the German Hypertension League J Hypertens 200826(7)1487-1496
bull Small studies no effect
TROPHY studyKaplan-Meier Curves of New Onset of Clinical
Hypertension in the Two Groups
0 1 2 3 4
Years in study
0
01
02
03
04
05
06
07
08
09
10
C
um
ula
tive
inci
den
ce
Candesartan
Placebo
Candesartan 391 356 309 191 128
Placebo 381 269 184 118 85
Numbers under the graph refer to hypertension-free individuals
2 YearsRR darr66AR darr 26
4 YearsRR darr158AR darr 96
P lt 00001
Julius S NesbittSD N Engl J Med 20063541-13
No effect
bull Lowering the tresholds for the initiation of pharmacologic therapy would have a tremendous economic effect on public health care system (Grassi N Eng J Med 2006)
bull The high-risk strategy identifes and treats those at greatest risk (eg 10y coronary heart disease risk gt20) While there benefits individual the population attributale risk remains significant since most events occur among those at lower risk levels (Egan Nesbitt Julius Therapevtic Advances in CV Disease)
Conclusion for our practice
bull Prehypertension is not an innocent stage and could be dangerous condition
bull It needs to be monitorised excluded masked hypertension
bull Regular blood pressure measurements HBPM ABPM telemonitoring
bull Life style modification versus pharmacological treatment
bull Subclinical organ damage assessmentbull Medical treatment as soon as it is needed
according present ESH guidelines
12 cohorts
Copenhagen (Denmark)
Dublin (Ireland)
Jingning (China)
Krakoacutew (Poland)
Maracaibo (Venezuela)
Montevideo (Uruguay)
Noorderkempen (Belgium)
Novosibirsk (Russia)
Ohasama (Japan)
Padova (Italy)
Pilsen (Czechia)
Uppsala (Sweden)
To study risk stratification by ABPM in people stratified by CBP
categories The International Database on Ambulatory blood
pressure in relation to Cardiovascular Outcomes (IDACO)
IDACO
Database
Standardised questionnaires
Anthropometric measurements
CBP and ABP
Blood sample (cholesterol glucose etc)
Outcome of participants
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
CV prediction
IDACOdatabase
Cardiovascualr risk based on BP measured in outpatient
8
7
6
5
4
3
2
1
0
0 3 6 9 12 15
20
15
10
05
0
0 3 6 9 12 15
Follow-up (years) Follow-up (years)
CV
eve
nts
(
)
Adjusted for cohort sex age BMI smoking and drinking serum cholesterol CV disease and DM
Cardiovascular events Stroke
Stro
ke(
)
HT
Pre-HT
NT
Plt00001
p=0012
HT
Pre-HT
NT
p=0015
Plt00001
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
05 1 2 4 8 05 1 2 4 8
NT 2441 63 2441 13
NT with masked HT 198 14 198 5
Pre-HT with masked HT 900 90 900 31
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
Daytime BP thresholds ge13585 mmHg
212 (p=00058)
222 (plt00001)
275 (p=0026)
301 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
NT 2527 67 2527 14
NT with masked HT 112 10 112 4
Pre-HT with masked HT 672 74 672 27
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
05 1 2 4 8 05 1 2 4 8
24h BP thresholds ge13080 mmHg
258 (p=00032)
213 (plt00001)
418 (p=00047)
317 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
Home blood pressure and ABPM in detecting masked hypertension (same sample N=128 )
CV riskUpgraded 117Downgraded 148No change 734
Masked hypertensionHome BPM748ABPM 131
MH = masked hypertensionNR = normotensionSH = sustained hypertension
RISHO2014
Baseline to follow-up reproducibility of home blood pressure measurements in tertiles of the follow up duration
RISHO2014
100 120 140 160
-40
-20
0
20
40
CR=176
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=161
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=198
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=218
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=212
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=242
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
a) 1tertile
b) 2tertile
c) 3tertile
Bland and Altman method CR=coefficient of reproducibility twice of SD of the difference between repeated measurement
Observation 24y
43y
59y
Home Blood Pressure as a Predictor of Future Blood Pressure Stability in Borderline HypertensionThe Tecumseh StudyS D Nesbitt J V Amerena EGrant K A Jamerson H Lu A Weder Stevo Julius
JAMA 2016315(23)2564-2575
Characteristics of Colorectal Cancer Screening Strategiesa
Screening for Colorectal Cancer vs ABPM in PrehypertensionUS Preventive Services Task Force Recommendation Statement
PrehypertensionOutpatient BP
Home BPEvery year
ABPMif expected risk MH or
large CV risk
Conformation of MH
Medical treatment on time
Confirmation with ABPM
Treat or not to treat prehypertension this is the question now
bull lifestyle modification for those with prehypertension-the good news is that it works
Ideal cardiovascular health behaviors and factors prevent the development of hypertension inprehypertensive subjects
Gao J Sun H Liang X Gao M Zhao H Qi Y Wang Y Liu Y Li J Zhu Y Zhao Y Wang W Ma L Wu SClinical amp Experimental Hypertension (New York) 37(8)650-5 2015
bull BACKGROUND Seven ideal health metrics were defined by AHA to monitor cardiovascular health This study aimed to investigate the impact of ideal cardiovascular health behaviors and factors on the development of hypertension in prehypertensive subjects
METHODS Thirty-two thousand eight-hundred and eighty-seven participants with prehypertension were included in the study after excluding for preexisting stroke myocardial infarction or malignancy Cox proportional hazards regression was used to calculate hazard ratios and 95 confidence intervals [CI] for the development of hypertension
RESULTS During a follow-up of 522 months 15500 prehypertensive participants developed hypertension The cumulative incidence of hypertension decreased with the number of ideal health metrics increased It was 7861 7108 6315 5607 and 6162 in prehypertensive individuals carrying lt 1 2 3 4 and gt 5 ideal health behaviors or factors respectively After adjustment for age gender family history of hypertension alcohol consumption resting heart rate plasma triglyceride high-density lipoprotein cholesterol low-density lipoprotein cholesterol and high-sensitivity C-reactive protein the risk ratios of incident hypertension in the subjects who carried 2 3 4 and gt 5 ideal health metrics were 0833 (95CI 0789-0880) 0710 (95CI 0672-0749) 0604 (95CI 0568-0642) and 0581 (95CI 0524-0643) respectively in comparison to those with lt 1 ideal health metric A similar trend was also observed in male and female populations Poor health metrics including body mass index diet (salt intake) physical activity total cholesterol and smoking were predictors for the development of hypertension in prehypertensive individuals
CONCLUSION Ideal cardiovascular health behaviors and factors are protective factors to prevent the progression from prehypertension to hypertension
Treat or not to treat prehypertension this is the question now
bull ProfBakris
bull The argument has always been to use lifestyle modification for those with prehypertension-the good news is that it works but the bad news is that nobody does it
How does story continue
bull TROPHY study (candesartan) Julius S Nesbitt SD Egan BM et al Feasibility of treating prehypertension with an angiotensin-receptor blocker N Engl J Med2006354(16)1685-1697
bull PHARAO study (Ramipril) Luumlders S Schrader J Berger J et al The PHARAO study prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure a prospective randomized controlled prevention trial of the German Hypertension League J Hypertens 200826(7)1487-1496
bull Small studies no effect
TROPHY studyKaplan-Meier Curves of New Onset of Clinical
Hypertension in the Two Groups
0 1 2 3 4
Years in study
0
01
02
03
04
05
06
07
08
09
10
C
um
ula
tive
inci
den
ce
Candesartan
Placebo
Candesartan 391 356 309 191 128
Placebo 381 269 184 118 85
Numbers under the graph refer to hypertension-free individuals
2 YearsRR darr66AR darr 26
4 YearsRR darr158AR darr 96
P lt 00001
Julius S NesbittSD N Engl J Med 20063541-13
No effect
bull Lowering the tresholds for the initiation of pharmacologic therapy would have a tremendous economic effect on public health care system (Grassi N Eng J Med 2006)
bull The high-risk strategy identifes and treats those at greatest risk (eg 10y coronary heart disease risk gt20) While there benefits individual the population attributale risk remains significant since most events occur among those at lower risk levels (Egan Nesbitt Julius Therapevtic Advances in CV Disease)
Conclusion for our practice
bull Prehypertension is not an innocent stage and could be dangerous condition
bull It needs to be monitorised excluded masked hypertension
bull Regular blood pressure measurements HBPM ABPM telemonitoring
bull Life style modification versus pharmacological treatment
bull Subclinical organ damage assessmentbull Medical treatment as soon as it is needed
according present ESH guidelines
IDACOdatabase
Cardiovascualr risk based on BP measured in outpatient
8
7
6
5
4
3
2
1
0
0 3 6 9 12 15
20
15
10
05
0
0 3 6 9 12 15
Follow-up (years) Follow-up (years)
CV
eve
nts
(
)
Adjusted for cohort sex age BMI smoking and drinking serum cholesterol CV disease and DM
Cardiovascular events Stroke
Stro
ke(
)
HT
Pre-HT
NT
Plt00001
p=0012
HT
Pre-HT
NT
p=0015
Plt00001
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
05 1 2 4 8 05 1 2 4 8
NT 2441 63 2441 13
NT with masked HT 198 14 198 5
Pre-HT with masked HT 900 90 900 31
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
Daytime BP thresholds ge13585 mmHg
212 (p=00058)
222 (plt00001)
275 (p=0026)
301 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
NT 2527 67 2527 14
NT with masked HT 112 10 112 4
Pre-HT with masked HT 672 74 672 27
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
05 1 2 4 8 05 1 2 4 8
24h BP thresholds ge13080 mmHg
258 (p=00032)
213 (plt00001)
418 (p=00047)
317 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
Home blood pressure and ABPM in detecting masked hypertension (same sample N=128 )
CV riskUpgraded 117Downgraded 148No change 734
Masked hypertensionHome BPM748ABPM 131
MH = masked hypertensionNR = normotensionSH = sustained hypertension
RISHO2014
Baseline to follow-up reproducibility of home blood pressure measurements in tertiles of the follow up duration
RISHO2014
100 120 140 160
-40
-20
0
20
40
CR=176
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=161
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=198
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=218
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=212
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=242
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
a) 1tertile
b) 2tertile
c) 3tertile
Bland and Altman method CR=coefficient of reproducibility twice of SD of the difference between repeated measurement
Observation 24y
43y
59y
Home Blood Pressure as a Predictor of Future Blood Pressure Stability in Borderline HypertensionThe Tecumseh StudyS D Nesbitt J V Amerena EGrant K A Jamerson H Lu A Weder Stevo Julius
JAMA 2016315(23)2564-2575
Characteristics of Colorectal Cancer Screening Strategiesa
Screening for Colorectal Cancer vs ABPM in PrehypertensionUS Preventive Services Task Force Recommendation Statement
PrehypertensionOutpatient BP
Home BPEvery year
ABPMif expected risk MH or
large CV risk
Conformation of MH
Medical treatment on time
Confirmation with ABPM
Treat or not to treat prehypertension this is the question now
bull lifestyle modification for those with prehypertension-the good news is that it works
Ideal cardiovascular health behaviors and factors prevent the development of hypertension inprehypertensive subjects
Gao J Sun H Liang X Gao M Zhao H Qi Y Wang Y Liu Y Li J Zhu Y Zhao Y Wang W Ma L Wu SClinical amp Experimental Hypertension (New York) 37(8)650-5 2015
bull BACKGROUND Seven ideal health metrics were defined by AHA to monitor cardiovascular health This study aimed to investigate the impact of ideal cardiovascular health behaviors and factors on the development of hypertension in prehypertensive subjects
METHODS Thirty-two thousand eight-hundred and eighty-seven participants with prehypertension were included in the study after excluding for preexisting stroke myocardial infarction or malignancy Cox proportional hazards regression was used to calculate hazard ratios and 95 confidence intervals [CI] for the development of hypertension
RESULTS During a follow-up of 522 months 15500 prehypertensive participants developed hypertension The cumulative incidence of hypertension decreased with the number of ideal health metrics increased It was 7861 7108 6315 5607 and 6162 in prehypertensive individuals carrying lt 1 2 3 4 and gt 5 ideal health behaviors or factors respectively After adjustment for age gender family history of hypertension alcohol consumption resting heart rate plasma triglyceride high-density lipoprotein cholesterol low-density lipoprotein cholesterol and high-sensitivity C-reactive protein the risk ratios of incident hypertension in the subjects who carried 2 3 4 and gt 5 ideal health metrics were 0833 (95CI 0789-0880) 0710 (95CI 0672-0749) 0604 (95CI 0568-0642) and 0581 (95CI 0524-0643) respectively in comparison to those with lt 1 ideal health metric A similar trend was also observed in male and female populations Poor health metrics including body mass index diet (salt intake) physical activity total cholesterol and smoking were predictors for the development of hypertension in prehypertensive individuals
CONCLUSION Ideal cardiovascular health behaviors and factors are protective factors to prevent the progression from prehypertension to hypertension
Treat or not to treat prehypertension this is the question now
bull ProfBakris
bull The argument has always been to use lifestyle modification for those with prehypertension-the good news is that it works but the bad news is that nobody does it
How does story continue
bull TROPHY study (candesartan) Julius S Nesbitt SD Egan BM et al Feasibility of treating prehypertension with an angiotensin-receptor blocker N Engl J Med2006354(16)1685-1697
bull PHARAO study (Ramipril) Luumlders S Schrader J Berger J et al The PHARAO study prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure a prospective randomized controlled prevention trial of the German Hypertension League J Hypertens 200826(7)1487-1496
bull Small studies no effect
TROPHY studyKaplan-Meier Curves of New Onset of Clinical
Hypertension in the Two Groups
0 1 2 3 4
Years in study
0
01
02
03
04
05
06
07
08
09
10
C
um
ula
tive
inci
den
ce
Candesartan
Placebo
Candesartan 391 356 309 191 128
Placebo 381 269 184 118 85
Numbers under the graph refer to hypertension-free individuals
2 YearsRR darr66AR darr 26
4 YearsRR darr158AR darr 96
P lt 00001
Julius S NesbittSD N Engl J Med 20063541-13
No effect
bull Lowering the tresholds for the initiation of pharmacologic therapy would have a tremendous economic effect on public health care system (Grassi N Eng J Med 2006)
bull The high-risk strategy identifes and treats those at greatest risk (eg 10y coronary heart disease risk gt20) While there benefits individual the population attributale risk remains significant since most events occur among those at lower risk levels (Egan Nesbitt Julius Therapevtic Advances in CV Disease)
Conclusion for our practice
bull Prehypertension is not an innocent stage and could be dangerous condition
bull It needs to be monitorised excluded masked hypertension
bull Regular blood pressure measurements HBPM ABPM telemonitoring
bull Life style modification versus pharmacological treatment
bull Subclinical organ damage assessmentbull Medical treatment as soon as it is needed
according present ESH guidelines
IDACO HRs (vs NT) associated with masked HT
05 1 2 4 8 05 1 2 4 8
NT 2441 63 2441 13
NT with masked HT 198 14 198 5
Pre-HT with masked HT 900 90 900 31
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
Daytime BP thresholds ge13585 mmHg
212 (p=00058)
222 (plt00001)
275 (p=0026)
301 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
IDACO HRs (vs NT) associated with masked HT
NT 2527 67 2527 14
NT with masked HT 112 10 112 4
Pre-HT with masked HT 672 74 672 27
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
05 1 2 4 8 05 1 2 4 8
24h BP thresholds ge13080 mmHg
258 (p=00032)
213 (plt00001)
418 (p=00047)
317 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
Home blood pressure and ABPM in detecting masked hypertension (same sample N=128 )
CV riskUpgraded 117Downgraded 148No change 734
Masked hypertensionHome BPM748ABPM 131
MH = masked hypertensionNR = normotensionSH = sustained hypertension
RISHO2014
Baseline to follow-up reproducibility of home blood pressure measurements in tertiles of the follow up duration
RISHO2014
100 120 140 160
-40
-20
0
20
40
CR=176
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=161
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=198
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=218
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=212
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=242
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
a) 1tertile
b) 2tertile
c) 3tertile
Bland and Altman method CR=coefficient of reproducibility twice of SD of the difference between repeated measurement
Observation 24y
43y
59y
Home Blood Pressure as a Predictor of Future Blood Pressure Stability in Borderline HypertensionThe Tecumseh StudyS D Nesbitt J V Amerena EGrant K A Jamerson H Lu A Weder Stevo Julius
JAMA 2016315(23)2564-2575
Characteristics of Colorectal Cancer Screening Strategiesa
Screening for Colorectal Cancer vs ABPM in PrehypertensionUS Preventive Services Task Force Recommendation Statement
PrehypertensionOutpatient BP
Home BPEvery year
ABPMif expected risk MH or
large CV risk
Conformation of MH
Medical treatment on time
Confirmation with ABPM
Treat or not to treat prehypertension this is the question now
bull lifestyle modification for those with prehypertension-the good news is that it works
Ideal cardiovascular health behaviors and factors prevent the development of hypertension inprehypertensive subjects
Gao J Sun H Liang X Gao M Zhao H Qi Y Wang Y Liu Y Li J Zhu Y Zhao Y Wang W Ma L Wu SClinical amp Experimental Hypertension (New York) 37(8)650-5 2015
bull BACKGROUND Seven ideal health metrics were defined by AHA to monitor cardiovascular health This study aimed to investigate the impact of ideal cardiovascular health behaviors and factors on the development of hypertension in prehypertensive subjects
METHODS Thirty-two thousand eight-hundred and eighty-seven participants with prehypertension were included in the study after excluding for preexisting stroke myocardial infarction or malignancy Cox proportional hazards regression was used to calculate hazard ratios and 95 confidence intervals [CI] for the development of hypertension
RESULTS During a follow-up of 522 months 15500 prehypertensive participants developed hypertension The cumulative incidence of hypertension decreased with the number of ideal health metrics increased It was 7861 7108 6315 5607 and 6162 in prehypertensive individuals carrying lt 1 2 3 4 and gt 5 ideal health behaviors or factors respectively After adjustment for age gender family history of hypertension alcohol consumption resting heart rate plasma triglyceride high-density lipoprotein cholesterol low-density lipoprotein cholesterol and high-sensitivity C-reactive protein the risk ratios of incident hypertension in the subjects who carried 2 3 4 and gt 5 ideal health metrics were 0833 (95CI 0789-0880) 0710 (95CI 0672-0749) 0604 (95CI 0568-0642) and 0581 (95CI 0524-0643) respectively in comparison to those with lt 1 ideal health metric A similar trend was also observed in male and female populations Poor health metrics including body mass index diet (salt intake) physical activity total cholesterol and smoking were predictors for the development of hypertension in prehypertensive individuals
CONCLUSION Ideal cardiovascular health behaviors and factors are protective factors to prevent the progression from prehypertension to hypertension
Treat or not to treat prehypertension this is the question now
bull ProfBakris
bull The argument has always been to use lifestyle modification for those with prehypertension-the good news is that it works but the bad news is that nobody does it
How does story continue
bull TROPHY study (candesartan) Julius S Nesbitt SD Egan BM et al Feasibility of treating prehypertension with an angiotensin-receptor blocker N Engl J Med2006354(16)1685-1697
bull PHARAO study (Ramipril) Luumlders S Schrader J Berger J et al The PHARAO study prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure a prospective randomized controlled prevention trial of the German Hypertension League J Hypertens 200826(7)1487-1496
bull Small studies no effect
TROPHY studyKaplan-Meier Curves of New Onset of Clinical
Hypertension in the Two Groups
0 1 2 3 4
Years in study
0
01
02
03
04
05
06
07
08
09
10
C
um
ula
tive
inci
den
ce
Candesartan
Placebo
Candesartan 391 356 309 191 128
Placebo 381 269 184 118 85
Numbers under the graph refer to hypertension-free individuals
2 YearsRR darr66AR darr 26
4 YearsRR darr158AR darr 96
P lt 00001
Julius S NesbittSD N Engl J Med 20063541-13
No effect
bull Lowering the tresholds for the initiation of pharmacologic therapy would have a tremendous economic effect on public health care system (Grassi N Eng J Med 2006)
bull The high-risk strategy identifes and treats those at greatest risk (eg 10y coronary heart disease risk gt20) While there benefits individual the population attributale risk remains significant since most events occur among those at lower risk levels (Egan Nesbitt Julius Therapevtic Advances in CV Disease)
Conclusion for our practice
bull Prehypertension is not an innocent stage and could be dangerous condition
bull It needs to be monitorised excluded masked hypertension
bull Regular blood pressure measurements HBPM ABPM telemonitoring
bull Life style modification versus pharmacological treatment
bull Subclinical organ damage assessmentbull Medical treatment as soon as it is needed
according present ESH guidelines
IDACO HRs (vs NT) associated with masked HT
NT 2527 67 2527 14
NT with masked HT 112 10 112 4
Pre-HT with masked HT 672 74 672 27
No ofsubjects
No ofevents
No ofsubjects
No ofevents
CV events Stroke
05 1 2 4 8 05 1 2 4 8
24h BP thresholds ge13080 mmHg
258 (p=00032)
213 (plt00001)
418 (p=00047)
317 (plt00001)
Brguljan-Hitij J Thijs L Li Y et all Am J Hypertens 2014 Feb 26
Home blood pressure and ABPM in detecting masked hypertension (same sample N=128 )
CV riskUpgraded 117Downgraded 148No change 734
Masked hypertensionHome BPM748ABPM 131
MH = masked hypertensionNR = normotensionSH = sustained hypertension
RISHO2014
Baseline to follow-up reproducibility of home blood pressure measurements in tertiles of the follow up duration
RISHO2014
100 120 140 160
-40
-20
0
20
40
CR=176
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=161
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=198
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=218
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=212
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=242
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
a) 1tertile
b) 2tertile
c) 3tertile
Bland and Altman method CR=coefficient of reproducibility twice of SD of the difference between repeated measurement
Observation 24y
43y
59y
Home Blood Pressure as a Predictor of Future Blood Pressure Stability in Borderline HypertensionThe Tecumseh StudyS D Nesbitt J V Amerena EGrant K A Jamerson H Lu A Weder Stevo Julius
JAMA 2016315(23)2564-2575
Characteristics of Colorectal Cancer Screening Strategiesa
Screening for Colorectal Cancer vs ABPM in PrehypertensionUS Preventive Services Task Force Recommendation Statement
PrehypertensionOutpatient BP
Home BPEvery year
ABPMif expected risk MH or
large CV risk
Conformation of MH
Medical treatment on time
Confirmation with ABPM
Treat or not to treat prehypertension this is the question now
bull lifestyle modification for those with prehypertension-the good news is that it works
Ideal cardiovascular health behaviors and factors prevent the development of hypertension inprehypertensive subjects
Gao J Sun H Liang X Gao M Zhao H Qi Y Wang Y Liu Y Li J Zhu Y Zhao Y Wang W Ma L Wu SClinical amp Experimental Hypertension (New York) 37(8)650-5 2015
bull BACKGROUND Seven ideal health metrics were defined by AHA to monitor cardiovascular health This study aimed to investigate the impact of ideal cardiovascular health behaviors and factors on the development of hypertension in prehypertensive subjects
METHODS Thirty-two thousand eight-hundred and eighty-seven participants with prehypertension were included in the study after excluding for preexisting stroke myocardial infarction or malignancy Cox proportional hazards regression was used to calculate hazard ratios and 95 confidence intervals [CI] for the development of hypertension
RESULTS During a follow-up of 522 months 15500 prehypertensive participants developed hypertension The cumulative incidence of hypertension decreased with the number of ideal health metrics increased It was 7861 7108 6315 5607 and 6162 in prehypertensive individuals carrying lt 1 2 3 4 and gt 5 ideal health behaviors or factors respectively After adjustment for age gender family history of hypertension alcohol consumption resting heart rate plasma triglyceride high-density lipoprotein cholesterol low-density lipoprotein cholesterol and high-sensitivity C-reactive protein the risk ratios of incident hypertension in the subjects who carried 2 3 4 and gt 5 ideal health metrics were 0833 (95CI 0789-0880) 0710 (95CI 0672-0749) 0604 (95CI 0568-0642) and 0581 (95CI 0524-0643) respectively in comparison to those with lt 1 ideal health metric A similar trend was also observed in male and female populations Poor health metrics including body mass index diet (salt intake) physical activity total cholesterol and smoking were predictors for the development of hypertension in prehypertensive individuals
CONCLUSION Ideal cardiovascular health behaviors and factors are protective factors to prevent the progression from prehypertension to hypertension
Treat or not to treat prehypertension this is the question now
bull ProfBakris
bull The argument has always been to use lifestyle modification for those with prehypertension-the good news is that it works but the bad news is that nobody does it
How does story continue
bull TROPHY study (candesartan) Julius S Nesbitt SD Egan BM et al Feasibility of treating prehypertension with an angiotensin-receptor blocker N Engl J Med2006354(16)1685-1697
bull PHARAO study (Ramipril) Luumlders S Schrader J Berger J et al The PHARAO study prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure a prospective randomized controlled prevention trial of the German Hypertension League J Hypertens 200826(7)1487-1496
bull Small studies no effect
TROPHY studyKaplan-Meier Curves of New Onset of Clinical
Hypertension in the Two Groups
0 1 2 3 4
Years in study
0
01
02
03
04
05
06
07
08
09
10
C
um
ula
tive
inci
den
ce
Candesartan
Placebo
Candesartan 391 356 309 191 128
Placebo 381 269 184 118 85
Numbers under the graph refer to hypertension-free individuals
2 YearsRR darr66AR darr 26
4 YearsRR darr158AR darr 96
P lt 00001
Julius S NesbittSD N Engl J Med 20063541-13
No effect
bull Lowering the tresholds for the initiation of pharmacologic therapy would have a tremendous economic effect on public health care system (Grassi N Eng J Med 2006)
bull The high-risk strategy identifes and treats those at greatest risk (eg 10y coronary heart disease risk gt20) While there benefits individual the population attributale risk remains significant since most events occur among those at lower risk levels (Egan Nesbitt Julius Therapevtic Advances in CV Disease)
Conclusion for our practice
bull Prehypertension is not an innocent stage and could be dangerous condition
bull It needs to be monitorised excluded masked hypertension
bull Regular blood pressure measurements HBPM ABPM telemonitoring
bull Life style modification versus pharmacological treatment
bull Subclinical organ damage assessmentbull Medical treatment as soon as it is needed
according present ESH guidelines
Home blood pressure and ABPM in detecting masked hypertension (same sample N=128 )
CV riskUpgraded 117Downgraded 148No change 734
Masked hypertensionHome BPM748ABPM 131
MH = masked hypertensionNR = normotensionSH = sustained hypertension
RISHO2014
Baseline to follow-up reproducibility of home blood pressure measurements in tertiles of the follow up duration
RISHO2014
100 120 140 160
-40
-20
0
20
40
CR=176
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=161
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=198
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=218
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=212
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=242
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
a) 1tertile
b) 2tertile
c) 3tertile
Bland and Altman method CR=coefficient of reproducibility twice of SD of the difference between repeated measurement
Observation 24y
43y
59y
Home Blood Pressure as a Predictor of Future Blood Pressure Stability in Borderline HypertensionThe Tecumseh StudyS D Nesbitt J V Amerena EGrant K A Jamerson H Lu A Weder Stevo Julius
JAMA 2016315(23)2564-2575
Characteristics of Colorectal Cancer Screening Strategiesa
Screening for Colorectal Cancer vs ABPM in PrehypertensionUS Preventive Services Task Force Recommendation Statement
PrehypertensionOutpatient BP
Home BPEvery year
ABPMif expected risk MH or
large CV risk
Conformation of MH
Medical treatment on time
Confirmation with ABPM
Treat or not to treat prehypertension this is the question now
bull lifestyle modification for those with prehypertension-the good news is that it works
Ideal cardiovascular health behaviors and factors prevent the development of hypertension inprehypertensive subjects
Gao J Sun H Liang X Gao M Zhao H Qi Y Wang Y Liu Y Li J Zhu Y Zhao Y Wang W Ma L Wu SClinical amp Experimental Hypertension (New York) 37(8)650-5 2015
bull BACKGROUND Seven ideal health metrics were defined by AHA to monitor cardiovascular health This study aimed to investigate the impact of ideal cardiovascular health behaviors and factors on the development of hypertension in prehypertensive subjects
METHODS Thirty-two thousand eight-hundred and eighty-seven participants with prehypertension were included in the study after excluding for preexisting stroke myocardial infarction or malignancy Cox proportional hazards regression was used to calculate hazard ratios and 95 confidence intervals [CI] for the development of hypertension
RESULTS During a follow-up of 522 months 15500 prehypertensive participants developed hypertension The cumulative incidence of hypertension decreased with the number of ideal health metrics increased It was 7861 7108 6315 5607 and 6162 in prehypertensive individuals carrying lt 1 2 3 4 and gt 5 ideal health behaviors or factors respectively After adjustment for age gender family history of hypertension alcohol consumption resting heart rate plasma triglyceride high-density lipoprotein cholesterol low-density lipoprotein cholesterol and high-sensitivity C-reactive protein the risk ratios of incident hypertension in the subjects who carried 2 3 4 and gt 5 ideal health metrics were 0833 (95CI 0789-0880) 0710 (95CI 0672-0749) 0604 (95CI 0568-0642) and 0581 (95CI 0524-0643) respectively in comparison to those with lt 1 ideal health metric A similar trend was also observed in male and female populations Poor health metrics including body mass index diet (salt intake) physical activity total cholesterol and smoking were predictors for the development of hypertension in prehypertensive individuals
CONCLUSION Ideal cardiovascular health behaviors and factors are protective factors to prevent the progression from prehypertension to hypertension
Treat or not to treat prehypertension this is the question now
bull ProfBakris
bull The argument has always been to use lifestyle modification for those with prehypertension-the good news is that it works but the bad news is that nobody does it
How does story continue
bull TROPHY study (candesartan) Julius S Nesbitt SD Egan BM et al Feasibility of treating prehypertension with an angiotensin-receptor blocker N Engl J Med2006354(16)1685-1697
bull PHARAO study (Ramipril) Luumlders S Schrader J Berger J et al The PHARAO study prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure a prospective randomized controlled prevention trial of the German Hypertension League J Hypertens 200826(7)1487-1496
bull Small studies no effect
TROPHY studyKaplan-Meier Curves of New Onset of Clinical
Hypertension in the Two Groups
0 1 2 3 4
Years in study
0
01
02
03
04
05
06
07
08
09
10
C
um
ula
tive
inci
den
ce
Candesartan
Placebo
Candesartan 391 356 309 191 128
Placebo 381 269 184 118 85
Numbers under the graph refer to hypertension-free individuals
2 YearsRR darr66AR darr 26
4 YearsRR darr158AR darr 96
P lt 00001
Julius S NesbittSD N Engl J Med 20063541-13
No effect
bull Lowering the tresholds for the initiation of pharmacologic therapy would have a tremendous economic effect on public health care system (Grassi N Eng J Med 2006)
bull The high-risk strategy identifes and treats those at greatest risk (eg 10y coronary heart disease risk gt20) While there benefits individual the population attributale risk remains significant since most events occur among those at lower risk levels (Egan Nesbitt Julius Therapevtic Advances in CV Disease)
Conclusion for our practice
bull Prehypertension is not an innocent stage and could be dangerous condition
bull It needs to be monitorised excluded masked hypertension
bull Regular blood pressure measurements HBPM ABPM telemonitoring
bull Life style modification versus pharmacological treatment
bull Subclinical organ damage assessmentbull Medical treatment as soon as it is needed
according present ESH guidelines
Baseline to follow-up reproducibility of home blood pressure measurements in tertiles of the follow up duration
RISHO2014
100 120 140 160
-40
-20
0
20
40
CR=176
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=161
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=198
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=218
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
100 120 140 160
-40
-20
0
20
40
CR=212
Average home SBP
(mmHg)
h
om
e S
BP
(mm
Hg
)
60 80 100 120
-40
-20
0
20
40
CR=242
Average home DBP
(mmHg)
h
om
e D
BP
(mm
Hg
)
a) 1tertile
b) 2tertile
c) 3tertile
Bland and Altman method CR=coefficient of reproducibility twice of SD of the difference between repeated measurement
Observation 24y
43y
59y
Home Blood Pressure as a Predictor of Future Blood Pressure Stability in Borderline HypertensionThe Tecumseh StudyS D Nesbitt J V Amerena EGrant K A Jamerson H Lu A Weder Stevo Julius
JAMA 2016315(23)2564-2575
Characteristics of Colorectal Cancer Screening Strategiesa
Screening for Colorectal Cancer vs ABPM in PrehypertensionUS Preventive Services Task Force Recommendation Statement
PrehypertensionOutpatient BP
Home BPEvery year
ABPMif expected risk MH or
large CV risk
Conformation of MH
Medical treatment on time
Confirmation with ABPM
Treat or not to treat prehypertension this is the question now
bull lifestyle modification for those with prehypertension-the good news is that it works
Ideal cardiovascular health behaviors and factors prevent the development of hypertension inprehypertensive subjects
Gao J Sun H Liang X Gao M Zhao H Qi Y Wang Y Liu Y Li J Zhu Y Zhao Y Wang W Ma L Wu SClinical amp Experimental Hypertension (New York) 37(8)650-5 2015
bull BACKGROUND Seven ideal health metrics were defined by AHA to monitor cardiovascular health This study aimed to investigate the impact of ideal cardiovascular health behaviors and factors on the development of hypertension in prehypertensive subjects
METHODS Thirty-two thousand eight-hundred and eighty-seven participants with prehypertension were included in the study after excluding for preexisting stroke myocardial infarction or malignancy Cox proportional hazards regression was used to calculate hazard ratios and 95 confidence intervals [CI] for the development of hypertension
RESULTS During a follow-up of 522 months 15500 prehypertensive participants developed hypertension The cumulative incidence of hypertension decreased with the number of ideal health metrics increased It was 7861 7108 6315 5607 and 6162 in prehypertensive individuals carrying lt 1 2 3 4 and gt 5 ideal health behaviors or factors respectively After adjustment for age gender family history of hypertension alcohol consumption resting heart rate plasma triglyceride high-density lipoprotein cholesterol low-density lipoprotein cholesterol and high-sensitivity C-reactive protein the risk ratios of incident hypertension in the subjects who carried 2 3 4 and gt 5 ideal health metrics were 0833 (95CI 0789-0880) 0710 (95CI 0672-0749) 0604 (95CI 0568-0642) and 0581 (95CI 0524-0643) respectively in comparison to those with lt 1 ideal health metric A similar trend was also observed in male and female populations Poor health metrics including body mass index diet (salt intake) physical activity total cholesterol and smoking were predictors for the development of hypertension in prehypertensive individuals
CONCLUSION Ideal cardiovascular health behaviors and factors are protective factors to prevent the progression from prehypertension to hypertension
Treat or not to treat prehypertension this is the question now
bull ProfBakris
bull The argument has always been to use lifestyle modification for those with prehypertension-the good news is that it works but the bad news is that nobody does it
How does story continue
bull TROPHY study (candesartan) Julius S Nesbitt SD Egan BM et al Feasibility of treating prehypertension with an angiotensin-receptor blocker N Engl J Med2006354(16)1685-1697
bull PHARAO study (Ramipril) Luumlders S Schrader J Berger J et al The PHARAO study prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure a prospective randomized controlled prevention trial of the German Hypertension League J Hypertens 200826(7)1487-1496
bull Small studies no effect
TROPHY studyKaplan-Meier Curves of New Onset of Clinical
Hypertension in the Two Groups
0 1 2 3 4
Years in study
0
01
02
03
04
05
06
07
08
09
10
C
um
ula
tive
inci
den
ce
Candesartan
Placebo
Candesartan 391 356 309 191 128
Placebo 381 269 184 118 85
Numbers under the graph refer to hypertension-free individuals
2 YearsRR darr66AR darr 26
4 YearsRR darr158AR darr 96
P lt 00001
Julius S NesbittSD N Engl J Med 20063541-13
No effect
bull Lowering the tresholds for the initiation of pharmacologic therapy would have a tremendous economic effect on public health care system (Grassi N Eng J Med 2006)
bull The high-risk strategy identifes and treats those at greatest risk (eg 10y coronary heart disease risk gt20) While there benefits individual the population attributale risk remains significant since most events occur among those at lower risk levels (Egan Nesbitt Julius Therapevtic Advances in CV Disease)
Conclusion for our practice
bull Prehypertension is not an innocent stage and could be dangerous condition
bull It needs to be monitorised excluded masked hypertension
bull Regular blood pressure measurements HBPM ABPM telemonitoring
bull Life style modification versus pharmacological treatment
bull Subclinical organ damage assessmentbull Medical treatment as soon as it is needed
according present ESH guidelines
Home Blood Pressure as a Predictor of Future Blood Pressure Stability in Borderline HypertensionThe Tecumseh StudyS D Nesbitt J V Amerena EGrant K A Jamerson H Lu A Weder Stevo Julius
JAMA 2016315(23)2564-2575
Characteristics of Colorectal Cancer Screening Strategiesa
Screening for Colorectal Cancer vs ABPM in PrehypertensionUS Preventive Services Task Force Recommendation Statement
PrehypertensionOutpatient BP
Home BPEvery year
ABPMif expected risk MH or
large CV risk
Conformation of MH
Medical treatment on time
Confirmation with ABPM
Treat or not to treat prehypertension this is the question now
bull lifestyle modification for those with prehypertension-the good news is that it works
Ideal cardiovascular health behaviors and factors prevent the development of hypertension inprehypertensive subjects
Gao J Sun H Liang X Gao M Zhao H Qi Y Wang Y Liu Y Li J Zhu Y Zhao Y Wang W Ma L Wu SClinical amp Experimental Hypertension (New York) 37(8)650-5 2015
bull BACKGROUND Seven ideal health metrics were defined by AHA to monitor cardiovascular health This study aimed to investigate the impact of ideal cardiovascular health behaviors and factors on the development of hypertension in prehypertensive subjects
METHODS Thirty-two thousand eight-hundred and eighty-seven participants with prehypertension were included in the study after excluding for preexisting stroke myocardial infarction or malignancy Cox proportional hazards regression was used to calculate hazard ratios and 95 confidence intervals [CI] for the development of hypertension
RESULTS During a follow-up of 522 months 15500 prehypertensive participants developed hypertension The cumulative incidence of hypertension decreased with the number of ideal health metrics increased It was 7861 7108 6315 5607 and 6162 in prehypertensive individuals carrying lt 1 2 3 4 and gt 5 ideal health behaviors or factors respectively After adjustment for age gender family history of hypertension alcohol consumption resting heart rate plasma triglyceride high-density lipoprotein cholesterol low-density lipoprotein cholesterol and high-sensitivity C-reactive protein the risk ratios of incident hypertension in the subjects who carried 2 3 4 and gt 5 ideal health metrics were 0833 (95CI 0789-0880) 0710 (95CI 0672-0749) 0604 (95CI 0568-0642) and 0581 (95CI 0524-0643) respectively in comparison to those with lt 1 ideal health metric A similar trend was also observed in male and female populations Poor health metrics including body mass index diet (salt intake) physical activity total cholesterol and smoking were predictors for the development of hypertension in prehypertensive individuals
CONCLUSION Ideal cardiovascular health behaviors and factors are protective factors to prevent the progression from prehypertension to hypertension
Treat or not to treat prehypertension this is the question now
bull ProfBakris
bull The argument has always been to use lifestyle modification for those with prehypertension-the good news is that it works but the bad news is that nobody does it
How does story continue
bull TROPHY study (candesartan) Julius S Nesbitt SD Egan BM et al Feasibility of treating prehypertension with an angiotensin-receptor blocker N Engl J Med2006354(16)1685-1697
bull PHARAO study (Ramipril) Luumlders S Schrader J Berger J et al The PHARAO study prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure a prospective randomized controlled prevention trial of the German Hypertension League J Hypertens 200826(7)1487-1496
bull Small studies no effect
TROPHY studyKaplan-Meier Curves of New Onset of Clinical
Hypertension in the Two Groups
0 1 2 3 4
Years in study
0
01
02
03
04
05
06
07
08
09
10
C
um
ula
tive
inci
den
ce
Candesartan
Placebo
Candesartan 391 356 309 191 128
Placebo 381 269 184 118 85
Numbers under the graph refer to hypertension-free individuals
2 YearsRR darr66AR darr 26
4 YearsRR darr158AR darr 96
P lt 00001
Julius S NesbittSD N Engl J Med 20063541-13
No effect
bull Lowering the tresholds for the initiation of pharmacologic therapy would have a tremendous economic effect on public health care system (Grassi N Eng J Med 2006)
bull The high-risk strategy identifes and treats those at greatest risk (eg 10y coronary heart disease risk gt20) While there benefits individual the population attributale risk remains significant since most events occur among those at lower risk levels (Egan Nesbitt Julius Therapevtic Advances in CV Disease)
Conclusion for our practice
bull Prehypertension is not an innocent stage and could be dangerous condition
bull It needs to be monitorised excluded masked hypertension
bull Regular blood pressure measurements HBPM ABPM telemonitoring
bull Life style modification versus pharmacological treatment
bull Subclinical organ damage assessmentbull Medical treatment as soon as it is needed
according present ESH guidelines
JAMA 2016315(23)2564-2575
Characteristics of Colorectal Cancer Screening Strategiesa
Screening for Colorectal Cancer vs ABPM in PrehypertensionUS Preventive Services Task Force Recommendation Statement
PrehypertensionOutpatient BP
Home BPEvery year
ABPMif expected risk MH or
large CV risk
Conformation of MH
Medical treatment on time
Confirmation with ABPM
Treat or not to treat prehypertension this is the question now
bull lifestyle modification for those with prehypertension-the good news is that it works
Ideal cardiovascular health behaviors and factors prevent the development of hypertension inprehypertensive subjects
Gao J Sun H Liang X Gao M Zhao H Qi Y Wang Y Liu Y Li J Zhu Y Zhao Y Wang W Ma L Wu SClinical amp Experimental Hypertension (New York) 37(8)650-5 2015
bull BACKGROUND Seven ideal health metrics were defined by AHA to monitor cardiovascular health This study aimed to investigate the impact of ideal cardiovascular health behaviors and factors on the development of hypertension in prehypertensive subjects
METHODS Thirty-two thousand eight-hundred and eighty-seven participants with prehypertension were included in the study after excluding for preexisting stroke myocardial infarction or malignancy Cox proportional hazards regression was used to calculate hazard ratios and 95 confidence intervals [CI] for the development of hypertension
RESULTS During a follow-up of 522 months 15500 prehypertensive participants developed hypertension The cumulative incidence of hypertension decreased with the number of ideal health metrics increased It was 7861 7108 6315 5607 and 6162 in prehypertensive individuals carrying lt 1 2 3 4 and gt 5 ideal health behaviors or factors respectively After adjustment for age gender family history of hypertension alcohol consumption resting heart rate plasma triglyceride high-density lipoprotein cholesterol low-density lipoprotein cholesterol and high-sensitivity C-reactive protein the risk ratios of incident hypertension in the subjects who carried 2 3 4 and gt 5 ideal health metrics were 0833 (95CI 0789-0880) 0710 (95CI 0672-0749) 0604 (95CI 0568-0642) and 0581 (95CI 0524-0643) respectively in comparison to those with lt 1 ideal health metric A similar trend was also observed in male and female populations Poor health metrics including body mass index diet (salt intake) physical activity total cholesterol and smoking were predictors for the development of hypertension in prehypertensive individuals
CONCLUSION Ideal cardiovascular health behaviors and factors are protective factors to prevent the progression from prehypertension to hypertension
Treat or not to treat prehypertension this is the question now
bull ProfBakris
bull The argument has always been to use lifestyle modification for those with prehypertension-the good news is that it works but the bad news is that nobody does it
How does story continue
bull TROPHY study (candesartan) Julius S Nesbitt SD Egan BM et al Feasibility of treating prehypertension with an angiotensin-receptor blocker N Engl J Med2006354(16)1685-1697
bull PHARAO study (Ramipril) Luumlders S Schrader J Berger J et al The PHARAO study prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure a prospective randomized controlled prevention trial of the German Hypertension League J Hypertens 200826(7)1487-1496
bull Small studies no effect
TROPHY studyKaplan-Meier Curves of New Onset of Clinical
Hypertension in the Two Groups
0 1 2 3 4
Years in study
0
01
02
03
04
05
06
07
08
09
10
C
um
ula
tive
inci
den
ce
Candesartan
Placebo
Candesartan 391 356 309 191 128
Placebo 381 269 184 118 85
Numbers under the graph refer to hypertension-free individuals
2 YearsRR darr66AR darr 26
4 YearsRR darr158AR darr 96
P lt 00001
Julius S NesbittSD N Engl J Med 20063541-13
No effect
bull Lowering the tresholds for the initiation of pharmacologic therapy would have a tremendous economic effect on public health care system (Grassi N Eng J Med 2006)
bull The high-risk strategy identifes and treats those at greatest risk (eg 10y coronary heart disease risk gt20) While there benefits individual the population attributale risk remains significant since most events occur among those at lower risk levels (Egan Nesbitt Julius Therapevtic Advances in CV Disease)
Conclusion for our practice
bull Prehypertension is not an innocent stage and could be dangerous condition
bull It needs to be monitorised excluded masked hypertension
bull Regular blood pressure measurements HBPM ABPM telemonitoring
bull Life style modification versus pharmacological treatment
bull Subclinical organ damage assessmentbull Medical treatment as soon as it is needed
according present ESH guidelines
Treat or not to treat prehypertension this is the question now
bull lifestyle modification for those with prehypertension-the good news is that it works
Ideal cardiovascular health behaviors and factors prevent the development of hypertension inprehypertensive subjects
Gao J Sun H Liang X Gao M Zhao H Qi Y Wang Y Liu Y Li J Zhu Y Zhao Y Wang W Ma L Wu SClinical amp Experimental Hypertension (New York) 37(8)650-5 2015
bull BACKGROUND Seven ideal health metrics were defined by AHA to monitor cardiovascular health This study aimed to investigate the impact of ideal cardiovascular health behaviors and factors on the development of hypertension in prehypertensive subjects
METHODS Thirty-two thousand eight-hundred and eighty-seven participants with prehypertension were included in the study after excluding for preexisting stroke myocardial infarction or malignancy Cox proportional hazards regression was used to calculate hazard ratios and 95 confidence intervals [CI] for the development of hypertension
RESULTS During a follow-up of 522 months 15500 prehypertensive participants developed hypertension The cumulative incidence of hypertension decreased with the number of ideal health metrics increased It was 7861 7108 6315 5607 and 6162 in prehypertensive individuals carrying lt 1 2 3 4 and gt 5 ideal health behaviors or factors respectively After adjustment for age gender family history of hypertension alcohol consumption resting heart rate plasma triglyceride high-density lipoprotein cholesterol low-density lipoprotein cholesterol and high-sensitivity C-reactive protein the risk ratios of incident hypertension in the subjects who carried 2 3 4 and gt 5 ideal health metrics were 0833 (95CI 0789-0880) 0710 (95CI 0672-0749) 0604 (95CI 0568-0642) and 0581 (95CI 0524-0643) respectively in comparison to those with lt 1 ideal health metric A similar trend was also observed in male and female populations Poor health metrics including body mass index diet (salt intake) physical activity total cholesterol and smoking were predictors for the development of hypertension in prehypertensive individuals
CONCLUSION Ideal cardiovascular health behaviors and factors are protective factors to prevent the progression from prehypertension to hypertension
Treat or not to treat prehypertension this is the question now
bull ProfBakris
bull The argument has always been to use lifestyle modification for those with prehypertension-the good news is that it works but the bad news is that nobody does it
How does story continue
bull TROPHY study (candesartan) Julius S Nesbitt SD Egan BM et al Feasibility of treating prehypertension with an angiotensin-receptor blocker N Engl J Med2006354(16)1685-1697
bull PHARAO study (Ramipril) Luumlders S Schrader J Berger J et al The PHARAO study prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure a prospective randomized controlled prevention trial of the German Hypertension League J Hypertens 200826(7)1487-1496
bull Small studies no effect
TROPHY studyKaplan-Meier Curves of New Onset of Clinical
Hypertension in the Two Groups
0 1 2 3 4
Years in study
0
01
02
03
04
05
06
07
08
09
10
C
um
ula
tive
inci
den
ce
Candesartan
Placebo
Candesartan 391 356 309 191 128
Placebo 381 269 184 118 85
Numbers under the graph refer to hypertension-free individuals
2 YearsRR darr66AR darr 26
4 YearsRR darr158AR darr 96
P lt 00001
Julius S NesbittSD N Engl J Med 20063541-13
No effect
bull Lowering the tresholds for the initiation of pharmacologic therapy would have a tremendous economic effect on public health care system (Grassi N Eng J Med 2006)
bull The high-risk strategy identifes and treats those at greatest risk (eg 10y coronary heart disease risk gt20) While there benefits individual the population attributale risk remains significant since most events occur among those at lower risk levels (Egan Nesbitt Julius Therapevtic Advances in CV Disease)
Conclusion for our practice
bull Prehypertension is not an innocent stage and could be dangerous condition
bull It needs to be monitorised excluded masked hypertension
bull Regular blood pressure measurements HBPM ABPM telemonitoring
bull Life style modification versus pharmacological treatment
bull Subclinical organ damage assessmentbull Medical treatment as soon as it is needed
according present ESH guidelines
Ideal cardiovascular health behaviors and factors prevent the development of hypertension inprehypertensive subjects
Gao J Sun H Liang X Gao M Zhao H Qi Y Wang Y Liu Y Li J Zhu Y Zhao Y Wang W Ma L Wu SClinical amp Experimental Hypertension (New York) 37(8)650-5 2015
bull BACKGROUND Seven ideal health metrics were defined by AHA to monitor cardiovascular health This study aimed to investigate the impact of ideal cardiovascular health behaviors and factors on the development of hypertension in prehypertensive subjects
METHODS Thirty-two thousand eight-hundred and eighty-seven participants with prehypertension were included in the study after excluding for preexisting stroke myocardial infarction or malignancy Cox proportional hazards regression was used to calculate hazard ratios and 95 confidence intervals [CI] for the development of hypertension
RESULTS During a follow-up of 522 months 15500 prehypertensive participants developed hypertension The cumulative incidence of hypertension decreased with the number of ideal health metrics increased It was 7861 7108 6315 5607 and 6162 in prehypertensive individuals carrying lt 1 2 3 4 and gt 5 ideal health behaviors or factors respectively After adjustment for age gender family history of hypertension alcohol consumption resting heart rate plasma triglyceride high-density lipoprotein cholesterol low-density lipoprotein cholesterol and high-sensitivity C-reactive protein the risk ratios of incident hypertension in the subjects who carried 2 3 4 and gt 5 ideal health metrics were 0833 (95CI 0789-0880) 0710 (95CI 0672-0749) 0604 (95CI 0568-0642) and 0581 (95CI 0524-0643) respectively in comparison to those with lt 1 ideal health metric A similar trend was also observed in male and female populations Poor health metrics including body mass index diet (salt intake) physical activity total cholesterol and smoking were predictors for the development of hypertension in prehypertensive individuals
CONCLUSION Ideal cardiovascular health behaviors and factors are protective factors to prevent the progression from prehypertension to hypertension
Treat or not to treat prehypertension this is the question now
bull ProfBakris
bull The argument has always been to use lifestyle modification for those with prehypertension-the good news is that it works but the bad news is that nobody does it
How does story continue
bull TROPHY study (candesartan) Julius S Nesbitt SD Egan BM et al Feasibility of treating prehypertension with an angiotensin-receptor blocker N Engl J Med2006354(16)1685-1697
bull PHARAO study (Ramipril) Luumlders S Schrader J Berger J et al The PHARAO study prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure a prospective randomized controlled prevention trial of the German Hypertension League J Hypertens 200826(7)1487-1496
bull Small studies no effect
TROPHY studyKaplan-Meier Curves of New Onset of Clinical
Hypertension in the Two Groups
0 1 2 3 4
Years in study
0
01
02
03
04
05
06
07
08
09
10
C
um
ula
tive
inci
den
ce
Candesartan
Placebo
Candesartan 391 356 309 191 128
Placebo 381 269 184 118 85
Numbers under the graph refer to hypertension-free individuals
2 YearsRR darr66AR darr 26
4 YearsRR darr158AR darr 96
P lt 00001
Julius S NesbittSD N Engl J Med 20063541-13
No effect
bull Lowering the tresholds for the initiation of pharmacologic therapy would have a tremendous economic effect on public health care system (Grassi N Eng J Med 2006)
bull The high-risk strategy identifes and treats those at greatest risk (eg 10y coronary heart disease risk gt20) While there benefits individual the population attributale risk remains significant since most events occur among those at lower risk levels (Egan Nesbitt Julius Therapevtic Advances in CV Disease)
Conclusion for our practice
bull Prehypertension is not an innocent stage and could be dangerous condition
bull It needs to be monitorised excluded masked hypertension
bull Regular blood pressure measurements HBPM ABPM telemonitoring
bull Life style modification versus pharmacological treatment
bull Subclinical organ damage assessmentbull Medical treatment as soon as it is needed
according present ESH guidelines
Treat or not to treat prehypertension this is the question now
bull ProfBakris
bull The argument has always been to use lifestyle modification for those with prehypertension-the good news is that it works but the bad news is that nobody does it
How does story continue
bull TROPHY study (candesartan) Julius S Nesbitt SD Egan BM et al Feasibility of treating prehypertension with an angiotensin-receptor blocker N Engl J Med2006354(16)1685-1697
bull PHARAO study (Ramipril) Luumlders S Schrader J Berger J et al The PHARAO study prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure a prospective randomized controlled prevention trial of the German Hypertension League J Hypertens 200826(7)1487-1496
bull Small studies no effect
TROPHY studyKaplan-Meier Curves of New Onset of Clinical
Hypertension in the Two Groups
0 1 2 3 4
Years in study
0
01
02
03
04
05
06
07
08
09
10
C
um
ula
tive
inci
den
ce
Candesartan
Placebo
Candesartan 391 356 309 191 128
Placebo 381 269 184 118 85
Numbers under the graph refer to hypertension-free individuals
2 YearsRR darr66AR darr 26
4 YearsRR darr158AR darr 96
P lt 00001
Julius S NesbittSD N Engl J Med 20063541-13
No effect
bull Lowering the tresholds for the initiation of pharmacologic therapy would have a tremendous economic effect on public health care system (Grassi N Eng J Med 2006)
bull The high-risk strategy identifes and treats those at greatest risk (eg 10y coronary heart disease risk gt20) While there benefits individual the population attributale risk remains significant since most events occur among those at lower risk levels (Egan Nesbitt Julius Therapevtic Advances in CV Disease)
Conclusion for our practice
bull Prehypertension is not an innocent stage and could be dangerous condition
bull It needs to be monitorised excluded masked hypertension
bull Regular blood pressure measurements HBPM ABPM telemonitoring
bull Life style modification versus pharmacological treatment
bull Subclinical organ damage assessmentbull Medical treatment as soon as it is needed
according present ESH guidelines
How does story continue
bull TROPHY study (candesartan) Julius S Nesbitt SD Egan BM et al Feasibility of treating prehypertension with an angiotensin-receptor blocker N Engl J Med2006354(16)1685-1697
bull PHARAO study (Ramipril) Luumlders S Schrader J Berger J et al The PHARAO study prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure a prospective randomized controlled prevention trial of the German Hypertension League J Hypertens 200826(7)1487-1496
bull Small studies no effect
TROPHY studyKaplan-Meier Curves of New Onset of Clinical
Hypertension in the Two Groups
0 1 2 3 4
Years in study
0
01
02
03
04
05
06
07
08
09
10
C
um
ula
tive
inci
den
ce
Candesartan
Placebo
Candesartan 391 356 309 191 128
Placebo 381 269 184 118 85
Numbers under the graph refer to hypertension-free individuals
2 YearsRR darr66AR darr 26
4 YearsRR darr158AR darr 96
P lt 00001
Julius S NesbittSD N Engl J Med 20063541-13
No effect
bull Lowering the tresholds for the initiation of pharmacologic therapy would have a tremendous economic effect on public health care system (Grassi N Eng J Med 2006)
bull The high-risk strategy identifes and treats those at greatest risk (eg 10y coronary heart disease risk gt20) While there benefits individual the population attributale risk remains significant since most events occur among those at lower risk levels (Egan Nesbitt Julius Therapevtic Advances in CV Disease)
Conclusion for our practice
bull Prehypertension is not an innocent stage and could be dangerous condition
bull It needs to be monitorised excluded masked hypertension
bull Regular blood pressure measurements HBPM ABPM telemonitoring
bull Life style modification versus pharmacological treatment
bull Subclinical organ damage assessmentbull Medical treatment as soon as it is needed
according present ESH guidelines
TROPHY studyKaplan-Meier Curves of New Onset of Clinical
Hypertension in the Two Groups
0 1 2 3 4
Years in study
0
01
02
03
04
05
06
07
08
09
10
C
um
ula
tive
inci
den
ce
Candesartan
Placebo
Candesartan 391 356 309 191 128
Placebo 381 269 184 118 85
Numbers under the graph refer to hypertension-free individuals
2 YearsRR darr66AR darr 26
4 YearsRR darr158AR darr 96
P lt 00001
Julius S NesbittSD N Engl J Med 20063541-13
No effect
bull Lowering the tresholds for the initiation of pharmacologic therapy would have a tremendous economic effect on public health care system (Grassi N Eng J Med 2006)
bull The high-risk strategy identifes and treats those at greatest risk (eg 10y coronary heart disease risk gt20) While there benefits individual the population attributale risk remains significant since most events occur among those at lower risk levels (Egan Nesbitt Julius Therapevtic Advances in CV Disease)
Conclusion for our practice
bull Prehypertension is not an innocent stage and could be dangerous condition
bull It needs to be monitorised excluded masked hypertension
bull Regular blood pressure measurements HBPM ABPM telemonitoring
bull Life style modification versus pharmacological treatment
bull Subclinical organ damage assessmentbull Medical treatment as soon as it is needed
according present ESH guidelines
No effect
bull Lowering the tresholds for the initiation of pharmacologic therapy would have a tremendous economic effect on public health care system (Grassi N Eng J Med 2006)
bull The high-risk strategy identifes and treats those at greatest risk (eg 10y coronary heart disease risk gt20) While there benefits individual the population attributale risk remains significant since most events occur among those at lower risk levels (Egan Nesbitt Julius Therapevtic Advances in CV Disease)
Conclusion for our practice
bull Prehypertension is not an innocent stage and could be dangerous condition
bull It needs to be monitorised excluded masked hypertension
bull Regular blood pressure measurements HBPM ABPM telemonitoring
bull Life style modification versus pharmacological treatment
bull Subclinical organ damage assessmentbull Medical treatment as soon as it is needed
according present ESH guidelines
bull Lowering the tresholds for the initiation of pharmacologic therapy would have a tremendous economic effect on public health care system (Grassi N Eng J Med 2006)
bull The high-risk strategy identifes and treats those at greatest risk (eg 10y coronary heart disease risk gt20) While there benefits individual the population attributale risk remains significant since most events occur among those at lower risk levels (Egan Nesbitt Julius Therapevtic Advances in CV Disease)
Conclusion for our practice
bull Prehypertension is not an innocent stage and could be dangerous condition
bull It needs to be monitorised excluded masked hypertension
bull Regular blood pressure measurements HBPM ABPM telemonitoring
bull Life style modification versus pharmacological treatment
bull Subclinical organ damage assessmentbull Medical treatment as soon as it is needed
according present ESH guidelines
Conclusion for our practice
bull Prehypertension is not an innocent stage and could be dangerous condition
bull It needs to be monitorised excluded masked hypertension
bull Regular blood pressure measurements HBPM ABPM telemonitoring
bull Life style modification versus pharmacological treatment
bull Subclinical organ damage assessmentbull Medical treatment as soon as it is needed
according present ESH guidelines